

CITATION REPORT

List of articles citing

Requirement of vascular integrin alpha v beta 3 for angiogenesis

DOI: 10.1126/science.7512751
Science, 1994, 264, 569-71.

Source: <https://exaly.com/paper-pdf/25295832/citation-report.pdf>
Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2346	Wound Repair. 1988 , 3-50		91
2345	Snake yolk sac as a site for in vivo organ incubation: A new method in the research of snake embryo development. 1994 , 270, 538-546		1
2344	Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. 1994 , 16, 901-6		212
2343	Angiogenesis inhibition: a review. 1994 , 63, 265-311		256
2342	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. 1994 , 371, 674-80		517
2341	Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. 1994 , 79, 1157-64		2082
2340	Wound repair in the context of extracellular matrix. 1994 , 6, 717-25		337
2339	Angiogenesis. 1995 , 22, 845-52		16
2338	Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 7657-61	11.5	293
2337	Integrins in the endometrium. 1995 , 4, 43-58		12
2336	Beta 1 integrins mediate adherent phenotype of human erythroblastic cell lines after phorbol 12-myristate 13-acetate induction. 1995 , 309 (Pt 2), 491-7		12
2335	Angiogenic properties of human immunodeficiency virus type 1 Tat protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 4838-42	11.5	191
2334	Approaches to studying cell adhesion molecules in angiogenesis. 1995 , 5, 69-74		106
2333	Mechanismen der Neubildung von Blutgefäßen. 1995 , 177, 493-502		6
2332	Distribution of vitronectin mRNA during murine development. 1995 , 203, 71-9		49
2331	Implication of the alpha v beta 3 integrin in the adhesion of the ovarian-adenocarcinoma cell line IGROV1. 1995 , 63, 530-6		24
2330	Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. 1995 , 17, 140-7		38

2329	In vitro structural and functional relationships between preosteoclastic and bone endothelial cells: a juxtacrine model for migration and adhesion of osteoclast precursors. 1995 , 162, 199-212	23
2328	The role of endothelial cells in tumor invasion and metastasis. 1995 , 23, 99-108	38
2327	Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study. 1995 , 36, 205-17	95
2326	The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. 1995 , 14, 241-52	45
2325	Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. 1995 , 73, 333-46	396
2324	Molecular foundations of cancer: new targets for intervention. 1995 , 1, 309-20	93
2323	Synthetic human antibodies. 1995 , 1, 837-9	38
2322	Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. 1995 , 376, 517-9	523
2321	Contents. 1995 , 7, 285	
2320	Bibliography of the current world literature. 1995 , 7, 405-432	
2319	Pharmaceutical biotechnology. 1995 , 6, 719-75	
2318	Molecular and cellular biology of osteopontin Potential role in cardiovascular disease. 1995 , 5, 88-95	89
2317	Progress against cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 633-47	4.9 8
2316	Differentiation of endothelium. 1995 , 9, 926-933	515
2315	Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. 1995 , 131, 1587-98	121
2314	Fibrin II induces endothelial cell capillary tube formation. 1995 , 130, 207-15	124
2313	Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. 1995 , 130, 441-50	180
2312	Soluble ligands of the alpha v beta 3 integrin mediate enhanced tyrosine phosphorylation of multiple proteins in adherent bovine pulmonary artery endothelial cells. 1995 , 270, 16781-7	62

2311	CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. 1995 , 130, 451-60	325
2310	Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. 1995 , 87, 1799-801; author reply 1801-2	10
2309	Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. 1995 , 34, 3948-55	117
2308	The pathophysiology of angiogenesis. 1995 , 6, 230-47	186
2307	Bi-directional stimulation of adherence to extracellular matrix components by human head and neck squamous carcinoma cells and endothelial cells. 1995 , 96, 253-60	9
2306	Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. 1995 , 116, 1829-34	117
2305	Osteopontin overview. 1995 , 760, 1-5	85
2304	REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. 1995 , 3, 367-74	127
2303	Definition of two angiogenic pathways by distinct alpha v integrins. <i>Science</i> , 1995 , 270, 1500-2	33.3 1211
2302	Angiogenesis: models and modulators. 1995 , 159, 113-60	138
2301	Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. 1995 , 118, 669-73; discussion 673-5	17
2300	The significance of adhesion molecules in diagnostic histopathology. 1995 , 2, 101-110	6
2299	Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. 1995 , 333, 1757-63	1931
2298	AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. 1996 , 10, 1031-49	24
2297	RGD and other recognition sequences for integrins. 1996 , 12, 697-715	2451
2296	Integrins: role in cell adhesion and communication. 1996 , 797, 93-106	36
2295	Cyclic RGD Peptides Containing ETurn Mimetics. 1996 , 118, 7881-7891	122
2294	Alternative adhesion sites in human fibrinogen for vascular endothelial cells. 1996 , 35, 4169-75	47

2293	Cell adhesion and integrin binding to recombinant human fibrillin-1. 1996 , 384, 247-50	134
2292	Common principles in cell adhesion. 1996 , 227, 1-11	182
2291	Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. 1996 , 74, 253-68	37
2290	Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. 1996 , 85, 683-93	1403
2289	Angiogenesis and the skin: a primer. 1996 , 34, 486-97	79
2288	Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. 1996 , 46, 107-15	42
2287	Genetic analyses of integrin function in mice. 1996 , 8, 641-6	110
2286	Integrins and cancer. 1996 , 8, 724-30	432
2285	Role of integrins in angiogenesis. 1996 , 32A, 2423-9	158
2284	New perspectives in clinical oncology from angiogenesis research. 1996 , 32A, 2534-9	198
2283	Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin α 5 β 1 Antagonists. 1996 , 118, 7461-7472	531
2282	How tumors become angiogenic. 1996 , 69, 135-74	348
2281	Polymorphisms of platelet receptors as risk factors in coronary thrombosis. 1996 , 17, 1293-4	3
2280	Ligand Function of Antigenized Antibodies Expressing the RGD Motif. 1996 , 65, 159-178	
2279	Progress towards a unifying hypothesis for angiogenesis. 1996 , 97, 1359	8
2278	Identification of a new biological function for the integrin alpha v beta 3: initiation of fibronectin matrix assembly. 1996 , 4, 149-58	90
2277	Section Review Oncologic, Endocrine & Metabolic: Recent developments in the treatment of angiogenesis. 1996 , 6, 619-625	2
2276	Chapter 20. Cell Adhesion Integrins as Pharmaceutical Targets. 1996 , 31, 191-200	13

2275	Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 9764-9	11.5	409
2274	Cell adhesion and angiogenesis. 1996 , 6, 462-8		159
2273	The role of alpha v-integrins in tumour progression and metastasis. 1996 , 7, 129-38		84
2272	Tyrosine Phosphorylation of a ~30 kD Protein Precedes avb3 Integrin-signaled Endothelial Cell Spreading and Motility on Matrix Proteins. 1996 , 2, 21-29		
2271	Norman MacAlister Gregg Lecture. The pathogenesis of diabetic retinopathy. 1996 , 24, 97-104		10
2270	The role of mechanical stresses in microvascular remodeling. 1996 , 3, 143-65		162
2269	Integrins, angiogenesis and vascular cell survival. 1996 , 3, 881-5		160
2268	L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin. 1996 , 26, 2508-16		97
2267	Tumour angiogenesis. 1996 , 179, 232-7		117
2266	Effects of basic fibroblast growth factor on human microvessel endothelial cell migration on collagen I correlates inversely with adhesion and is cell density dependent. 1996 , 168, 294-304		28
2265	Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. 1996 , 15, 165-76		153
2264	Cell adhesion molecules in angiogenesis. 1996 , 15, 187-94		88
2263	A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). 1996 , 15, 247-72		107
2262	Radicular cysts are involved in the recruitment of osteoclast precursors. 1996 , 25, 325-30		7
2261	Expression of adhesion molecules in endemic and epidemic Kaposi's sarcoma. 1996 , 29, 337-46		17
2260	Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. 1996 , 2, 529-33		308
2259	The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. 1996 , 383, 441-3		591
2258	An allosteric Ca ²⁺ binding site on the beta3-integrins that regulates the dissociation rate for RGD ligands. 1996 , 271, 21745-51		71

2257	Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. 1996 , 271, 24144-50	114
2256	Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. 1996 , 134, 1313-22	107
2255	Mechanisms of integrin-mediated calcium signaling in MDCK cells: regulation of adhesion by IP3- and store-independent calcium influx. 1996 , 7, 1025-41	65
2254	Trans-dominant inhibition of integrin function. 1996 , 7, 1939-51	156
2253	Cloning of mouse integrin alphaV cDNA and role of the alphaV-related matrix receptors in metanephric development. 1996 , 132, 1161-76	64
2252	Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. 1996 , 134, 1323-32	170
2251	A novel monoclonal antibody, L1A3, is directed to the functional site of the alpha v integrin subunit. 1996 , 15, 279-88	8
2250	The ligand recognition specificity of beta3 integrins. 1996 , 271, 10365-71	61
2249	Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. 1996 , 271, 29393-9	195
2248	Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. 1996 , 271, 21-4	316
2247	Review : Angiogenesis: A new target for antineoplastic therapy. 1996 , 2, 43-60	
2246	Immunological aspects of endometriosis. 1996 , 2, 371-84	70
2245	In vivo neutralization of vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. 1996 , 8, 505-11	7
2244	Tenascin in human neoplasia. 1996 , 8, 741-55	3
2243	Distribution of connective tissue proteins during development and neovascularization of the epicardium. 1996 , 31, E104-E115	11
2242	Section Review Oncologic, Endocrine & Metabolic: Angiogenesis inhibition as a drug target for disease: an update. 1996 , 5, 1617-1637	17
2241	Angiogenesis and the fibrinolytic system. 1996 , 22, 517-24	19
2240	The Biological Activities of Disintegrins and Their Possible Applications. 1997 , 16, 135-161	7

2239	Harvesting molecular diversity--biology's new commodity. 1997 , 14, 51-65	2
2238	Regulation of Angiogenesis. 1997 ,	3
2237	Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. 1997 , 8, 1329-41	72
2236	alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. 1997 , 8, 2449-61	130
2235	Defining extracellular integrin alpha-chain sites that affect cell adhesion and adhesion strengthening without altering soluble ligand binding. 1997 , 8, 2647-57	39
2234	Evidence that the integrin beta3 and beta5 subunits contain a metal ion-dependent adhesion site-like motif but lack an I domain. 1997 , 272, 14236-43	48
2233	Regulation of cell motility by mitogen-activated protein kinase. 1997 , 137, 481-92	1108
2232	Beta 1 integrin is essential for teratoma growth and angiogenesis. 1997 , 139, 265-78	157
2231	In vitro and in vivo systems to assess role of C-X-C chemokines in regulation of angiogenesis. 1997 , 288, 190-220	32
2230	Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. 1997 , 36, 408-28	144
2229	Matrix Metalloproteinase Inhibitor Drugs. 1997 , 2, 205-230	25
2228	Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins. 1997 , 272, 4103-7	18
2227	The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin. 1997 , 272, 29380-9	78
2226	Enhancement of migration by protein kinase Calpha and inhibition of proliferation and cell cycle progression by protein kinase Cdelta in capillary endothelial cells. 1997 , 272, 7390-7	103
2225	Role of vascular permeability factor/vascular endothelial growth factor in eye disease. 1997 , 81, 501-12	64
2224	The cell adhesion domain in plasma vitronectin is cryptic. 1997 , 272, 13705-10	99
2223	Biological roles of fibroblast growth factor-2. 1997 , 18, 26-45	677
2222	Induction of the angiogenic phenotype by Hox D3. 1997 , 139, 257-64	188

2221	Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. 1997 , 79, 391-411	48
2220	Platelet Function and Pharmacology of Antiplatelet Drugs. 1997 , 7, 2-9	5
2219	Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. 1997 , 41, 1052-9	43
2218	Antiangiogenic Drug Therapy for Macular Degeneration. 1997 , 12, 10-13	
2217	Arterial wall neovascularization--potential role in atherosclerosis and restenosis. 1997 , 61, 893-904	19
2216	Angiogenesis and (anti)angiogenic drugs. 1997 , 443-450	
2215	The biochemistry of cancer dissemination. 1997 , 32, 175-253	130
2214	Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions. 1997 , 21, 537-44	18
2213	Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists. 1997 , 40, 2289-92	118
2212	Stereoisomerism and Biological Activity of the Selective and Superactive $\alpha_5\beta_3$ Integrin Inhibitor cyclo(-RGDFV-) and Its Retro-Inverso Peptide. 1997 , 119, 1328-1335	123
2211	Mechanisms by Which Fibrin and Fibronectin Appear in Healing Wounds: Implications for Peyronie's Disease. 1997 , 157, 306-310	47
2210	Peptidomimetics in Drug Design. 1997 , 29, 1-78	50
2209	Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. 1997 , 16, 861-9	125
2208	Cross talk between adhesion molecules: control of N-cadherin activity by intracellular signals elicited by beta1 and beta3 integrins in migrating neural crest cells. 1997 , 137, 1663-81	143
2207	Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. <i>Science</i> , 1997 , 278, 290-4	333 447
2206	Early Development of Endothelial Tubes. 1997 , 8, 683-685	
2205	Interleukin-15 promotes angiogenesis in vivo. 1997 , 233, 231-7	93
2204	Characterization of the novel murine monoclonal anti-von Willebrand factor (vWf) antibody GUR76-23 which inhibits vWf interaction with alpha IIb beta 3 but not alpha v beta 3 integrin. 1997 , 234, 147-52	6

2203	Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells. 1997 , 23, 230-41	11
2202	Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. 1997 , 233, 340-9	88
2201	Wound healing--aiming for perfect skin regeneration. <i>Science</i> , 1997 , 276, 75-81	33.3 3663
2200	Loss of alpha-v integrin expression and recurrence in node-negative lung carcinoma. 1997 , 64, 949-53	7
2199	Cell adhesion and angiogenesis. 1997 , 99, 373-6	88
2198	Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. 1997 , 1336, 445-54	72
2197	Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. 1997 , 49, 123-31	43
2196	Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. 1997 , 99, 2152-64	647
2195	Tumour-induced angiogenesis: a novel target for drug therapy?. 1997 , 2, 175-190	1
2194	Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. 1997 , 273, F899-906	19
2193	Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. 1997 , 99, 2691-700	323
2192	A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins. 1997 , 139, 1567-81	114
2191	Vascular development: cellular and molecular regulation. 1997 , 11, 365-373	436
2190	Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. 1997 , 99, 2139-51	699
2189	Manipulating angiogenesis. From basic science to the bedside. 1997 , 17, 605-19	218
2188	Cytokine Treatment of Endothelial Cells Increases Glycoprotein Ib-Dependent Adhesion to von Willebrand Factor. 1997 , 89, 4071-4077	23
2187	Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody. 1997 , 88, 1171-80	6
2186	Microvascular responses to cerebral ischemia/inflammation. 1997 , 823, 132-47	111

2185	Endothelial cells and angiogenesis. 1997 , 6, 272-3	9
2184	Design, synthesis and biological evaluation of carbohydrate-based mimetics of cRGDFV. 1997 , 53, 8751-8778	67
2183	Alpha v integrins as receptors for tumor targeting by circulating ligands. 1997 , 15, 542-6	659
2182	On target with tumor blood vessel markers. 1997 , 15, 1243-4	33
2181	Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. 1997 , 3, 887-93	258
2180	Integrins as signaling molecules and targets for tumor therapy. 1997 , 51, 1413-7	77
2179	The solid state environment orchestrates embryonic development and tissue remodeling. 1997 , 51, 1427-33	26
2178	Modulation of cell proliferation by the integrin cytoplasmic domain. 1997 , 51, 1434-40	6
2177	Role of alpha v integrins in mesangial cell adhesion to vitronectin and von Willebrand factor. 1997 , 51, 1900-7	11
2176	Integrin and basement membrane normalization in mouse grafts of human keratinocytes--implications for epidermal homeostasis. 1997 , 61, 195-209	56
2175	Angiogenesis and osteogenesis in an orthopedically expanded suture. 1997 , 111, 382-90	46
2174	Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications. 1997 , 2, 187-199	57
2173	Targeting the vasculature of solid tumours. 1997 , 48, 277-288	8
2172	Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. 1997 , 15, 15-28	57
2171	An improved method for the quantitation of cellular migration: Role of α 5 β 1 integrin in endothelial and smooth muscle cell migration. 1997 , 19, 179-187	4
2170	Osteopontin: Potential roles in vascular function and dystrophic calcification. 1997 , 15, 179-183	19
2169	Localization of vitronectin in the normal and atherosclerotic human vessel wall. 1997 , 107, 313-20	40
2168	In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization. 1997 , 33, 763-73	79

2167	Apoptosis in metastatic cancer cells. 1997 , 25, 175-86	24
2166	Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?. 1997 , 26, 147-62	16
2165	Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. 1997 , 136, 859-865	21
2164	Interdonor variability of platelet response to thrombin receptor activation: influence of PLA2 polymorphism. 1997 , 99, 801-7	48
2163	Ultrastructural analysis of the distribution of the vitronectin receptor (alpha v beta 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the alpha-granule membrane. 1997 , 96, 823-35	34
2162	Enhancement of cell interactions with collagen/glycosaminoglycan matrices by RGD derivatization. 1997 , 18, 1625-32	67
2161	Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy. 1997 , 36, 588-590	46
2160	Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the $\alpha_5\beta_1$ Integrin for a New Cancer Therapy. 1997 , 36, 1374-1389	368
2159	Integrin-mediated calcium signaling and regulation of cell adhesion by intracellular calcium. 1997 , 19, 47-55	133
2158	Integrinantagonisten und andere niedermolekulare Verbindungen als Inhibitoren der Angiogenese - neue Wirkstoffe in der Tumorthherapie. 1997 , 109, 606-609	16
2157	Deracemisierung durch enantiodifferenzierende Inversion an 1,3-Diolen. 1997 , 109, 609-612	3
2156	Stereoisomere Peptid-Bibliotheken und Peptidmimetika zum Design von selektiven Inhibitoren des $\alpha_5\beta_1$ -Integrins für eine neuartige Krebstherapie. 1997 , 109, 1440-1456	75
2155	Synthesis of Unnatural Lipophilic N-(9H-Fluoren-9-ylmethoxy)carbonyl-Substituted α -Amino Acids and Their Incorporation into Cyclic RGD-Peptides: A structure-activity study. 1997 , 80, 1280-1300	18
2154	Abstracts (Continue in Part VIII). 1997 , 1997, 351-400	
2153	The association between tumour progression and vascularity in the oral mucosa. 1997 , 183, 39-43	110
2152	Diverse aspects of metanephric development. 1997 , 39, 261-84	7
2151	Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. 1997 , 173, 84-92	59
2150	Immunohistochemical analysis of integrin $\alpha_v\beta_3$ expression on tumor-associated vessels of human carcinomas. 1997 , 71, 320-4	131

2149	A new synthetic matrix metalloproteinase inhibitor modulates both angiogenesis and urokinase type plasminogen activator activity. 1998 , 2, 319-29	5
2148	CXC chemokines mechanism of action in regulating tumor angiogenesis. 1998 , 2, 123-34	26
2147	Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. 1998 , 17, 307-15	20
2146	Clinical significance of angiogenic factors in breast cancer. 1998 , 52, 159-73	53
2145	Growth retardation and discordant twin pregnancy. An immunomorphological and biochemical characterisation of the human umbilical cord. 1998 , 46, 795-805	
2144	Alpha4beta1 and alpha5beta1 control cell migration on fibronectin by differentially regulating cell speed and motile cell phenotype. 1998 , 26, 1091-101	19
2143	Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. 1998 , 86, 199-208	29
2142	Apoptosis in metastatic carcinoma of the central nervous system. 1998 , 18, 370-375	
2141	Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. 1998 , 5, 747-54	47
2140	Gestational age-dependent extravillous cytotrophoblast osteopontin immunolocalization differentiates between normal and preeclamptic pregnancies. 1998 , 40, 339-46	16
2139	Death to a blood vessel, death to a tumor. 1998 , 4, 395-6	30
2138	Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. 1998 , 4, 408-14	405
2137	Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. 1998 , 4, 623-6	808
2136	N-methylformamide induces changes on adhesive properties and lung-colonizing potential of M14 melanoma cells. 1998 , 77, 210-5	3
2135	Morphogenesis of the first blood vessels. 1998 , 857, 155-79	112
2134	The Mechanics of Vascular Cell Motility. 1998 , 5, 239-257	23
2133	Characterization of the integrin alpha(v) gene promoter in mice. 1998 , 1395, 209-19	8
2132	Review: angiogenesis: implications for rheumatoid arthritis. 1998 , 41, 951-62	406

2131	Vitronectin decreases microvascular endothelial cell apoptosis. 1998 , 175, 149-55	50
2130	Reduced viability of human vascular endothelial cells cultured on Matrigel. 1998 , 176, 92-8	13
2129	Virally activated Ras cooperates with integrin to induce tubulogenesis in sinusoidal endothelial cell lines. 1998 , 176, 223-34	28
2128	P2Y nucleotide receptors in the immune system: Signaling by a P2Y2 receptor in U937 monocytes. 1998 , 45, 222-228	16
2127	Current concepts of tumor-induced angiogenesis. 1998 , 4, 62-75	38
2126	Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. 1998 , 4, 230-41	149
2125	What have snakes taught us about integrins?. 1998 , 54, 527-40	95
2124	Design, synthesis and biological evaluation of nonpeptide integrin antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 1998 , 6, 1185-208	3-4 66
2123	Vascular development and disorders: molecular analysis and pathogenic insights. 1998 , 53, 1519-49	84
2122	Selenium, calcium channel blockers, and cancer risk--the Yin and Yang of apoptosis?. 1998 , 50, 423-33	5
2121	Neovascularization: the Achilles' heel of tumors?. 1998 , 1, 86-7	2
2120	Adhesion molecules in high-grade soft tissue sarcomas: correlation to clinical outcome. 1998 , 34, 496-502	14
2119	Mechanisms of tumour metastasis. 1998 , 34, 214-21	155
2118	Role of vitronectin and its receptors in haemostasis and vascular remodeling. 1998 , 89, 1-21	198
2117	Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. 1998 , 92, 391-400	549
2116	Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. 1998 , 95, 507-19	570
2115	Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. 1998 , 95, 365-77	621
2114	Chloramine T-induced structural and biochemical changes in echistatin. 1998 , 429, 239-48	13

2113	Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique. 1998 , 32, 2072-9	161
2112	Clinical research on antiangiogenic therapy. 1998 , 37, 1-16	36
2111	Integrin expression is upregulated during early healing in a canine intrasynovial flexor tendon repair and controlled passive motion model. 1998 , 39, 309-16	27
2110	A series of function blocking antibodies against the alpha v beta 3 integrin bind allosteric to the ligand binding site and induce ligand dissociation. 1998 , 6, 451-64	12
2109	Angiogenesis: a new theory for endometriosis. 1998 , 4, 736-40	140
2108	Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. <i>Science</i> , 1998 , 279, 377-80	333 1734
2107	Angiostatin upregulates E-selectin in proliferating endothelial cells. 1998 , 245, 906-11	30
2106	A key function for alphav containing integrins in mesodermal cell migration during Pleurodeles waltl gastrulation. 1998 , 195, 158-73	11
2105	VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. 1998 , 238, 324-34	189
2104	Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during in vitro angiogenesis. 1998 , 239, 1-10	40
2103	Changes in matrix composition during the growth and regression of human hemangiomas. 1998 , 80, 9-15	36
2102	Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. 1998 , 153, 1099-112	142
2101	Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression. 1998 , 153, 1347-51	59
2100	Tumor vasculature targeted therapies: getting the players organized. 1998 , 55, 1939-45	41
2099	Angiogenesis and tumor metastasis. 1998 , 49, 407-24	761
2098	Current Techniques in Neurosurgery. 1998 ,	
2097	Integrin-mediated signaling events in human endothelial cells. 1998 , 9, 1969-80	140
2096	Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. 1998 , 12, 21-33	185

2095	Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. 1998 , 140, 1255-63	358
2094	Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. 1998 , 9, 3179-93	406
2093	Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. 1998 , 9, 701-13	36
2092	Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. 1998 , 188, 2349-56	269
2091	Endometrial microvascular growth in normal and dysfunctional states. 1998 , 4, 503-8	54
2090	Growth factor-dependent activation of alphavbeta3 integrin in normal epithelial cells: implications for tumor invasion. 1998 , 142, 1145-56	102
2089	Integrins, adhesion, and cardiac remodeling. 1998 , 31, 176-80	48
2088	Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. 1998 , 188, 133-43	48
2087	Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. 1998 , 139, 1401-10	42
2086	The role of integrins in tumorigenesis and metastasis. 1998 , 16, 329-44	59
2085	Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. 1998 , 6, 371-9	34
2084	Glycoproteins of the human milk fat globule in the protection of the breast-fed infant against infections. 1998 , 74, 143-62	121
2083	Cell adhesion molecules and extracellular matrix proteins: potential therapeutic applications. 1998 , 7, 1159-71	10
2082	Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. 1998 , 29, 1698-706; discussion 1707	138
2081	Phosphorylation of vitronectin by casein kinase II. Identification of the sites and their promotion of cell adhesion and spreading. 1998 , 273, 24805-13	46
2080	A human vascular endothelial cell model to study angiogenesis and tumorigenesis. 1998 , 19, 673-81	40
2079	Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. 1998 , 273, 3090-6	171
2078	Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. 1998 , 273, 30719-28	89

2077	pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 11661-6	11.5	206
2076	Angiogenesis, vascular endothelial growth factor and the endometrium. 1998 , 4, 509-19		147
2075	Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. 1998 , 98, 1085-91		227
2074	NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. 1998 , 141, 1083-93		432
2073	Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. 1998 , 18, 1730-7		26
2072	Gene Therapy Strategies for Tumor Antiangiogenesis. 1998 , 90, 261-263		2
2071	A role for the alphavbeta3 integrin in the transmigration of monocytes. 1998 , 142, 595-607		116
2070	Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. 1998 , 12, 261-8		45
2069	Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6037-42	11.5	132
2068	Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. 1998 , 102, 2033-9		90
2067	A new approach to fighting cancer?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 5843-4	11.5	14
2066	Demystified ... adhesion molecules. 1998 , 51, 175-84		12
2065	A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 8910-5	11.5	85
2064	Differential expression of alphav integrins in K1735 melanoma cells. 1998 , 18, 1-14		27
2063	Autoregulation of angiogenesis by cells of the vessel wall. 1999 , 185, 1-43		54
2062	Cell adhesion molecules: their role in pregnancy. 1998 , 10, 21-44		6
2061	Transmembrane-truncated alphavbeta3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor?. 1998 , 330 (Pt 2), 861-9		73
2060	cDNA cloning reveals two mouse beta5 integrin transcripts distinct in cytoplasmic domains as a result of alternative splicing. 1998 , 331 (Pt 2), 631-7		6

2059	The Role of α Integrins during Angiogenesis. 1998 , 4, 741-750	65
2058	Role of Integrin α in Vascular Biology. 1998 , 80, 726-734	144
2057	Accutin, a New Disintegrin, Inhibits Angiogenesis In Vitro and In Vivo by Acting as Integrin α Antagonist and Inducing Apoptosis. 1998 , 92, 3268-3276	115
2056	Therapeutic angiogenesis. 1998 , 3, e49-69	31
2055	Molecular Mechanisms of Vascular Development. 1999 , 221-252	15
2054	A role for angiogenesis in rheumatoid arthritis. 1999 , 32, 573-81	32
2053	Integrins in vascular development. 1999 , 32, 501-10	100
2052	Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells--possible role of osteopontin. 1999 , 14, 1861-6	4
2051	Assessment of Tumor Vascularization: Immunohistochemical and Non-Invasive Methods. 1999 , 14, 218-231	26
2050	Insights and Questions Arising from Studies of a Mouse Model of Glanzmann Thrombasthenia. 1999 , 82, 481-485	27
2049	Gene Trap, Gene Knockout, Gene Knock-In, and Transgenics in Vascular Development. 1999 , 82, 865-869	8
2048	Beyond Anatomy. 1999 , 8, 171-183	10
2047	Binding of Abciximab to α and Activated β Receptors: With a Review of Platelet-Leukocyte Interactions. 1999 , 82, 326-336	83
2046	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. 1999 , 94, 4143-4155	235
2045	Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. 1999 , 17, 275-90	175
2044	Expression of integrin transcripts in human cancer cells. 1999 , 129, 91-101	2
2043	Antiangiogenic Agents in Cancer Therapy. 1999 ,	4
2042	Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. 1999 , 84, 1223-33	113

2041	Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alpha β 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. 1999 , 84, 1268-76		63
2040	Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours. 1999 , 52, 895-900		10
2039	A natural variant of the cysteine protease virulence factor of group A Streptococcus with an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins alpha β 3 and alpha β 3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 242-7	11.5	87
2038	Focal adhesion targeting: the critical determinant of FAK regulation and substrate phosphorylation. 1999 , 10, 2507-18		92
2037	Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. 1999 , 274, 21609-16		137
2036	Potential of cell migration by adhesion-dependent cooperative signals from the GTPase Rac and Raf kinase. 1999 , 274, 37855-61		43
2035	Role of endothelial nitric oxide synthase in endothelial cell migration. 1999 , 19, 1156-61		250
2034	Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist. 1999 , 35-71		1
2033	A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. 1999 , 10, 3401-7		56
2032	Integrin Protocols. 1999 ,		2
2031	Synergy between an antiangiogenic integrin alpha β antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 1591-6	11.5	106
2030	Exposure of human vascular endothelial cells to sustained hydrostatic pressure stimulates proliferation. Involvement of the alpha β integrins. 1999 , 84, 315-22		72
2029	Anti-integrins as a potential therapeutic target in angiogenesis. 1999 , 9, 1237-1248		11
2028	Requirements for alpha(5)beta(1) integrin-mediated retraction of fibronectin-fibrin matrices. 1999 , 274, 20943-8		35
2027	Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). 1999 , 274, 35562-70		115
2026	Use of the 10-day-old chick embryo model for studying angiogenesis. 1999 , 129, 257-69		66
2025	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. 1999 , 9, 1807-12		35
2024	Localized paclitaxel delivery. 1999 , 183, 85-100		102

2023	New strategies in anti-vascular cancer therapy. 1999 , 29, 802-9	34
2022	Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of $\alpha v \beta 3$ mRNA by fibrin1. 1999 , 113, 913-9	72
2021	Regulation of $\alpha v \beta 3$ and $\alpha 5 \beta 1$ integrin receptors by basic fibroblast growth factor and platelet-derived growth factor-BB in intrasynovial flexor tendon cells. 1999 , 7, 381-8	49
2020	Human monoclonal antibodies: a tool for cancer detection in vivo. 1999 , 94, 5-42	1
2019	Matrix remodeling after stroke. De novo expression of matrix proteins and integrin receptors. 1999 , 890, 204-22	86
2018	On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. 1999 , 169, 175-94	218
2017	Growth factor signaling pathways in vascular development. <i>Oncogene</i> , 1999 , 18, 7917-32	9.2 90
2016	Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. 1999 , 81, 1155-61	12
2015	Activated microvessels express vascular endothelial growth factor and integrin $\alpha v \beta 3$ during focal cerebral ischemia. 1999 , 19, 1038-50	118
2014	Role of endothelial cell survival and death signals in angiogenesis. 1999 , 3, 101-16	45
2013	Contortrostatin, a dimeric disintegrin from <i>Agkistrodon contortrix</i> contortrix, inhibits angiogenesis. 1999 , 3, 259-69	47
2012	Expression of PECAM-1/CD31 isoforms in human brain gliomas. 1999 , 43, 19-25	37
2011	Cell adhesion molecules in the development and progression of malignant melanoma. 1999 , 18, 345-57	211
2010	Toward checkmate: biology and breast cancer therapy for the new millennium. 1999 , 17, 417-27	9
2009	Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. 1999 , 17, 195-212	73
2008	Molecular role(s) for integrins in human melanoma invasion. 1999 , 18, 359-75	93
2007	Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. 1999 , 17, 655-62	30
2006	A novel approach for studying angiogenesis: a human skin equivalent with a capillary-like network. 1999 , 15, 81-90	38

2005	Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). 1999 , 3, 53-60	32
2004	Oligodeoxynucleotide targeted to the alphav gene inhibits alphav integrin synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis. 1999 , 14, 1867-79	22
2003	New approaches to the investigation of focal hepatic lesions. 1999 , 13, 529-43	2
2002	Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. 1999 , 18, 6240-8	184
2001	Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. 1999 , 18, 882-92	521
2000	The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. 1999 , 18, 2106-18	92
1999	Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. 1999 , 18, 2165-73	170
1998	Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. 1999 , 135, 173-209	50
1997	Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. 1999 , 82, 169-93	60
1996	Apoptosis-inducing members of the tumor necrosis factor supergene family: Potential functions in placenta: A review. 1999 , 20, 243-257	
1995	The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis?. 1999 , 5, 304-9	44
1994	Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. 1999 , 11, 573-81	60
1993	Covalent immobilization of recombinant human alphavbeta3 integrin on a solid support with retention of functionality. 1999 , 266, 153-64	13
1992	ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. 1999 , 178, 121-32	176
1991	Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. 1999 , 85, 375-82	59
1990	Alpha9 and beta8 integrin expression correlates with the merger of the developing mouse eyelids. 1999 , 214, 216-28	26
1989	Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: involvement of intravascular thrombosis and fibrinogenesis. 1999 , 82, 853-9	7
1988	New approaches to cancer therapies. 1999 , 187, 138-46	16

1987	The role of the vascular phase in solid tumor growth: a historical review. 1999 , 1, 293-302	112
1986	Antiplatelet therapy for treatment of acute coronary syndromes. 1999 , 17, 345-57, ix	5
1985	Factors promoting tumor angiogenesis. 1999 , 17, 594-623	90
1984	Inhibitors of human mast cell serine proteases and potential therapeutic applications. 1999 , 9, 1537-1555	6
1983	Potential non-glycoprotein IIb/IIIa effects of abciximab. 1999 , 138, S1-5	71
1982	A link between integrins and MMPs in angiogenesis. 1999 , 13, 226-238	11
1981	Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. 1999 , 4, 915-24	679
1980	Surgical implications of therapeutic angiogenesis. 1999 , 125, 243-249	8
1979	Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. 1999 , 30, 753-8	45
1978	The rationale and future potential of angiogenesis inhibitors in neoplasia. 1999 , 58, 17-38	127
1977	Cutaneous wound healing. 1999 , 341, 738-46	4433
1976	Specific binding of integrin alpha v beta 3 to the fibrinogen gamma and alpha E chain C-terminal domains. 1999 , 38, 5872-7	62
1975	Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. 1999 , 38, 10217-24	51
1974	Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. 1999 , 154, 1743-53	156
1973	Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells. 1999 , 154, 1755-62	135
1972	Induction of apoptotic cell death in vascular endothelial cells cultured in three-dimensional collagen lattice. 1999 , 248, 498-508	53
1971	The CCN family of angiogenic regulators: the integrin connection. 1999 , 248, 44-57	573
1970	Integrin alpha(v)beta(3)-mediated activation of apoptosis. 1999 , 251, 33-45	86

1969	Cytokines modulate integrin alpha(v)beta(3)-mediated human endothelial cell adhesion and calcium signaling. 1999 , 251, 57-66	28
1968	Glycoprotein Ibalph can mediate endothelial cell migration on von Willebrand factor-containing substrata. 1999 , 252, 114-22	10
1967	Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. 1999 , 252, 262-72	64
1966	Beta3 integrin activation improves alphavbeta3-mediated retraction of fibrin matrices. 1999 , 83, 27-31	8
1965	Mapping regions of the beta1 integrin cytoplasmic domain involved in migration and survival in primary oligodendrocyte precursors using cell-permeable homeopeptides. 1999 , 259, 121-7	17
1964	Increased blood vessel density in decidua parietalis is associated with spontaneous human first trimester abortion. 1999 , 14, 1628-34	35
1963	Extracellular matrix receptors and the differentiation of human megakaryocytes in vitro. 1999 , 33, 15-23	9
1962	Extracellular matrix and integrin signalling: the shape of things to come. 1999 , 339, 481-488	449
1961	Extracellular matrix and integrin signalling: the shape of things to come. 1999 , 339, 481	197
1960	Chapter 7 Angiogenesis in prostate cancer. 1999 , 3, 139-154	
1959	The Role of Adhesion in Metastasis:. 1999 , 345-365	2
1958	Adhesion Receptors:: Critical Effectors of Trophoblast Differentiation During Implantation and Placentation. 1999 , 28, 389-408	
1957	Role of the Extracellular Matrix in Coronary Angiogenesis. 1999 , 59-90	
1956	P2Y receptors in the nervous system: molecular studies of a P2Y2 receptor subtype from NG108-15 neuroblastoma x glioma hybrid cells. 1999 , 120, 33-43	14
1955	Integrins as novel drug discovery targets: potential therapeutic and diagnostic implications. 2000 , 4, 143-153	14
1954	Endoproteolytic processing of integrin pro- β subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. 2000 , 346, 133	32
1953	Endoproteolytic processing of integrin pro- β subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. 2000 , 346, 133-138	86
1952	Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. 2000 , 47, 1185-95	43

1951	Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. 2000 , 105, 1034-42	54
1950	Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein--IAP (CD47) in human glomerular diseases. 2000 , 7, 441-51	19
1949	Molecular cloning and characterization of antigens expressed on rat tumor vascular endothelial cells. 2000 , 86, 799-805	7
1948	Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. 2000 , 68, 689-96	26
1947	Hypothesis: thalidomide embryopathy-proposed mechanism of action. 2000 , 61, 189-95	85
1946	Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. 2000 , 50, 405-9	169
1945	Human three-dimensional fibroblast cultures express angiogenic activity. 2000 , 183, 74-82	86
1944	Integrins as receptors for laminins. 2000 , 51, 280-301	280
1943	Angiogenesis: new insights and therapeutic potential. 2000 , 261, 126-35	118
1942	In vivo therapy of malignant melanoma by means of antagonists of $\alpha_5\beta_1$ integrins. 2000 , 87, 716-723	157
1941	Salivary carcinoma in HER-2/neu transgenic male mice: An angiogenic switch is not required for tumor onset and progression. 2000 , 88, 329-335	13
1940	Contortrostatin, a snake venom disintegrin, induces $\alpha_5\beta_1$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells. 2000 , 79, 28-37	33
1939	Hypoxia induces differential expression of the integrin receptors $\alpha_5\beta_1$ and $\alpha_5\beta_3$ in cultured human endothelial cells. 2000 , 78, 674-80	38
1938	Retinal and choroidal neovascularization. 2000 , 184, 301-10	315
1937	Magnetic resonance contrast enhancement of neovasculature with $\alpha_5\beta_1$ -targeted nanoparticles. 2000 , 44, 433-9	259
1936	Matrix metalloproteinases: pro- and anti-angiogenic activities. 2000 , 5, 47-54	73
1935	Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. 2000 , 5, 67-73	55
1934	Angiogenesis in wound healing. 2000 , 5, 40-6	777

1933	Differential gene expression by endothelial cells in distinct angiogenic states. 2000 , 267, 2820-30		100
1932	Adenovirus type 7 penton purification of soluble pentamers from Escherichia coli and development of an integrin-dependent gene delivery system. 2000 , 267, 6074-81		7
1931	An improved synthesis of a selective $\alpha_5\beta_1$ -integrin antagonist cyclo(-RGDfK-). 2000 , 41, 6295-6298		38
1930	Molecular and cell biology of the gingiva. 2000 , 24, 28-55		138
1929	Target molecules for anti-angiogenic therapy: from basic research to clinical trials. 2000 , 34, 89-110		87
1928	E1A stimulates FGF-2 release promoting differentiation of primary endothelial cells. 2000 , 7, 292-301		10
1927	Disruption of integrin-dependent adhesion and survival of endothelial cells by recombinant adenovirus expressing isolated beta integrin cytoplasmic domains. 2000 , 7, 1292-303		22
1926	Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. <i>Oncogene</i> , 2000 , 19, 6122-9	9.2	212
1925	The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. <i>Oncogene</i> , 2000 , 19, 6043-52	9.2	309
1924	An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. 2000 , 80, 501-11		46
1923	ANGIOGENESIS and ANGIOGENIC MEDIATORS IN HAEMATOLOGICAL MALIGNANCIES. 2000 , 111, 43-51		2
1922	Preferential activity of wild-type and mutant tumor necrosis factor-alpha against tumor-derived endothelial-like cells. 2000 , 91, 59-67		11
1921	Expression of Endothelial Cell Adhesion Molecules in Neovascularized Tissue. 2000 , 7, 249-258		22
1920	Endometrial angiogenesis. 2000 , 14, 919-36		23
1919	Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. 2000 , 79, 502-12		28
1918	Mouse integrin alphav promoter is regulated by transcriptional factors Ets and Sp1 in melanoma cells. 2000 , 1492, 377-84		22
1917	Mechanism of action in thalidomide teratogenesis. 2000 , 59, 1489-99		195
1916	IIb's are not IIb's. 2000 , 85, 23C-31C		39

1915	Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. 2000 , 46, 135-44	69
1914	Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. 2000 , 61, 249-60	81
1913	Genes that regulate metastasis and angiogenesis. 2000 , 50, 71-87	66
1912	Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. 2000 , 50, 189-200	67
1911	Anti-angiogenic treatment strategies for malignant brain tumors. 2000 , 50, 149-63	51
1910	A unique monoclonal antibody mNI-11 rapidly enhances spread formation in human umbilical vein endothelial cells. 2000 , 20, 317-24	11
1909	Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. 2000 , 82, 1967-73	78
1908	Angiogenesis and surgery: from mice to man. 2000 , 166, 435-46	7
1907	Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. 2000 , 19, 147-57	48
1906	Angiogenesis inhibitors. 2000 , 2, 11-6	10
1905	Epithelio-mesenchymal transformation in the embryonic face: implications for craniofacial malformations. 2000 , 23, 217-223	3
1904	The biology of cell locomotion within three-dimensional extracellular matrix. 2000 , 57, 41-64	516
1903	Tissue engineering of the vascular system: From capillaries to larger blood vessels. 2000 , 38, 232-240	28
1902	Active interaction of human A375 melanoma cells with the lymphatics in vivo. 2000 , 114, 373-85	66
1901	Immunohistochemical tenascin-C expression in paediatric supratentorial glioblastoma multiforme. 2000 , 16, 357-62	2
1900	Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. 2000 , 95, 2304-2311	115
1899	Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. 2000 , 96, 176-181	68
1898	Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. 2000 , 277-295	

1897	Retinoic acid upregulates beta(1)-integrin in vascular smooth muscle cells and alters adhesion to fibronectin. 2000 , 279, H382-7		26
1896	Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. 2000 , 278, L217-26		68
1895	WOUND REPAIR: BASIC BIOLOGY TO TISSUE ENGINEERING. 2000 , 857-878		15
1894	Current Status Of Burn Wound Pathophysiology. 2000 , 27, 11-21		82
1893	Multiple Myeloma: New Insights and Therapeutic Approaches. 2000 , 2000, 147-165		5
1892	Evidence for New Endothelial Cell Binding Sites on Fibrinogen. 2000 , 84, 819-825		10
1891	Vascular endothelial growth factor and endometriotic angiogenesis. 2000 , 6, 45-55		196
1890	Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 1749-53	11.5	448
1889	Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 12227-32	11.5	127
1888	Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. 2000 , 275, 32281-8		30
1887	Agkistatin, a snake venom-derived glycoprotein Ib antagonist, disrupts von Willebrand factor-endothelial cell interaction and inhibits angiogenesis. 2000 , 275, 18615-8		27
1886	Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. 2000 , 275, 24653-60		154
1885	Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. 2000 , 275, 23745-50		191
1884	Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. 2000 , 37, 119-27		105
1883	Advances in Eicosanoid Research. 2000 ,		
1882	Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. 2000 , 275, 16891-6		71
1881	CD9 participates in endothelial cell migration during in vitro wound repair. 2000 , 20, 360-9		56
1880	Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. 2000 , 275, 38371-7		48

1879	Autologous platelet-derived wound healing factor promotes angiogenesis via alphavbeta3-integrin expression in chronic wounds. 2000 , 6, 515-9	21
1878	Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury.. 2000 , 6, 433	
1877	The chimeric human/mouse model of angiogenesis. 2000 , 137, 213-21	
1876	Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. 2000 , 92, 1329-36	98
1875	Integrins as therapeutic targets. 2000 , 4, 397-411	4
1874	New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. 2000 , 79, 1-38	131
1873	Distinct antitumor properties of a type IV collagen domain derived from basement membrane. 2000 , 275, 21340-8	266
1872	The role of angiogenesis in rheumatoid arthritis: recent developments. 2000 , 59 Suppl 1, i65-71	73
1871	The role of homeobox genes in vascular remodeling and angiogenesis. 2000 , 87, 865-72	77
1870	Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. 2000 , 11, 2885-900	126
1869	Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. 2000 , 275, 33920-8	172
1868	Blockade of the alpha(v)beta(3) integrin adversely affects implantation in the mouse. 2000 , 62, 1285-90	163
1867	New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. 2000 , 275, 8051-61	262
1866	Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. 2000 , 86, 885-91	101
1865	Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 2202-7	11.5 348
1864	Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells. 2000 , 275, 32658-63	32
1863	Expression and function of alpha(v)beta(3) and alpha(v)beta(5) integrins in the developing pancreas: roles in the adhesion and migration of putative endocrine progenitor cells. 2000 , 150, 1445-60	138
1862	Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. 2000 , 267, 350-5	43

1861	A non-transmembrane form of Jagged-1 regulates the formation of matrix-dependent chord-like structures. 2000 , 268, 853-9	30
1860	Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. 2000 , 279, 846-52	50
1859	VEGF regulates cell behavior during vasculogenesis. 2000 , 224, 178-88	103
1858	Multiple roles of integrins in cell motility. 2000 , 261, 69-74	140
1857	Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. 2000 , 301, 1179-90	182
1856	Nitric oxide induces angiogenesis and upregulates alpha(v)beta(3) integrin expression on endothelial cells. 2000 , 60, 269-80	56
1855	Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. 2000 , 156, 1489-98	349
1854	RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. 2000 , 156, 1673-83	242
1853	Is endometriosis an endometrial disease?. 2000 , 91, 113-25	91
1852	Tumour vasculature as a target for anticancer therapy. 2000 , 26, 191-204	132
1851	Tumour micrometastases: the influence of angiogenesis. 2000 , 26, 105-15	29
1850	Bi-directional signal transduction by integrin receptors. 2000 , 32, 171-88	125
1849	Angiogenesis and non-small cell lung cancer. 2000 , 27, 81-100	74
1848	Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. 2000 , 238, 88-93	20
1847	Constitutive expression of the DNA-binding domain of Ets1 increases endothelial cell adhesion and stimulates their organization into capillary-like structures. <i>Oncogene</i> , 2000 , 19, 762-72	9.2 33
1846	Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction. 2000 , 31, 375-81	34
1845	Developmental Biology Protocols. 2000 ,	1
1844	An address system in the vasculature of normal tissues and tumors. 2000 , 18, 813-27	199

1843	Role of radionuclide imaging in trials of antiangiogenic therapy. 2000 , 7, 851-67	31
1842	Ligands to the integrin receptor $\alpha_5\beta_1$. 2000 , 10, 1367-1383	49
1841	Angiogenesis: new targets for the development of anticancer chemotherapies. 2000 , 6, 417-39	82
1840	Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. 2000 , 275, 1209-15	336
1839	Small molecule $\alpha(v)$ integrin antagonists: novel anticancer agents. 2000 , 9, 1271-9	33
1838	Isoxazolines as potent antagonists of the integrin $\alpha(v)\beta_3$. 2000 , 43, 27-40	78
1837	Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. 2000 , 7, 824-39	151
1836	In vivo monitoring of tumor angiogenesis with MR imaging. 2000 , 7, 812-23	104
1835	Tumor necrosis factor: clinical use and mechanisms of action. 2000 , 3, 271-276	8
1834	Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. 2000 , 83, 156-63	76
1833	Platelets and restenosis. 2000 , 35, 555-62	117
1832	Increased expression of endoglin in the eutopic endometrium of women with endometriosis. 2001 , 76, 918-22	26
1831	Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. 2001 , 3, 357-61	98
1830	Microscopic assessment of angiogenesis in tumors. 2001 , 46, 29-46	6
1829	A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf==V-) is the potent inhibitor of angiogenesis. 2001 , 288, 711-7	22
1828	Expression and cellular distribution of $\alpha(v)$ integrins in β_1 integrin-deficient embryonic stem cell-derived cardiac cells. 2001 , 33, 521-32	16
1827	Inhibition of FGF-2-mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions. 2001 , 268, 169-78	19
1826	Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro. 2001 , 62, 315-26	76

1825	Effect of HGF-like basic hexapeptides on angiogenesis. 2001 , 62, 440-4	10
1824	Postnatal vasculogenesis. 2001 , 100, 157-63	101
1823	In vitro models of vasculogenesis and angiogenesis. 2001 , 81, 439-52	254
1822	Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. 2001 , 4, 314-21	41
1821	[The mechanisms of angiogenesis. Medical and therapeutic applications]. 2001 , 22, 1064-82	8
1820	Angiogenesis and reproduction. 2001 , 108, 777-783	32
1819	Cell-matrix interactions, alteration with aging and age associated diseases. A review. 2001 , 49, 349-52	14
1818	Theories of endometriosis. 2001 , 96, 21-34	191
1817	Interactions between endothelial cells and HIV-1. 2001 , 33, 371-90	53
1816	Domain IVa of laminin alpha5 chain is cell-adhesive and binds beta1 and alphaVbeta3 integrins through Arg-Gly-Asp. 2001 , 509, 181-5	74
1815	Antagonists of integrin $\alpha_5\beta_1$ in brain cancer. 2001 , 11, 499-502	
1814	Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). 2001 , 123, 1280-8	62
1813	Marching at the front and dragging behind: differential alphaVbeta3-integrin turnover regulates focal adhesion behavior. 2001 , 155, 1319-32	306
1812	Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. 2001 , 276, 47901-5	38
1811	Suppression of tumor angiogenesis by nonsteroidal anti-inflammatory drugs: a new function for old drugs. 2001 , 1, 808-11	6
1810	Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle and their modification in muscle pathology. 2001 , 6, d75-89	10
1809	rhVEGF and Experimental Rat Skin Flaps: Systemic or Local Administration and Morphological Characteristics. 2001 , 24, 743-751	7
1808	A Naturally Occurring Point Mutation in the β_3 Integrin MIDAS-like Domain Affects Differently $\alpha_5\beta_3$ and $\alpha_6\beta_3$ Receptor Function. 2001 , 86, 1425-1434	21

1807	Extracellular Signal-regulated Kinase (ERK) Activation Is Required for GP I β -dependent Endothelial Cell Migration. 2001 , 86, 1555-1562	4
1806	Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. 2001 , 6, D75-89	64
1805	Therapeutic anti-angiogenesis for malignant brain tumors. 2001 , 24, 423-30	7
1804	Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. 2001 , 49, 380-9; discussion 390	253
1803	Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. 2001 , 48, 151-7	190
1802	Pleiotropic and epistatic effects in sickle cell anemia. 2001 , 8, 105-10	20
1801	Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an α Integrin Antagonist. 2001 , 48, 151-157	143
1800	Anginex, a designed peptide that inhibits angiogenesis. 2001 , 354, 233-42	87
1799	Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins. 2001 , 356, 11-7	8
1798	Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of α and β integrins. 2001 , 356, 11-17	12
1797	Tumour Vasculature Targeting. 2001 , 233-254	2
1796	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. 2001 , 15, 1021-7	89
1795	Cytoskeletal involvement in apoptosis. 2001 , 5, 237-267	
1794	α β and α β Integrin Expression in Glioma Periphery. 2001 , 49, 380-390	177
1793	Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. 2001 , 59, 1333-42	94
1792	Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. 2001 , 61, 315-22	82
1791	Viper venom components affecting angiogenesis. 2001 , 31, 192-206	9
1790	Progress toward understanding vascular malformations. 2001 , 107, 1509-23	63

1789	Bone disease in myeloma. 2001 , 2, 271-83	10
1788	Brain metastases: biology and the role of the brain microenvironment. 2001 , 3, 467-75	27
1787	A preliminary study of angiogenesis in paediatric glioblastoma multiforme and its correlation with survival. 2001 , 17, 577-83	5
1786	Immunohistochemical evaluation of psoriatic plaques following selective photothermolysis of the superficial capillaries. 2001 , 145, 45-53	52
1785	Solid-phase syntheses of constrained RGD scaffolds and their binding to the $\alpha_5\beta_1$ integrin receptor. 2001 , 42, 7387-7391	28
1784	A convenient access to $\alpha_5\beta_1/\alpha_5\beta_3$ integrin ligand conjugates: regioselective solid-phase functionalisation of an RGD based peptide. 2001 , 42, 2787-2790	39
1783	Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. 2001 , 37, 97-114	94
1782	Antiangiogenic agents and their promising potential in combined therapy. 2001 , 39, 155-71	45
1781	Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane. 2001 , 55, 100-7	14
1780	Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. 2001 , 92, 1347-8	83
1779	Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats. 2001 , 58, 313-8	34
1778	Environmental modulation of alpha(v), alpha(2) and beta(1) integrin subunit expression in human oesophageal squamous cell carcinomas. 2001 , 25, 61-9	13
1777	Thiolutin, an inhibitor of HUVEC adhesion to vitronectin, reduces paxillin in HUVECs and suppresses tumor cell-induced angiogenesis. 2001 , 93, 307-16	50
1776	Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. 2001 , 93, 516-25	59
1775	Integrin alpha(v)beta(3) is involved in stimulated migration of vascular adventitial fibroblasts by basic fibroblast growth factor but not platelet-derived growth factor. 2001 , 83, 129-35	17
1774	Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the blockade of integrin alphavbeta3 on vascular endothelial cells. 2001 , 188, 394-402	50
1773	Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. 2001 , 264, 317-24	207
1772	Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. 2001 , 44, 128-37	60

1771	Breast cancer in the clinic: treatments past, treatments future. 2001 , 6, 487-95		8
1770	Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. 2001 , 4, 269-75		88
1769	Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. 2001 , 16, 319-27		45
1768	Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. 2001 , 224, 81-9		40
1767	Tissue-specific gene therapy directed to tumor angiogenesis. 2001 , 8, 819-27		68
1766	Angiogenesis and reproduction. 2001 , 108, 777-83		19
1765	Phenotype of the endothelium in the human term placenta. 2001 , 22, 32-43		65
1764	Monoclonal antibody strategies to block angiogenesis. 2001 , 6, 517-528		60
1763	Tumor angiogenesis as a therapeutic target. 2001 , 6, 1005-1024		103
1762	A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 620-4	11.5	178
1761	Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. 2001 , 21, 3192-205		113
1760	Antiangiogenic therapy in leukemia. 2001 , 106, 190-207		25
1759	Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. 2001 , 38, 389-97		60
1758	Collateral growth and angiogenesis around cortical stroke. 2001 , 32, 2179-84		250
1757	Integrin and growth factor receptor crosstalk. 2001 , 89, 1104-10		320
1756	Contortrostatin, a homodimeric disintegrin, actively disrupts focal adhesion and cytoskeletal structure and inhibits cell motility through a novel mechanism. 2001 , 8, 71-86		12
1755	Anginex, a designed peptide that inhibits angiogenesis. 2001 , 354, 233-242		145
1754	Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. 2001 , 276, 14187-94		108

1753	Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. 2001 , 8, 265-8	33
1752	Angiogenesis Protocols. 2001 ,	8
1751	General aspects of anti-angiogenesis and cancer therapy. 2001 , 1, 253-75	39
1750	Evidence of IL-18 as a novel angiogenic mediator. 2001 , 167, 1644-53	231
1749	Role of osteopontin in cellular signaling and toxicant injury. 2001 , 41, 723-49	287
1748	Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. 2001 , 155, 459-70	473
1747	Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. 2001 , 3, 186-96	106
1746	Cell-cell interactions in vascular development. 2001 , 52, 107-49	91
1745	An RGD sequence in the P2Y(2) receptor interacts with alpha(v)beta(3) integrins and is required for G(o)-mediated signal transduction. 2001 , 153, 491-501	137
1744	IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. 2001 , 166, 3890-9	132
1743	Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity. 2001 , 167, 5362-6	31
1742	Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. 2001 , 276, 31959-68	173
1741	Structure and function of a vimentin-associated matrix adhesion in endothelial cells. 2001 , 12, 85-100	135
1740	NCK and PAK participate in the signaling pathway by which vascular endothelial growth factor stimulates the assembly of focal adhesions. 2001 , 276, 22748-55	47
1739	The CK2 phosphorylation of vitronectin. Promotion of cell adhesion via the alpha(v)beta 3-phosphatidylinositol 3-kinase pathway. 2001 , 276, 16998-7006	40
1738	Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. 2001 , 276, 15240-8	177
1737	Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. 2001 , 276, 47171-7	42
1736	An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. 2001 , 15, 1389-97	75

1735	Cross talk between beta(1) and alpha(V) integrins: beta(1) affects beta(3) mRNA stability. 2001 , 12, 3126-38	55
1734	Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. 2001 , 276, 39562-8	155
1733	Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. 2001 , 276, 8135-41	133
1732	Hold that line. Angiomotin regulates endothelial cell motility. 2001 , 152, F35-6	8
1731	Integrins in vascular development. 2001 , 89, 566-72	92
1730	Integrin activation controls metastasis in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 1853-8	11.5 475
1729	Topical application of integrin antagonists inhibits proliferative retinopathy. 2001 , 33, 307-11	24
1728	Therapeutic inhibition of angiogenesis. 2001 , 46, 3-26	1
1727	Process extension and myelin sheet formation in maturing oligodendrocytes. 2001 , 132, 115-30	17
1726	Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. 2001 , 15, 1428-30	84
1725	A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. 2001 , 16, 125-32	146
1724	Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. 2002 , 17, 641-6	142
1723	Regulation of endothelial cell survival and apoptosis during angiogenesis. 2002 , 22, 887-93	208
1722	Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. 2002 , 277, 13371-4	22
1721	Three-dimensional model of the human platelet integrin alpha IIb beta 3 based on electron cryomicroscopy and x-ray crystallography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 14059-64	11.5 139
1720	P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. 2002 , 158, 1287-97	82
1719	Dynamin controls Beta 2 integrin avidity by modulating cytoskeletal constraint on integrin molecules. 2002 , 277, 32963-9	17
1718	Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 7455-60	11.5 142

1717	Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. 2002 , 45, 1045-51		174
1716	Rac regulates endothelial morphogenesis and capillary assembly. 2002 , 13, 2474-85		146
1715	Mechanisms of normal and tumor-derived angiogenesis. 2002 , 282, C947-70		551
1714	Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. 2002 , 31, 51-69		19
1713	An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. 2002 , 6, 664-672		
1712	Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. 2002 , 61 Suppl 2, ii96-9		141
1711	A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 178-83	11.5	135
1710	DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. 2002 , 277, 6779-87		39
1709	Mechanisms and future directions for angiogenesis-based cancer therapies. 2002 , 20, 3906-27		219
1708	Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. 2002 , 86, 244-9		104
1707	Microfilament-dependent movement of the beta3 integrin subunit within focal contacts of endothelial cells. 2002 , 16, 866-8		66
1706	The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. 2002 , 16, 1991-3		90
1705	Complex interactions between the laminin alpha 4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 16075-80	11.5	108
1704	Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. 2002 , 383, 1407-13		73
1703	Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. 2002 , 22, 108-14		108
1702	Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. 2002 , 15, 310-26		96
1701	Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. 2002 , 16, 2000-2		62
1700	Morphological characteristics of the microvasculature in healing myocardial infarcts. 2002 , 50, 71-9		137

1699	Recombinant human laminin-10 (alpha5beta1gamma1). Production, purification, and migration-promoting activity on vascular endothelial cells. 2002 , 277, 12741-8	104
1698	Vitronectin receptor alpha(V)beta(3) integrin antagonists: chemical and structural requirements for activity and selectivity. 2002 , 2, 531-42	27
1697	Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. 2002 , 8, 133-65	12
1696	Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. 2002 , 16, 1307-9	186
1695	Anticoagulants in thrombosis and cancer: the missing link. 2002 , 28, 45-52	64
1694	Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. 2002 , 4, 253-60	41
1693	Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?. 2002 , 9, 151-60	50
1692	TUMOR VASCULATURE AS A TARGET. 2002 , 123-cp2	1
1691	Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. 2002 , 157, 149-60	296
1690	Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. 2002 , 22, 2830-41	143
1689	Tiny dancers: the integrin-growth factor nexus in angiogenic signaling. 2002 , 158, 17-21	48
1688	Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. 2002 , 22, 5912-22	113
1687	Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. 2002 , 55, 569-74	56
1686	Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. 2002 , 277, 27109-19	24
1685	p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. 2002 , 156, 149-60	172
1684	Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. 2002 , 16, 1453-5	105
1683	Role of Akt signaling in vascular homeostasis and angiogenesis. 2002 , 90, 1243-50	791
1682	Direct myocardial revascularization and therapeutic angiogenesis. 2002 , 23, 1492-502	1

1681	Abnormal hepatic expression of fibrillin-1 in children with cholestasis. 2002 , 26, 637-46	13
1680	Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. 2002 , 99, 2045-53	49
1679	Role of matrix metalloproteinase-7 in angiogenesis associated with age-related macular degeneration. 2002 , 51, 127-31	5
1678	The Role of Integrins in the Human Reproductive Process.. 2002 , 48, 215-232	1
1677	An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. 2002 , 6, 664-672	117
1676	Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. 2002 , 19, 557-70	25
1675	In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. 2002 , 13, 561-70	75
1674	Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. 2002 , 41, 10519-28	72
1673	The alpha v integrin antagonists as novel anticancer agents: an update. 2002 , 11, 1765-74	46
1672	Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. 2002 , 273, 21-33	98
1671	The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. 2002 , 64, 148-61	76
1670	Adenovirus-mediated murine interferon-gamma receptor transfer enhances the efficacy of IFN-gamma in vivo. 2002 , 290, 1042-7	3
1669	Inhibitors of protein-protein interactions. 2002 , 12, 393-400	14
1668	Characterization of human chorionic gonadotropin as a novel angiogenic factor. 2002 , 87, 5290-6	274
1667	Endothelial cell heterogeneity and organ specificity. 2002 , 11, 81-90	118
1666	Ovarian Cancer. 2002 ,	1
1665	Main Sessions. 2002 , 81, S67-S74	
1664	Angiogenesis in non-small cell lung cancer. A new target for therapy. 2002 , 1, 325-38	4

1663	Thalidomide in cancer treatment: a potential role in the elderly?. 2002 , 19, 85-100	15
1662	Diastereoselective synthesis of new psi[(E)-CH=CMe]- and psi[(Z)-CH=CMe]-type alkene dipeptide isosteres by organocopper reagents and application to conformationally restricted cyclic RGD peptidomimetics. 2002 , 67, 6162-73	48
1661	A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. 2002 , 277, 43137-42	86
1660	Development of radiocontrast agents for vascular imaging: progress to date. 2002 , 2, 357-65	11
1659	Integrin-dependent interaction of human vascular endothelial cells on biomimetic peptide surfactant polymers. 2002 , 9, 59-73	19
1658	Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. 2002 , 60, 531-6	103
1657	ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. 2002 , 2002, pe7	109
1656	Cell-matrix adhesion research and the development of biotherapeutics. 2002 , 69, 17-23	2
1655	Angiogenesis: an expanding universe. 2002 , 33, 1061-3	13
1654	Advances towards understanding heart valve response to injury. 2002 , 11, 69-77	103
1653	Angiogenesis and anti-angiogenesis in neuroblastoma. 2002 , 38, 750-7	41
1652	Hypoxia as a target for combined modality treatments. 2002 , 38, 240-57	159
1651	Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. 2002 , 197, 239-50	87
1650	New Classes of MRI Contrast Agents. 2002 , 123-164	119
1649	The Role of $\alpha_5\beta_1$ in Prostate Cancer Progression. 2002 , 4, 191-194	174
1648	Anti-angiogenic agents for the treatment of brain tumors. 2002 , 12, 477-99	11
1647	. 2002 ,	5
1646	Acute Hyperglycaemia Induces Changes in the Transcription Levels of 4 Major Genes in Human Endothelial Cells: Macroarrays-based Expression Analysis. 2002 , 87, 141-148	23

1645	Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. 2002 , 22, 7667-77	148
1644	Molecular targets as therapeutic strategies in the management of breast cancer. 2002 , 12, 341-51	8
1643	The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo. 2002 , 81, 599-607	42
1642	Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. 2002 , 46, 270-8	20
1641	Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. 2002 , 83, 241-51	57
1640	Acute cellular rejection following human heart transplantation is associated with increased expression of vitronectin receptor (integrin alphavbeta3). 2002 , 2, 129-33	9
1639	Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. 2002 , 70, 547-60	132
1638	The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 , 12, 83-8	53
1637	Angiogenesis in bladder cancer--prognostic marker and target for future therapy. 2002 , 11, 85-100	44
1636	Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues. 2002 , 3, 1078-88	20
1635	Immunocytokines: Versatile Molecules for Biotherapy of Malignant Disease. 2002 , 311-346	
1634	Nuclear medicine applications in molecular imaging. 2002 , 16, 352-61	70
1633	Targeted imaging using ultrasound. 2002 , 16, 362-77	192
1632	Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. 2002 , 268, 252-75	207
1631	alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. 2002 , 98, 690-7	162
1630	Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. 2002 , 102, 469-75	61
1629	Combined modality radioimmunotherapy. Promise and peril. 2002 , 94, 1320-31	34
1628	Combined vascular targeted imaging and therapy: a paradigm for personalized treatment. 2002 , 39, 65-71	19

1627	Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. 2002 , 193, 253-62	29
1626	Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. 2002 , 45, 262-7	34
1625	The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?. 2002 , 71, 293-9	37
1624	Cyclooxygenase, lipoxygenase and tumor angiogenesis. 2002 , 59, 799-807	121
1623	Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. 2002 , 29, 754-9	68
1622	Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. 2002 , 29, 699-709	26
1621	[Evaluating angiogenesis and osteogenesis modified by vascular endothelial growth factor (VEGF)]. 2002 , 6, 175-82	11
1620	Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists. 2002 , 12, 1379-82	14
1619	Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. 2002 , 6, 534-41	59
1618	Angiogenesis modulates the tumour immune response. 1998 , 79, 363-8	23
1617	Recent advances in cutaneous angiogenesis. 2002 , 147, 418-25	49
1616	Dermatological aspects of angiogenesis. 2002 , 147, 841-52	38
1615	Biological behaviour and clinical implications of micrometastases. 2000 , 87, 1629-39	59
1614	Angiogenesis and Antiangiogenic Therapy. 2002 , 26, 6-59	21
1613	Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. 2002 , 54, 1259-75	25
1612	Four-dimensional orthogonal solid-phase synthesis of new scaffolds based on cyclic tetra-peptides. 2002 , 43, 2029-2032	19
1611	Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. 2002 , 9, 587-96	20
1610	Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. 2002 , 9, 547-53	17

1609	Anti-angiogenic activity of the purine analog 6-thioguanine. 2002 , 16, 1490-9		26
1608	Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. <i>Oncogene</i> , 2002 , 21, 87-95	9.2	30
1607	Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. <i>Oncogene</i> , 2002 , 21, 3889-97	9.2	56
1606	Networks and crosstalk: integrin signalling spreads. 2002 , 4, E65-8		649
1605	Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. 2002 , 8, 27-34		561
1604	A reevaluation of integrins as regulators of angiogenesis. 2002 , 8, 918-21		483
1603	Specialization of tumour vasculature. 2002 , 2, 83-90		574
1602	Role of integrins in cell invasion and migration. 2002 , 2, 91-100		1422
1601	Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. 2002 , 86, 788-95		101
1600	Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. 2002 , 86, 803-10		20
1599	The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. 2002 , 12, 105-12		79
1598	Anticoagulants in thrombosis and cancer: the missing link. 2002 , 2, 227-33		22
1597	Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. 2002 , 19, 665-72		16
1596	Angiogenesis in psoriasis. 2002 , 5, 231-6		115
1595	Anti-angiogenic therapy: rationale, challenges and clinical studies. 2002 , 5, 237-56		108
1594	Angiogenesis and antiangiogenic strategies in pancreatic cancer. 2003 , 33, 79-88		22
1593	Therapeutic inhibition of angiogenesis. 2003 , 25, 185-200		3
1592	Molecular targets in the inhibition of angiogenesis. 2003 , 7, 527-41		10

1591	Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. 2003 , 20, 413-20	63
1590	Positron emission tomography (PET): expanding the horizons of oncology drug development. 2003 , 21, 309-40	20
1589	A common mechanism for the mechanosensitive regulation of apoptosis in different cell types and for different mechanical stimuli. 2003 , 8, 531-8	19
1588	Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. 2003 , 64, 193-201	16
1587	Targeting diphtheria toxin A-chain transcription to activated endothelial cells using an E-selectin promoter. 2003 , 6, 31-8	7
1586	Discovery and development of anti-angiogenic peptides: A structural link. 2003 , 6, 83-91	18
1585	alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. 2003 , 6, 105-19	170
1584	Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. 2003 , 6, 213-24	38
1583	Expression and characterization of recombinant NH2-terminal cell binding fragment of vitronectin in E. coli. 2003 , 25, 1973-5	2
1582	Lake Tahoe invitation meeting 2002. 2003 , 10, 223-57	11
1581	Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?. 2003 , 22, 103-15	44
1580	Structure and function of RGD peptides involved in bone biology. 2003 , 60, 119-32	131
1579	A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. 2003 , 40, 77-89	60
1578	Optimization of protein therapeutics by directed evolution. 2003 , 8, 118-26	40
1577	Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. 2003 , 22, 721-48	193
1576	Tyrosine kinase signal specificity: lessons from the HGF receptor. 2003 , 28, 527-33	146
1575	Angiogenic response induced by acellular brain scaffolds grafted onto the chick embryo chorioallantoic membrane. 2003 , 989, 9-15	54
1574	The role of COX-2 in angiogenesis and rheumatoid arthritis. 2003 , 74, 282-90	60

1573	High flow drives vascular endothelial cell proliferation during flow-induced arterial remodeling associated with the expression of vascular endothelial growth factor. 2003 , 75, 1-11	59
1572	Modulation of VE-cadherin and PECAM-1 mediated cell-cell adhesions by mitogen-activated protein kinases. 2003 , 90, 121-37	37
1571	Molecular imaging: The latest generation of contrast agents and tissue characterization techniques. 2003 , 90, 443-53	27
1570	RGD-Porphyrin Conjugates: Synthesis and Potential Application in Photodynamic Therapy. 2003 , 2003, 1486-1493	37
1569	Endothelial cell-matrix interactions. 2003 , 60, 13-22	82
1568	Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. 2003 , 60, 107-14	477
1567	Microfilaments and microtubules maintain endothelial integrity. 2003 , 60, 115-27	79
1566	Angiogenesis of the heart. 2003 , 60, 138-58	38
1565	Biology of angiogenesis in tumors of the gastrointestinal tract. 2003 , 60, 199-207	88
1564	alphaV Vitronectin receptors in vascular-mediated disorders. 2003 , 23, 190-9	31
1563	Kombinatorische Flüssigphasensynthese von Bibliotheken: auf der Suche nach Modulatoren für Protein-Protein- und Protein-DNA-Wechselwirkungen in der zellulären Signaltransduktion. 2003 , 115, 4270-4309	31
1562	Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. 2003 , 42, 4138-76	159
1561	Incorporation of thioether building blocks into an alphaVbeta3-specific RGD peptide: synthesis and biological activity. 2003 , 71, 686-95	15
1560	Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. 2003 , 267, 1-12	41
1559	In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting. 2003 , 38, 825-36	15
1558	Peptide-targeted PEG-liposomes in anti-angiogenic therapy. 2003 , 254, 55-8	73
1557	Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones. 2003 , 13, 165-9	10
1556	Thiophene-based vitronectin receptor antagonists. 2003 , 13, 503-6	10

1555	Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. 2003 , 12, 296-306	35
1554	Severely impaired wound healing in the collagenase-resistant mouse. 2003 , 120, 153-63	45
1553	Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis. 2003 , 120, 1100-9	29
1552	Inflammatory events are involved in acne lesion initiation. 2003 , 121, 20-7	312
1551	Role of alpha8 integrin in mesangial cell adhesion, migration, and proliferation. 2003 , 64, 119-27	46
1550	Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. 2003 , 1, 2097-102	76
1549	[Chronic venous venous ulcer cruris. Pathogenesis and the significance of "aggressive micro-milieus"]. 2003 , 1, 58-67; quiz 68	9
1548	Significance of angiogenesis in cancer therapy. 1998 , 85, 1044-55	36
1547	Integrin-dependent pathologies. 2003 , 200, 481-7	84
1546	Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. 2003 , 88, 553-9	24
1545	Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. 2003 , 424, 391-7	492
1544	Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. 2003 , 10, 63-81	46
1543	Ocular neovascularization: a valuable model system. <i>Oncogene</i> , 2003 , 22, 6537-48	9.2 90
1542	Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. 2003 , 83, 927-38	37
1541	Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design. 2003 , 46, 4393-404	111
1540	Biology of colorectal liver metastases. 2003 , 12, 135-50	17
1539	Angiogenesis and hepatic colorectal metastases. 2003 , 12, 151-63	9
1538	Mechanobiology and diseases of mechanotransduction. 2003 , 35, 564-77	597

1537	The tissue engineering puzzle: a molecular perspective. 2003 , 5, 441-63	119
1536	Angiogenesis as a target in rheumatoid arthritis. 2003 , 62 Suppl 2, ii60-7	108
1535	Synthesis of 5-Carbonyl-1,3-dihydro- 1,3-dioxo-2H-isoindole-2-propanoic Acid Integrin Antagonists. 2003 , 33, 2109-2117	1
1534	Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. 2003 , 108, 336-41	400
1533	Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. 2003 , 162, 2059-68	106
1532	Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. 2003 , 38, 660-7	47
1531	Amphiphysin1 inhibits vitronectin-mediated cell adhesion, spreading, and migration in vitro. 2003 , 301, 769-75	7
1530	Specific alpha v integrin receptors modulate K1735 murine melanoma cell behavior. 2003 , 308, 814-9	12
1529	Identification of redundant angiogenic sites in laminin alpha1 and gamma1 chains. 2003 , 285, 189-95	35
1528	Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell-cell and cell-ECM interactions in regulating cell viability. 2003 , 286, 115-27	58
1527	Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. 2003 , 48, 257-93	757
1526	The tendon treatment center: new horizons in the treatment of tendinosis. 2003 , 19 Suppl 1, 213-23	38
1525	Angiogenesis and vasculogenesis in pregnancy. 2003 , 110 Suppl 1, S10-8	309
1524	Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. 2003 , 21, 2667-77	11
1523	Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. 2003 , 117, 1037-46	472
1522	Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. 2003 , 39, 917-26	210
1521	Nanoparticle-mediated gene delivery to tumour neovasculature. 2003 , 9, 2-4	41
1520	Resistance in the anti-angiogenic era: nay-saying or a word of caution?. 2003 , 9, 24-9	40

1519	Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging. 2003 , 30, 1-9	65
1518	Foot-and-mouth disease virus receptors: comparison of bovine alpha(V) integrin utilization by type A and O viruses. 2003 , 77, 2500-11	66
1517	The fibroblast growth factors. 2003 , 747-781	1
1516	A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. 2003 , 102, 184-91	161
1515	Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. 2003 , 60, 1135-57	124
1514	Mechanisms in Carcinogenesis and Cancer Prevention. 2003 ,	
1513	Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro. 2003 , 10, 1-16	15
1512	Update on GPIIb/IIIa antagonists. 2003 , 13, 1173-1188	2
1511	Integrin beta3 Leu33Pro homozygosity and risk of cancer. 2003 , 95, 1150-7	65
1510	Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 11435-8	11.5 61
1509	VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. 2003 , 17, 1931-3	34
1508	The effect of ethanol exposure on extraembryonic vascular development in the chick area vasculosa. 2003 , 175, 84-97	17
1507	Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. 2003 , 107, 1046-52	109
1506	Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha V integrin expression. 2003 , 93, e72	5
1505	Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. 2003 , 5, 188-96	24
1504	Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. 2003 , 116, 3479-89	86
1503	Free radicals and lipid signaling in endothelial cells. 2003 , 5, 195-203	26
1502	Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. 2003 , 1, 291-9	39

1501	Connective Tissue Growth Factor and Its Correlation to Other Growth Factors in Experimental Granulation Tissue. 2003 , 44, 19-29		16
1500	Development and characterization of endothelial cells from rat microlymphatics. 2003 , 1, 101-19		28
1499	Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. 2003 , 44, 937-48		11
1498	Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. 2003 , 12, 1899-924		31
1497	Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. 2003 , 278, 19272-9		57
1496	Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. 2003 , 278, 25902-9		104
1495	Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5396-400	11.5	79
1494	Platelet and osteoclast beta3 integrins are critical for bone metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 14205-10	11.5	194
1493	Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. 2003 , 107, 455-60		309
1492	Development of Kidney Blood Vessels. 2003 , 251-266		2
1491	Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. 2003 , 162, 933-43		224
1490	Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. 2003 , 64, 1076-84		85
1489	Intra-plaque production of platelet-activating factor correlates with neoangiogenesis in human carotid atherosclerotic lesions. 2003 , 12, 327		
1488	Ultrasonic enhancement of /spl alpha//sub v//spl beta//sub 3/ expressing-cells with targeted contrast agents.		
1487	Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. 2003 , 4, 123-31		226
1486	Endothelial expression of the alpha6beta4 integrin is negatively regulated during angiogenesis. 2003 , 116, 3771-81		37
1485	Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration. 2003 , 23, 2165-71		77
1484	Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. 2003 , 9, 1545-64		142

1483	Tumor angiogenesis: a potential target in cancer control by phytochemicals. 2003 , 3, 205-17	59
1482	Cell adhesion molecules: potential therapeutic and diagnostic implications. 2004 , 93, 157-74	5
1481	IS20I, a Specific $\alpha\beta$ Integrin Inhibitor, Reduces Glioma Growth in Vivo. 2003 , 52, 177-186	2
1480	The role of platelet receptors and adhesion molecules in coronary artery disease. 2003 , 14, 65-79	30
1479	IS20I, a specific $\alpha\text{v}\beta 3$ integrin inhibitor, reduces glioma growth in vivo. 2003 , 52, 177-85; discussion 185-6	29
1478	Signaling through JAM-1 and $\alpha\text{v}\beta 3$ is required for the angiogenic action of bFGF: dissociation of the JAM-1 and $\alpha\text{v}\beta 3$ complex. 2003 , 102, 2108-14	116
1477	Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. 2003 , 89, 530-537	19
1476	Peptidomimetics: Modern Approaches and Medical Perspectives. 2003 , 354-365	
1475	Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. 2003 , 90, 577-85	39
1474	IS20I, a Specific $\alpha\beta$ Integrin Inhibitor, Reduces Glioma Growth in Vivo. 2003 ,	
1473	Ultrasonic Analysis of Peptide- and Antibody-Targeted Microbubble Contrast Agents for Molecular Imaging of $\alpha\beta$ -Expressing Cells. 2004 , 3, 153535002004031	1
1472	Near-Infrared Optical Imaging of Integrin $\alpha\beta$ in Human Tumor Xenografts. 2004 , 3, 153535002004041	
1471	Adult neoplasia: overview. 2004 , 279-287	
1470	Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro. 2004 , 279, 18247-55	53
1469	Eicosanoid regulation of angiogenesis in tumors. 2004 , 30, 119-25	33
1468	Red light, green light: signals that control endothelial cell proliferation during embryonic vascular development. 2004 , 3, 1506-11	28
1467	Colon cancer angiogenesis and antiangiogenic therapy. 2004 , 13, 631-41	15
1466	Ocular neovascularisation and excessive vascular permeability. 2004 , 4, 1395-402	60

1465	Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. 2004 , 4, 129-40	13
1464	Role of thrombin in angiogenesis and tumor progression. 2004 , 30, 63-9	90
1463	Tissue factor and fibrin in tumor angiogenesis. 2004 , 30, 31-44	108
1462	Methods in Endothelial Cell Biology. 2004 ,	13
1461	Principles of Molecular Oncology. 2004 ,	6
1460	Senescent impairment in synergistic cytokine pathways that provide rapid cardioprotection in the rat heart. 2004 , 199, 797-804	40
1459	Angiogenesis assays in the chick CAM. 2005 , 294, 123-36	33
1458	The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. 2004 , 15, 2834-41	116
1457	Immunohistochemical identification of an extracellular matrix scaffold that microguides capillary sprouting in vivo. 2004 , 52, 1063-72	69
1456	Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I. 2004 , 117, 2731-44	62
1455	Integrin-linked kinase regulates endothelial cell survival and vascular development. 2004 , 24, 8134-44	119
1454	Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. 2004 , 64, 2751-8	51
1453	Down syndrome candidate region 1,a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. 2004 , 41, 334-44	66
1452	Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. 2004 , 109, 1564-9	51
1451	Cloning and characterization of Adinbitor, a novel disintegrin from the snake venom of Agkistrodon halys brevicaudus stejneger. 2004 , 36, 425-9	16
1450	Integrins and angiogenesis. 2004 , 64, 207-38	230
1449	Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.. 2004 , 14, 529	3
1448	Alphav-integrin utilization in human beta-cell adhesion, spreading, and motility. 2004 , 279, 17731-7	57

1447	alphavbeta3 integrin-dependent endothelial cell dynamics in vivo. 2004 , 131, 2887-97	60
1446	Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor by distinct regulation of the gene and protein expression profile in endothelial cells. 2004 , 279, 23766-72	48
1445	The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. 2004 , 279, 1513-25	215
1444	Characterization of smooth muscle cell and pericyte differentiation in the rat retina in vivo. 2004 , 45, 2795-806	159
1443	The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. 2004 , 279, 4862-8	103
1442	Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. 2004 , 200, 1657-66	32
1441	Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. 2004 , 36, 524-33	61
1440	Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. 2004 , 14, 100-13	57
1439	Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. 2004 , 109, 1314-9	60
1438	Synovial expression of osteopontin correlates with angiogenesis in juvenile idiopathic arthritis. 2004 , 43, 1091-6	20
1437	COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cells. 2004 , 57, 553-5	3
1436	Local rh-VEGF administration enhances skin flap survival more than other types of rh-VEGF administration: a clinical, morphological and immunohistochemical study. 2004 , 13, 682-90	32
1435	Targeted therapy for brain tumours. 2004 , 3, 499-508	173
1434	Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. 2004 , 11, 363-70	28
1433	Retroviral delivery of homeobox D3 gene induces cerebral angiogenesis in mice. 2004 , 24, 1280-7	32
1432	Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. 2004 , 95, 579-88	174
1431	PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin. 2004 , 97, 157-71	34
1430	Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. 2004 , 5, 329-39	429

1429	Angiogenesis and its role in colorectal tumor and metastasis formation. 2004 , 31, 3-9	38
1428	Molecular imaging with single photon emission computed tomography. How new tracers can be employed in the nuclear medicine clinic. 2004 , 23, 51-7	7
1427	Targeted imaging using ultrasound contrast agents. Progress and opportunities for clinical and research applications. 2004 , 23, 18-29	102
1426	Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. 2004 , 1654, 51-67	48
1425	Roles of alphav integrins in vascular biology and pulmonary pathology. 2004 , 16, 552-7	79
1424	Quantitative angiogenesis assays in vivo--a review. 2004 , 7, 1-16	73
1423	A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. 2004 , 21, 119-28	91
1422	Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. 2004 , 21, 129-38	57
1421	Liposomes modified with cyclic RGD peptide for tumor targeting. 2004 , 12, 257-64	125
1420	Angiogenesis in neuroblastoma. 2004 , 1028, 133-42	55
1419	Expression of integrin subunits alphav and beta3 in acute lung inflammation. 2004 , 121, 383-90	18
1418	Anti-migratory and anti-angiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. 2004 , 7, 323-33	27
1417	Development of a novel optical bionanosensor. 2004 , 19, 1505-11	18
1416	Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model. 2004 , 14, 2567-70	5
1415	Mathematical modeling of tumor-induced angiogenesis. 2004 , 49, 111-87	231
1414	Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. 2004 , 53, 576-84	62
1413	Haemangiomas are formed by cells expressing high levels of alphavbeta3 integrin and lacking acetylated LDL uptake. 2004 , 203, 700-9	8
1412	Angiogenic response induced by acellular aortic matrix in vivo. 2004 , 281, 1303-7	19

1411	The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes. 2004 , 34, 1608-16	25
1410	Vascular-targeting therapies for treatment of malignant disease. 2004 , 100, 2491-9	274
1409	Modulation of prostate cancer growth in bone microenvironments. 2004 , 91, 686-705	61
1408	A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. 2004 , 58, 1215-27	146
1407	Imaging of angiogenesis. 2004 , 11, 617-33	35
1406	Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3. 2004 , 14, 657-61	8
1405	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. 2004 , 50, 87-100	268
1404	Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists. 2004 , 14, 1471-6	15
1403	Peptide-mediated gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. 2004 , 12, 215-21	29
1402	MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. 2004 , 15, 41-9	211
1401	Integrins: roles in cancer development and as treatment targets. 2004 , 90, 561-5	439
1400	Effect of shear stress on microvessel network formation of endothelial cells with in vitro three-dimensional model. 2004 , 287, H994-1002	53
1399	A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. 2004 , 15, 433-43	119
1398	Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. 2004 , 43, 6519-34	35
1397	Human integrin alphavbeta5: homology modeling and ligand binding. 2004 , 47, 4166-77	51
1396	The role of integrins in tumor angiogenesis. 2004 , 18, 991-1006, vii	75
1395	Therapeutic strategies that selectively target and disrupt established tumor vasculature. 2004 , 18, 1023-37, viii	10
1394	Targeted ultrasound imaging using microbubbles. 2004 , 22, 283-98, vii	39

1393	Breast cancer: the role of angiogenesis and antiangiogenic therapy. 2004 , 18, 1071-86, ix	11
1392	Vascular endothelium and immune responses: implications for inflammation and angiogenesis. 2004 , 30, 97-114	56
1391	Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist. 2004 , 28, 359-66	27
1390	Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. 2004 , 126, 5730-9	186
1389	Cell Migration. 2004 ,	2
1388	Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?. 2004 , 6, 128-32	18
1387	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. 2004 , 7, 125-38	62
1386	c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. 2004 , 317, 133-41	35
1385	Tenascin-C deposition requires beta3 integrin and Src. 2004 , 322, 935-42	11
1384	Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. 2004 , 31, 11-9	174
1383	Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. 2004 , 165, 247-58	98
1382	Desmin-positive pericytes in the chick embryo chorioallantoic membrane in response to fibroblast growth factor-2. 2004 , 68, 13-9	18
1381	Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. 2004 , 35, 739-44	47
1380	The involvement of integrin alphavbeta3 in polymorphonuclear leukocyte-induced angiogenesis in bovine aortic endothelial cells. 2004 , 75, 421-34	4
1379	Crystal structure of schistatin, a disintegrin homodimer from saw-scaled viper (Echis carinatus) at 2.5 Å resolution. 2004 , 341, 829-37	47
1378	Stimulation of in vitro angiogenesis by nitric oxide through the induction of transcription factor ETS-1. 2004 , 36, 114-22	13
1377	Expression of angiopoietin 1 and 2 in ectopic endometrium on the chicken chorioallantoic membrane. 2004 , 81 Suppl 1, 869-75	15
1376	Drug delivery systems using immobilized intact liposomes: a comparative and critical review. 2004 , 1, 299-312	23

1375	Gene microarray analysis of human brain arteriovenous malformations. 2004 , 54, 410-23; discussion 423-5	102
1374	Tendon Treatment Center. 2004 , 12, 210-219	1
1373	Aggretin, a snake venom-derived endothelial integrin alpha 2 beta 1 agonist, induces angiogenesis via expression of vascular endothelial growth factor. 2004 , 103, 2105-13	41
1372	Antiangiogenic therapy. 2004 , 10, 27-37	12
1371	Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. 2004 , 48, 411-24	432
1370	Atomic force microscopy measurement of leukocyte-endothelial interaction. 2004 , 286, H359-67	92
1369	Structure-activity relationship studies on cyclic RGD peptides utilizing novel alkene dipeptide isosteres. 2004 , 124, 269-77	0
1368	Novel Imaging Agents for Molecular MR Imaging of Cancer. 2005 , 1309-1341	
1367	Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138. 2005 , 45, 109-13	2
1366	Molecular imaging in transplantation: basic concepts and strategies for potential application. 2005 , 26, 947-55	3
1365	Physiological mechanisms of tumor-cell invasion and migration. 2005 , 20, 194-200	103
1364	Anti-angiogenic properties of plaunotol. 2005 , 16, 401-7	9
1363	Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species. 2005 , 45, 462-7	6
1362	Molecular imaging with targeted ultrasound contrast microbubbles. 2005 , 171-91	15
1361	Normal Cutaneous Wound Healing. 2005 , 31, 674-686	324
1360	Transglutaminase-mediated oligomerization of the fibrin(ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. 2005 , 105, 3561-8	73
1359	Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. 2005 , 105, 1992-9	102
1358	Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. 2005 , 105, 4353-61	53

1357	Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. 2005 , 296, 133-41	23
1356	Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 3763-71	3-4 37
1355	Angiogenesis and the growth potential of craniopharyngiomas. 2005 , 16, 219-28	2
1354	Bone-targeting macromolecular therapeutics. 2005 , 57, 1049-76	157
1353	Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. 2005 , 5739-41	169
1352	Integrins as a distinct subtype of dependence receptors. 2005 , 12, 1021-30	72
1351	Variable impairment of wound healing in the heterozygous collagenase-resistant mouse. 2005 , 13, 27-40	10
1350	Targeting tumor angiogenic vasculature using polymer-RGD conjugates. 2005 , 102, 191-201	133
1349	Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. 2005 , 293, 404-410	159
1348	VEGF-activated angiogenesis during bone regeneration. 2005 , 63, 1310-6	120
1347	Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. 2005 , 94, 374-88	50
1346	Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. 2005 , 96, 16-24	23
1345	alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca ²⁺ /calmodulin-dependent protein kinase IV. 2005 , 95, 1214-23	55
1344	Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. 2005 , 202, 205-14	94
1343	Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. 2005 , 26, 94-103	11
1342	In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. 2005 , 113, 881-90	19
1341	Adhesion molecules as determinants of disease: from molecular biology to surgical research. 1996 , 83, 588-601	82
1340	Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. 2005 , 43, 225-36	83

1339	Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. 2005 , 53, 621-7	240
1338	Self-assembled nanoparticles of bile acid-modified glycol chitosans and their applications for cancer therapy. 2005 , 13, 167-175	31
1337	Influence of histamine on the process of human trophoblast differentiation. 2005 , 54 Suppl 1, S78-9	3
1336	Integrin-actin interactions. 2005 , 62, 1081-99	152
1335	Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?. 2005 , 55, 67-81	24
1334	Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells. 2005 , 9, 271-281	4
1333	Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. 2005 , 11, 229-35	43
1332	Water extracts of <i>Aralia elata</i> root bark enhances migration and matrix metalloproteinases secretion in porcine coronary artery endothelial cells. 2005 , 10, 372-377	5
1331	Integrin signaling in malignant melanoma. 2005 , 24, 195-222	219
1330	Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. 2005 , 22, 1-10	231
1329	Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. 2005 , 22, 933-9	63
1328	Activation of nuclear factor kappa B (NF-kappaB) by connective tissue growth factor (CCN2) is involved in sustaining the survival of primary rat hepatic stellate cells. 2005 , 3, 14	18
1327	Anti-lipid phosphate phosphohydrolase-3 (LPP3) antibody inhibits bFGF- and VEGF-induced capillary morphogenesis of endothelial cells. 2005 , 3, 9	22
1326	Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. 2005 , 65, 151-8	33
1325	Angiogenesis in rheumatoid arthritis. 2005 , 10, 1739-53	75
1324	Multimodality tumor imaging targeting integrin alphavbeta3. 2005 , 39, S14-25	51
1323	Expression and function of laminins in the embryonic and mature vasculature. 2005 , 85, 979-1000	410
1322	Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. 2005 , 168, 643-53	112

1321	A Novel alphavbeta3 integrin antagonist suppresses neointima formation for more than 4 weeks after balloon injury in rats. 2005 , 25, 1376-82	10
1320	Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. 2005 , 2, e70	398
1319	Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer. 2005 , 11, 2119-34	17
1318	alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. 2005 , 202, 61-72	36
1317	Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. 2005 , 170, 993-1004	147
1316	Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. 2005 , 11, 7851-60	129
1315	Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 2040-5	11.5 47
1314	Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. 2005 , 68, 1543-50	26
1313	Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. 2005 , 65, 5292-300	57
1312	Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. 2005 , 11, 6270-9	191
1311	Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. 2005 , 115, 1542-51	151
1310	Role of angiogenesis in cardiovascular disease: a critical appraisal. 2005 , 112, 1813-24	347
1309	Novel integrin antagonists derived from thrombospondins. 2005 , 11, 849-66	26
1308	Unoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. 2005 , 19, 771-80	74
1307	Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. 2005 , 103, 1058-66	24
1306	New antiangiogenic strategies for the treatment of proliferative synovitis. 2005 , 14, 1-17	28
1305	Thyroid hormones: rapid reply by surface delivery only. 2005 , 146, 2861-3	18
1304	Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. 2005 , 34, 169-76	41

1303	A SNAKE VENOM DISINTEGRIN WITH POTENT ANTITUMOR AND ANTIANGIOGENIC ACTIVITY. 2005 , 24, 113-142	2
1302	Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. 2005 , 12, 634-43	74
1301	Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. 2005 , 111, 3248-54	163
1300	Use of Synthetic Peptides for Non-viral Gene Delivery. 2005 , 87-102	1
1299	Pro-angiogenic signaling by the endothelial presence of CEACAM1. 2005 , 280, 2361-9	47
1298	Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. 2005 , 280, 1077-85	45
1297	Molecular Imaging. 2005 ,	
1296	Integrins. 2005 , 201-227	
1295	Bone Metastasis. 2005 ,	1
1294	Convenient solid-phase synthesis of diethylenetriaminepenta-acetic acid (DTPA)- conjugated cyclic RGD peptide analogues. 2005 , 20, 547-56	9
1293	Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. 2005 , 53, 104-10	54
1292	Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model. 2005 , 52, 59-65	31
1291	Drugs to suppress cough. 2005 , 14, 19-27	34
1290	Integration/Interaction of Oncologic Growth. 2005 ,	3
1289	Role of Brain Microenvironment in Brain Metastases. 2005 , 127-147	
1288	Specific targets in tumor tissue for the delivery of therapeutic genes. 2005 , 5, 157-71	33
1287	Targeting invasion induction as a therapeutic strategy for the treatment of cancer. 2005 , 5, 489-503	16
1286	Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. 2005 , 23, 1295-311	169

1285	Quantifying molecular specificity of alphavbeta3 integrin-targeted optical contrast agents with dynamic optical imaging. 2005 , 10, 034019	25
1284	Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. 2005 , 27, 525	5
1283	Anti-angiogenic strategies for cancer therapy (Review). 2005 , 27, 563	2
1282	Angiogenesis en la psoriasis. 2005 , 20, 438-442	
1281	VEGF profiling and angiogenesis in human microtissues. 2005 , 118, 213-29	75
1280	. 2005 , 93, 809-818	25
1279	Cardiovascular molecular imaging. 2005 , 35, 73-81	31
1278	Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. 2005 , 7, 1001-10	118
1277	PET imaging of tumor integrin expression.	
1276	Contrast ultrasound assessment of angiogenesis by perfusion and molecular imaging. 2005 , 5, 447-55	14
1275	Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. 2005 , 39, 293-306	176
1274	Neutral postgrafted colloidal particles for gene delivery. 2005 , 16, 608-14	44
1273	Imaging Gene Expression. 2005 , 284-386	
1272	Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. 2005 , 11, 6317-24	61
1271	New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. 2005 , 12, 1168-75	81
1270	Crystal structure of the disintegrin heterodimer from saw-scaled viper (<i>Echis carinatus</i>) at 1.9 Å resolution. 2005 , 44, 11058-66	35
1269	Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1670-80	6.1 70
1268	The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. 2005 , 103, 526-37	8

1267	Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization. 2005 , 16, 729-34	30
1266	Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. 2005 , 48, 4204-7	70
1265	Genetic and functional analysis of Haemophilus somnus high molecular weight-immunoglobulin binding proteins. 2005 , 39, 159-70	25
1264	Expression of the integrin genes in the developing cochlea of rats. 2005 , 201, 21-6	18
1263	Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. 2005 , 222, 89-94	10
1262	Vascular changes in the subventricular zone after distal cortical lesions. 2005 , 194, 139-50	40
1261	Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. 2005 , 166, 901-11	42
1260	Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. 2005 , 167, 193-211	69
1259	Cellular interactions with elastin. 2005 , 53, 390-8	91
1258	PMA-enhanced neutrophil [18F]FDG uptake is independent of integrin occupancy but requires PI3K activity. 2005 , 32, 561-6	8
1257	Volume, trend and citation analyses of skin related publications from 1966 to 2003. 2005 , 37, 125-36	10
1256	Angiogenesis and stem cell transplantation as potential treatments of cerebral ischemic stroke. 2005 , 12, 47-62	41
1255	Non-viral Gene Therapy. 2005 ,	15
1254	Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. 2006 , 8, R20	205
1253	Nanotechnology for antiangiogenic cancer therapy. 2006 , 1, 17-22	17
1252	Noninvasive MRI of endothelial cell response to human breast cancer cells. 2006 , 8, 207-13	13
1251	Dipeptidyl Aminopeptidases. 2006 ,	2
1250	Inhibition of experimental metastasis by targeting the HU1V26 cryptic epitope in collagen. 2006 , 168, 1576-86	26

1249	Synthesis of poly(beta-amino ester)s with thiol-reactive side chains for DNA delivery. 2006 , 128, 12726-34	188
1248	Integrins and angiogenesis: a sticky business. 2006 , 312, 651-8	174
1247	Evidence for a differential functional regulation of the two beta(3)-integrins alpha(V)beta(3) and alpha(IIb)beta(3). 2006 , 312, 925-37	20
1246	Biosensing using lipid bilayers suspended on porous silicon. 2006 , 22, 7078-83	69
1245	Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. 2006 , 130, 2060-73	308
1244	Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. 2006 , 6, 669-76	836
1243	Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. 2006 , 49, 4526-34	100
1242	^{99m} Tc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. 2006 , 17, 1069-76	61
1241	Delivery of sphingosine 1-phosphate from poly(ethylene glycol) hydrogels. 2006 , 7, 1335-43	49
1240	Downregulation of vascular endothelial growth factor and integrinbeta3 by endostatin in a mouse model of retinal neovascularization. 2006 , 82, 74-80	18
1239	Regulators of angiogenesis and strategies for their therapeutic manipulation. 2006 , 38, 333-57	123
1238	Macromolecular MRI contrast agents for imaging tumor angiogenesis. 2006 , 60, 353-66	130
1237	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. 2006 , 54, 1003-12	86
1236	Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. 2006 , 296, 177-89	231
1235	Molecular imaging of myocardial infarction. 2006 , 41, 921-33	40
1234	Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli. 2006 , 45, 60-5	17
1233	Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. 2006 , 33, 349-58	114
1232	Dynamic Functions of the $\beta 3$ Integrin in Carcinoma. 2006 , 159-187	1

1231	The Role of Microvasculature in Metastasis Formation. 2006 , 31-62	5
1230	Cerebral perfusion in a high-grade glioma evaluated with sonographic contrast pulse sequencing technology. 2006 , 25, 1215-8	3
1229	3D power Doppler in the study of fetal and maternal angiogenesis and vasculogenesis. 2006 , 6, 1-19	1
1228	. 2006 ,	22
1227	Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective. 2006 , 63-80	
1226	DNA nanoparticles for gene delivery to cells and tissue. 2006 , 3, 416	37
1225	cRGD-Encoded, MRI-Visible Polymeric Micelles for Tumor-Targeted Drug Delivery. 2006 , 465-475	
1224	RGD-Modified Liposomes for Tumor Targeting. 2006 , 643-661	1
1223	Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy. 2006 , 159-184	
1222	Polymeric Nanoparticles for Tumor-Targeted Drug Delivery. 2006 , 215-229	
1221	FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. 2006 , 107, 126-31	76
1220	The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. 2006 , 107, 3564-71	147
1219	Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. 2006 , 108, 3035-44	83
1218	Matrix, Extracellular and Interstitial. 2006 ,	4
1217	Tumor Angiogenesis. 1087-1106	0
1216	Review of selected patents for cancer therapy targeting tumor angiogenesis. 2006 , 1, 153-61	4
1215	Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. 2006 , 59, 1304-12; discussion 1312	99
1214	Protein and Peptide Drugs to Suppress Tumor Angiogenesis. 2006 , 255-284	

1213	Electroconvulsive seizure increases adult hippocampal angiogenesis in rats. 2006 , 24, 819-28	45
1212	The role of the extracellular matrix in angiogenesis in malignant glioma tumors. 2005 , 15, 318-26	38
1211	Proteases and glioma angiogenesis. 2005 , 15, 327-41	91
1210	Normal cutaneous wound healing: clinical correlation with cellular and molecular events. 2005 , 31, 674-86; discussion 686	250
1209	Fibronectin promotes brain capillary endothelial cell survival and proliferation through alpha5beta1 and alphavbeta3 integrins via MAP kinase signalling. 2006 , 96, 148-59	90
1208	Genetic and epigenetic mechanisms in the early development of the vascular system. 2006 , 208, 139-52	41
1207	Discovery of diphenylmethanepropionic and dihydrostilbeneacetic acids as antagonists of the integrin alphavbeta3. 2006 , 67, 177-81	5
1206	Peptide-based molecules in angiogenesis. 2006 , 67, 115-26	81
1205	Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. 2000 , 905, 165-76	18
1204	Fibrin and wound healing. 2001 , 936, 355-67	318
1203	Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. 2006 , 155, 1191-6	29
1202	Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. 2006 , 94, 1621-6	131
1201	Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. 2006 , 16, 313-8	58
1200	Interaction of fibrin with VE-cadherin. 2001 , 936, 386-405	52
1199	Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists. 2006 , 16, 3156-61	31
1198	Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. <i>Bioorganic and Medicinal Chemistry</i> , 2006 , 14, 169-80	3-4 58
1197	The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation. 2006 , 65, 517-27	15
1196	Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. 2006 , 65, 1536-43	113

1195	Spectroscopic techniques applied to the study of laminin fragments inserted into model membranes. <i>Journal of Colloid and Interface Science</i> , 2006 , 295, 264-9	93	7
1194	Therapeutic effects of paclitaxel-containing ultrasound contrast agents. 2006 , 32, 1771-80		131
1193	Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. 2006 , 3, 472-87		280
1192	Normal endothelium. 2006 , 1-40		139
1191	Construction, expression, and characterization of a new targeted bifunctional fusion protein: tumstatin45-132-TNF. 2006 , 58, 647-53		12
1190	Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. 2007 , 25, 49-55		30
1189	Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. 2006 , 8, 9-15		30
1188	Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. 2006 , 8, 226-36		93
1187	In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. 2006 , 8, 315-23		77
1186	Mechanisms of angiogenesis in gliomas. 2006 , 78, 281-93		122
1185	Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis. 2005 , 8, 361-72		9
1184	Exercise preconditioning upregulates cerebral integrins and enhances cerebrovascular integrity in ischemic rats. 2006 , 112, 74-84		50
1183	Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. 2006 , 31, 188-93		137
1182	Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists. 2006 , 16, 839-44		38
1181	Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties. 2006 , 16, 845-9		7
1180	Targeted approaches for the management of metastatic prostate cancer. 2006 , 8, 206-12		3
1179	Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. 2006 , 312, 2515-27		64
1178	Distinct roles of beta1 integrins during angiogenesis. 2006 , 85, 243-7		41

1177	Nuclear cardiology: present and future. 2006 , 31, 557-629	41
1176	Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. 2006 , 1765, 155-77	18
1175	Vascular targeting: recent advances and therapeutic perspectives. 2006 , 16, 80-8	118
1174	Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. 2006 , 114, 175-83	77
1173	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. 2006 , 6, 285	91
1172	Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. 2006 , 4, 299-302	63
1171	PECAM-1 isoform-specific activation of MAPK/ERKs and small GTPases: implications in inflammation and angiogenesis. 2006 , 98, 451-68	30
1170	Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis. 2006 , 208, 161-6	12
1169	Activatable fluorescent probes for tumour-targeting imaging in live mice. 2006 , 1, 1069-72	47
1168	Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. 2006 , 118, 755-64	24
1167	Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. 2006 , 119, 423-31	34
1166	Quantification of the expression level of integrin receptor alpha(v)beta3 in cell lines and MR imaging with antibody-coated iron oxide particles. 2006 , 56, 711-6	44
1165	Inhibition of integrin alphavbeta3 reduces blood-brain barrier breakdown in focal ischemia in rats. 2006 , 84, 1837-47	33
1164	Cell adhesion molecules for targeted drug delivery. 2006 , 95, 1856-72	93
1163	Integrins in the ovary. 2006 , 24, 251-61	22
1162	Inhibition of integrin alphavbeta3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. 2006 , 37, 1902-9	66
1161	Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function. 2006 , 33, 244-253	10
1160	Cerebral ischemia and angiogenesis. 2006 , 3, 119-29	77

1159 Integrins and Cancer: Gene Expression, Epigenetics and Metastasis. **2006**, 7, 323-331

1158 Antineovascular agents in the treatment of eye diseases. **2006**, 12, 2645-60

27

1157 Integrins in cancer treatment. **2006**, 6, 89-105

77

1156 Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. **2006**, 108, 1243-50

217

1155 Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. **2006**, 12, 2723-47

246

1154 Multimodality imaging of tumor integrin alphavbeta3 expression. **2006**, 6, 227-34

93

1153 Angiogenesis as a therapeutic target in arthritis: lessons from oncology. **2006**, 12, 2631-44

28

1152 Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. **2006**, 69, 1820-8

72

1151 Identification of sokotrasterol sulfate as a novel proangiogenic steroid. **2006**, 99, 257-65

14

1150 Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. *Molecular Cancer Therapeutics*, **2006**, 5, 3122-9

6.1 83

1149 Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. **2006**, 281, 19700-8

126

1148 Ocular Angiogenesis. **2006**,

3

1147 Molecular mediators of alphavbeta3-induced endothelial cell survival. **2006**, 43, 422-36

25

1146 The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. **2006**, 66, 4652-61

112

1145 In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. **2006**, 66, 9673-81

176

1144 Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. **2006**, 66, 9196-201

122

1143 SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. **2006**, 47, 1600-5

48

1142 Integrin signaling is critical for pathological angiogenesis. **2006**, 203, 2495-507

157

1141	Endothelial cell activation and neovascularization are prominent in dermatomyositis. 2006 , 3, 2	62
1140	Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. 2006 , 13, 113-35	144
1139	Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. 2006 , 119, 490-9	80
1138	Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. 2006 , 26, 2005-11	71
1137	Cell Motility in Cancer Invasion and Metastasis. 2006 ,	5
1136	Necl-5/poliovirus receptor interacts in cis with integrin alphaVbeta3 and regulates its clustering and focal complex formation. 2007 , 282, 18481-18496	39
1135	Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. 2007 , 86, 927-36	27
1134	Molecular imaging can accelerate anti-angiogenic drug development and testing. 2007 , 4, 556-7	23
1133	Molecular imaging by cardiovascular MR. 2007 , 9, 827-43	17
1132	Targeting the tumor vasculature to improve the efficacy of oncolytic virus therapy. 2007 , 99, 1739-41	6
1131	Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. 2007 , 18, 1400-7	92
1130	Angiogenesis blockade as a new therapeutic approach to experimental colitis. 2007 , 56, 855-62	99
1129	Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. 2007 , 2, 143-58	49
1128	Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. 2007 , 7, 552-8	150
1127	Uterine receptivity: alterations associated with benign gynecological disease. 2007 , 25, 461-75	123
1126	Evaluating integrin function in models of angiogenesis and vascular permeability. 2007 , 426, 505-28	24
1125	Methods to study lymphatic vessel integrins. 2007 , 426, 415-38	26
1124	Nonclassic endogenous novel [corrected] regulators of angiogenesis. 2007 , 59, 185-205	148

1123	Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. 2007 , 282, 22964-76	87
1122	The role of osteopontin in tumor progression and metastasis in breast cancer. 2007 , 16, 1087-97	168
1121	Pathophysiological mechanisms of angiogenesis. 2007 , 44, 187-221	32
1120	Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin. 2007 , 67, 4353-63	22
1119	Regulation of igf-I signaling in retinal endothelial cells by hyperglycemia. 2007 , 48, 3878-87	21
1118	Phase I evaluation of a fully human anti-alpha _v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. 2007 , 13, 2128-35	124
1117	(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha _v beta ₃ integrin expression. 2007 , 48, 1162-71	207
1116	Zoledronate inhibits alpha _v beta ₃ and alpha _v beta ₅ integrin cell surface expression in endothelial cells. 2007 , 14, 123-30	19
1115	The Dynamics of Cell-ECM Interactions. 2007 , 81-99	1
1114	Saxatilin, a snake venom disintegrin, regulates platelet activation associated with human vascular endothelial cell migration and invasion. 2007 , 44, 129-37	13
1113	Regulation of postangiogenic neovessel survival by beta1 and beta3 integrins in collagen and fibrin matrices. 2007 , 44, 40-50	23
1112	Cadherins, RhoA, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. 2007 , 101, e44-52	102
1111	Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. 2007 , 21, 3272-8	25
1110	Cooperation between VEGF and beta3 integrin during cardiac vascular development. 2007 , 109, 1962-70	62
1109	The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. 2007 , 110, 2041-8	111
1108	Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. 2007 , 8, 257-68	42
1107	Ocular neovascularization: basic mechanisms and therapeutic advances. 2007 , 52 Suppl 1, S3-19	96
1106	Differences in binding of (99m)Tc-disintegrins to integrin alpha _v beta ₃ on tumor and vascular cells. 2007 , 34, 371-81	6

1105	Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. 2007 , 357, 1016-20	25
1104	A NPxY-independent beta5 integrin activation signal regulates phagocytosis of apoptotic cells. 2007 , 364, 540-8	27
1103	The role of integrin alpha5beta1 in the regulation of corneal neovascularization. 2007 , 85, 356-65	37
1102	Anti-angiogenic gene therapy of cancer: current status and future prospects. 2007 , 28, 87-114	52
1101	Integrins: signaling, disease, and therapy. 2007 , 83, 743-51	89
1100	Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. 2007 , 28, 297-321	278
1099	Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. 2007 , 171, 361-72	93
1098	Electron microscopy of integrins. 2007 , 426, 337-73	11
1097	Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. 2007 , 5, 935-44	171
1096	Wound Repair. 2007 , 1149-1166	4
1095	Gene Therapy for Cancer. 2007 ,	3
1094	In Vivo Imaging of Cancer Therapy. 2007 ,	2
1093	Targeting - Cancer Small Molecules. 2007 , 447-506	2
1092	Angiogenesis and Cancer. 2007 , 35-61	2
1091	Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. 2007 , 18, 438-46	120
1090	Angiogenesis. 2007 , 369-388	
1089	Neurologic Tumors. 2007 , 569-583	
1088	Molecular imaging of cardiovascular disease. 2007 , 116, 1052-61	173

1087	[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. 2007 , 13, 6610-6	198
1086	Antiangiogenic agents for the treatment of glioblastoma. 2007 , 16, 1895-908	22
1085	Inhibition of osteopontin would suppress angiogenesis in gastric cancer. 2007 , 85, 103-10	23
1084	Polymeric ultrasound contrast agents targeted to integrins: importance of process methods and surface density of ligands. 2007 , 8, 516-22	28
1083	Quantitative measurements of the strength of adhesion of human neutrophils to a substratum in a microfluidic device. 2007 , 79, 2249-58	36
1082	Biosynthetic-Synthetic Polymer Conjugates. 2007 , 47, 63-92	91
1081	Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. 2007 , 67, 1555-62	302
1080	Osteopontin: an emerging therapeutic target for anticancer therapy. 2007 , 11, 81-90	38
1079	Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. 2007 , 8, 874-84	104
1078	Fibronectin type III domain based monobody with high avidity. 2007 , 46, 12656-64	23
1077	Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. 2007 , 39, 557-65	30
1076	Identification and molecular characterization of multiple phenotypes in integrin knockout mice. 2007 , 426, 291-305	17
1075	Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures. 2007 , 18, 1756-62	51
1074	Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. 2007 , 18, 1415-23	164
1073	Part B: Directed Differentiation of Human Embryonic Stem Cells into Endothelial Cells. 229-248	
1072	Molecular ultrasound imaging using microbubble contrast agents. 2007 , 12, 5124-42	107
1071	Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. 2007 , 48, 5184-90	35
1070	Drug Targeting to Endothelium. 1734-1746	

1069	Mechanisms initiating integrin-stimulated flow recruitment in arteriolar networks. 2007 , 102, 2279-87	10
1068	Endothelial Cell Apoptosis. 1081-1097	3
1067	Angiogenesis. 1444-1456	
1066	. 2007 ,	9
1065	Bifunctional ligands that target cells displaying the alpha v beta3 integrin. 2007 , 8, 68-82	61
1064	Mechanisms controlling human endothelial lumen formation and tube assembly in three-dimensional extracellular matrices. 2007 , 81, 270-85	108
1063	Engineered blood and lymphatic capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow. 2007 , 96, 167-76	107
1062	Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) affects RhoA activation in endothelial cells. 2007 , 211, 708-15	6
1061	Nonpeptide Integrin Antagonists: RGD Mimetics Incorporating Substituted Azabicycloalkanes as Amino Acid Replacements. 2007 , 2007, 1309-1317	9
1060	Ligand-based vascular targeting of disease. 2007 , 2, 22-40	45
1059	Zone-specific remodeling of tumor blood vessels affects tumor growth. 2007 , 110, 2347-62	29
1058	MRI of tumor angiogenesis. 2007 , 26, 235-49	232
1057	Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 3390-412	3-4 11
1056	R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 3783-800	3-4 13
1055	Synthesis of Tc-99m labeled glucosamino-Asp-cyclic(Arg-Gly-Asp-d-Phe-Lys) as a potential angiogenesis imaging agent. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 7755-64	3-4 12
1054	Synthesis and antiangiogenic activities of 5-amino-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanoic acid derivatives. 2007 , 18, 7-9	3
1053	Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. 2007 , 35, 205-20	64
1052	Microenvironmental regulation of biomacromolecular therapies. 2007 , 6, 455-63	121

1051	Synergistic control of cell adhesion by integrins and syndecans. 2007 , 8, 957-69	435
1050	Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. 2007 , 14, 422-35	42
1049	Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. 2007 , 26, 2832-42	86
1048	Integrin alpha2beta1 is required for regulation of murine wound angiogenesis but is dispensable for reepithelialization. 2007 , 127, 467-78	97
1047	Angiostatin and integrin alphavbeta3 in the feline, bovine, canine, equine, porcine and murine retina and cornea. 2007 , 10, 313-9	16
1046	Genes that distinguish physiological and pathological angiogenesis. 2007 , 11, 539-54	326
1045	Effect of plasma fibronectin on the incisional wound healing in rats. 2007 , 141, 254-61	15
1044	(-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes. 2007 , 64, 2690-701	28
1043	Antibody-based targeting of the tumor vasculature. 2007 , 1776, 175-92	35
1042	In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. 2007 , 34, 745-754	60
1041	18F-labeled mini-PEG spacers RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. 2007 , 34, 1823-1831	103
1040	In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. 2007 , 34, 2037-47	55
1039	Gene expression profiles of endothelial progenitor cells by oligonucleotide microarray analysis. 2007 , 298, 125-38	37
1038	Functionalized micellar systems for cancer targeted drug delivery. 2007 , 24, 1029-46	473
1037	Integrin trafficking and its role in cancer metastasis. 2007 , 26, 567-78	102
1036	Recombinant alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation. 2007 , 245, 581-7	3
1035	Molecular imaging with targeted contrast ultrasound. 2007 , 18, 11-6	174
1034	A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. 2008 , 25, 53-64	75

1033	Synthesis and characterization of arginine-glycine-aspartic peptides conjugated poly(lactic acid-co-L-lysine) diblock copolymer. 2008 , 19, 1275-81	20
1032	Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. 2008 , 26, 35-43	74
1031	(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. 2008 , 35, 1100-8	173
1030	Cell adhesion molecules: potential therapeutic & diagnostic implications. 2008 , 38, 33-40	78
1029	Rho GTPases mediated integrin alpha v beta 3 activation in sphingosine-1-phosphate stimulated chemotaxis of endothelial cells. 2008 , 129, 579-88	23
1028	Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. 2008 , 9, 2811-3	62
1027	Prodrug strategies in anticancer chemotherapy. 2008 , 3, 20-53	386
1026	A potent integrin antagonist from a small library of cyclic RGD pentapeptide mimics including benzyl-substituted azabicycloalkane amino acids. 2008 , 3, 1589-603	23
1025	Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. 2008 , 3, 9-18	78
1024	Integrin alpha(v)beta(3)-Targeted Cancer Therapy. 2008 , 69, 329-339	205
1023	alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. 2008 , 123, 709-15	47
1022	Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. 2008 , 103, 691-708	35
1021	A stimulus-responsive contrast agent for ultrasound molecular imaging. 2008 , 29, 597-606	94
1020	An efficient route to dimeric porphyrinRGD peptide conjugates via olefin metathesis. 2008 , 64, 364-371	29
1019	Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. 2008 , 29, 1920-30	188
1018	Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. 2008 , 19, 2471-9	133
1017	Simultaneous Molecular and Hypoxia Imaging of Brain Tumors In Vivo Using Spectroscopic Photoacoustic Tomography. 2008 , 96, 481-489	239
1016	Markers for microscopic imaging of lymphangiogenesis and angiogenesis. 2008 , 1131, 1-12	168

1015	Fibrinogen interaction of CHO cells expressing chimeric alphaIIb/alphavbeta3 integrin. 2008 , 29, 204-10	5
1014	RGD-FasL induces apoptosis of pituitary adenoma cells. 2008 , 5, 61-8	11
1013	Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. <i>Oncogene</i> , 2008 , 27, 6698-706	9.2 176
1012	Regulation of angiogenesis: apoptotic cues from the ECM. <i>Oncogene</i> , 2008 , 27, 6285-98	9.2 109
1011	Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. 2008 , 8, 212-26	347
1010	Integrins in angiogenesis and lymphangiogenesis. 2008 , 8, 604-17	801
1009	Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition. 2008 , 128, 300-10	28
1008	Endothelium-platelet interactions in inflammatory lung disease. 2008 , 49, 141-50	49
1007	The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. 2008 , 314, 774-88	17
1006	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. 2008 , 9, 201	46
1005	Del-1 gene transfer induces cerebral angiogenesis in mice. 2008 , 1219, 1-7	19
1004	alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. 2008 , 20, 514-9	107
1003	The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. 2008 , 87, 617-29	86
1002	Contributions of integrin-linked kinase to breast cancer metastasis and tumourigenesis. 2008 , 12, 1517-26	13
1001	beta-Adrenergic receptor modulation of wound repair. 2008 , 58, 158-64	32
1000	Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling. 2008 , 173, 1220-8	26
999	Radionuclide imaging: a molecular key to the atherosclerotic plaque. 2008 , 52, 1-12	733
998	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. 2008 , 27, 86	80

997	Vascular involvement in rheumatic diseases: 'vascular rheumatology'. 2008 , 10, 224	123
996	Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. 2008 , 19, 39-49	193
995	Hunter-killer peptide (HKP) for targeted therapy. 2008 , 51, 5887-92	26
994	Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. 2008 , 5, 1080-92	124
993	Expression of integrins in human proliferative diabetic retinopathy membranes. 2008 , 43, 683-8	15
992	Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. 2008 , 35, 111-21	38
991	Cyanine Dye-Based Compounds for Tumor Imaging With and Without Photodynamic Therapy. 2008 , 41-74	25
990	Metalloproteinases and their inhibitors: regulators of wound healing. 2008 , 40, 1334-47	521
989	Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells. 2008 , 87, 342-8	21
988	A putative role for apelin in the etiology of obesity. 2008 , 368, 815-9	40
987	. 2008 , 96, 397-415	14
986	Combination of Antiangiogenic Therapy with Other Anticancer Therapies. 2008 , 431-449	
985	Inflammatory angiogenesis in atherogenesis--a double-edged sword. 2008 , 40, 606-21	90
984	Apoptosis of mesenchymal cells during the pseudoglandular stage of lung development affects branching morphogenesis. 2008 , 34, 481-99	14
983	Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. 2009 , 24, 608-18	77
982	Roles of integrins in tumor angiogenesis and lymphangiogenesis. 2008 , 6, 155-63	73
981	In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy. 2008 , 7, 290-8	46
980	alpha v beta 3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3761-70	6.1 33

979	Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. 2008 , 4, 1160-9	58
978	Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. 2008 , 130, 687-94	296
977	Engineering the microcirculation. 2008 , 14, 87-103	117
976	Capillary electrophoresis frontal analysis for characterization of alphavbeta3 integrin binding interactions. 2008 , 80, 3105-11	27
975	Modularly assembled magnetite nanoparticles enhance in vivo targeting for magnetic resonance cancer imaging. 2008 , 19, 1972-9	38
974	Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. 2008 , 51, 7980-90	103
973	Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. 2008 , 183, 143-55	308
972	New molecular targets in angiogenic vessels of glioblastoma tumours. 2008 , 10, e23	54
971	Streptococcal pyrogenic exotoxin B-induced apoptosis in A549 cells is mediated through alpha(v)beta(3) integrin and Fas. 2008 , 76, 1349-57	14
970	Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. 2008 , 19, 2278-88	40
969	The future of cardiovascular imaging in the diagnosis and management of heart failure, part 1: tasks and tools. 2008 , 1, 58-69	17
968	Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. 2008 , 82, 1570-80	104
967	Angiogenesis. 2008 ,	25
966	Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. 2008 , 45, 78-86	27
965	Integrins: the keys to unlocking angiogenesis. 2008 , 28, 1703-13	203
964	Antimigratory effect of TK1-2 is mediated in part by interfering with integrin alpha2beta1. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2133-41	6.1 16
963	Generation of fusion proteins for selective occlusion of tumor vessels. 2008 , 5, 1-8	29
962	Integrin affinity modulation in angiogenesis. 2008 , 7, 335-47	66

961	Antiangiogenic strategies in medulloblastoma: reality or mystery. 2008 , 63, 584-90	19
960	Clinical approaches toward tumor angiogenesis: past, present and future. 2008 , 14, 3820-34	26
959	Inhibitors of tumor angiogenesis. 2008 , 351-381	
958	Principles of Molecular Oncology. 2008 ,	1
957	Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. 2008 , 181, 43-50	118
956	Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. 2008 , 78, 395-403	107
955	Integrins and matrix in the glomerulus: old mysteries and new insights. 2008 , 19, 650-1	2
954	Are podocytes passive or provocative in proteinuric glomerular pathology?. 2008 , 19, 651-3	13
953	Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. 2008 , 283, 18066-75	96
952	The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. 2008 , 183, 1145-57	41
951	hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells. 2008 , 7, 228-36	26
950	Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome. 2008 , 49, 1845-51	53
949	Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model. 2008 , 23, 691-700	17
948	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. 2008 , 17, 1225-35	152
947	Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. 2008 , 104, 1504-12	35
946	alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. 2008 , 111, 1980-8	66
945	Functional analysis of the cytoplasmic domain of the integrin {alpha}1 subunit in endothelial cells. 2008 , 112, 3242-54	34
944	Imaging of integrins as biomarkers for tumor angiogenesis. 2008 , 14, 2943-73	174

943	Radionuclide carriers for targeting of cancer. 2008 , 3, 181-99	69
942	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. 2008 , 1, 1-12	13
941	The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. 2008 , 3, e2657	32
940	Angiogenesis and Vasculogenesis at 7-Day of Reperfused Acute Myocardial Infarction. 2008 ,	
939	Anatomical and molecular imaging of skin cancer. 2008 , 1, 1-17	15
938	Noninvasively characterizing the different alphavbeta3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner. 2009 , 4, 241-9	23
937	Endothelial Cells and Angiogenesis. 2009 , 168-179	
936	Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy, and Single-Photon Emission Computed Tomography Using a Cyclic RGD Peptide Labeled with a Near-Infrared Fluorescent Dye and a Radionuclide. 2009 , 8, 7290.2009.00014	48
935	Dual-Modality Probes for in Vivo Molecular Imaging. 2009 , 8, 7290.2009.00013	63
934	Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. 2009 , 14, 887-99	63
933	Cellular aspects of wound healing. 2009 , 84, 257-62	87
932	¹¹¹ In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}{4}{beta}{1} Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. 2009 , 50, 625-34	34
931	Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 10666-71.5	148
930	Radionuclide imaging of tumor angiogenesis. 2009 , 24, 637-47	39
929	Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer ¹⁸ F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. 2009 , 2, 331-8	127
928	Alternatively spliced tissue factor induces angiogenesis through integrin ligation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19497-502	11.5 117
927	Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. 2009 , 284, 33966-81	74
926	MODELLING VASCULAR MORPHOGENESIS: CURRENT VIEWS ON BLOOD VESSELS DEVELOPMENT. 2009 , 19, 1483-1537	17

925	Delayed wound healing in elderly people. 2009 , 19, 171-184	4
924	Multimodality cardiovascular molecular imaging, Part II. 2009 , 2, 56-70	119
923	RGD-Human Serum Albumin Conjugates as Efficient Tumor Targeting Probes. 2009 , 8, 7290.2009.00011	34
922	Molecular imaging with targeted contrast ultrasound. 2009 , 27 Suppl 2, 66-74	24
921	Comparison of endothelial cell phenotypic markers of late-outgrowth endothelial progenitor cells isolated from patients with coronary artery disease and healthy volunteers. 2009 , 15, 3473-86	59
920	Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. 2009 , 69, 3695-703	69
919	Foxc2 transcription factor as a regulator of angiogenesis via induction of integrin beta3 expression. 2009 , 3, 24-6	12
918	The promise of antiangiogenic therapy for ovarian cancer. 2009 , 8, 2273-4	3
917	Peptides for tumour therapy and diagnosis: current status and future directions. 2009 , 16, 780-95	32
916	Current thoughts on angiogenesis. 2009 , 18, 12-4, 16	4
915	Functional and molecular ultrasound imaging: concepts and contrast agents. 2009 , 16, 627-42	106
914	Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. 2009 , 206, 691-705	216
913	Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. 2009 , 69, 4760-8	26
912	Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. 2009 , 23, 1459-69	63
911	Integrins as "functional hubs" in the regulation of pathological angiogenesis. 2009 , 19, 318-28	39
910	The functional role of cell adhesion molecules in tumor angiogenesis. 2009 , 19, 298-309	55
909	Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. 2009 , 140, 166-73	278
908	Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. 2009 , 315, 248-63	18

907	Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. 2009 , 124, 2719-27	105
906	Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting. 2009 , 4, 615-32	40
905	ADAM8 is selectively up-regulated in endothelial cells and is associated with angiogenesis after spinal cord injury in adult mice. 2009 , 512, 243-55	40
904	Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the worm. 2009 , 238, 277-93	41
903	Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation. 2010 , 222, 685-94	45
902	Absence of beta3 integrin accelerates early skeletal repair. 2010 , 28, 32-7	8
901	Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. 2009 , 61, 1022-32	69
900	Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice. 2009 , 247, 515-22	9
899	Invited review: activity-induced angiogenesis. 2009 , 457, 963-77	170
898	Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. 2009 , 12, 177-85	185
897	Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix. 2009 , 12, 275-85	36
896	Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation. 2009 , 266, 89-96	27
895	Binding and Uptake of RGD-Containing Ligands to Cellular $\alpha_5\beta_1$ Integrins. 2009 , 15, 49-59	26
894	Efficient siRNA delivery with non-viral polymeric vehicles. 2009 , 26, 657-66	148
893	Noninvasive monitoring of HPMa copolymer-RGDfK conjugates by magnetic resonance imaging. 2009 , 26, 1121-9	32
892	Targetable HPMa copolymer-aminoethylgeldanamycin conjugates for prostate cancer therapy. 2009 , 26, 1407-18	43
891	Molecular imaging in clinical trials. 2009 , 4, 151-68	36
890	Molecular imaging of ventricular remodeling. 2009 , 16, 456-65	

889	Non-invasive Monitoring of Angiogenesis in Cardiology. 2009 , 2, 59-66	6
888	Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. 2009 , 36, 1296-307	102
887	Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. 2009 , 77, 359-69	128
886	Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. 2009 , 1, 254-272	27
885	Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. 2009 , 16, 33	18
884	Angiogenesis drives psoriasis pathogenesis. 2009 , 90, 232-48	222
883	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. 2009 , 15, 392-400	390
882	Lowered albumin extravasation rate in heart but not in other organs in beta3-integrin-deficient mice. 2009 , 197, 305-11	1
881	Interactions between extracellular matrix and growth factors in wound healing. 2009 , 17, 153-62	737
880	Biology of angiogenesis and invasion in glioma. 2009 , 6, 447-57	160
879	Tissue assembly and organization: developmental mechanisms in microfabricated tissues. 2009 , 30, 4851-8	107
878	Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. 2009 , 6 Suppl 3, S325-39	164
877	Angiogenesis and Angiogenic Diversity in Lung Cancer Metastasis. 2009 , 135-154	
876	Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. 2009 , 6, 1836-47	35
875	Integrin alphaVbeta3 targeted gene delivery using RGD peptidomimetic conjugates with copolymers of PEGylated poly(ethylene imine). 2009 , 20, 1270-80	38
874	Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. 2009 , 20, 1404-11	36
873	Nanomechanical characterization of phospholipid bilayer islands on flat and porous substrates: a force spectroscopy study. 2009 , 113, 10339-47	25
872	Synthesis and self-assembly of RGD-functionalized PEO-PB amphiphiles. 2009 , 10, 1554-63	37

871	In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2. 2009 , 6, 1856-67	6
870	A novel method for direct site-specific radiolabeling of peptides using [18F]FDG. 2009 , 20, 432-6	72
869	RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. 2009 , 20, 1853-9	35
868	Evaluation of a novel Arg-Gly-Asp-conjugated β -melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. 2009 , 20, 1634-42	36
867	Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. 2009 , 20, 750-9	116
866	Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. 2009 , 20, 2199-213	276
865	(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. 2009 , 20, 1016-25	116
864	The role of cell adhesion pathways in angiogenesis. 2009 , 41, 521-30	49
863	The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. 2009 , 41, 1572-80	45
862	(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. 2009 , 36, 277-85	84
861	New targeted probes for radioimaging of angiogenesis. 2009 , 48, 188-92	34
860	Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. 2009 , 385, 1064-75	108
859	HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. 2009 , 46, 406-15	35
858	Dendrimers in oncology: an expanding horizon. 2009 , 109, 49-87	415
857	Pharmacologic and chemical adjuvants in tumor virotherapy. 2009 , 109, 3125-40	41
856	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. 2009 , 9, 1583-98	20
855	alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. 2009 , 52, 7029-43	31
854	Advanced Imaging in Biology and Medicine. 2009 ,	6

853	Current and future therapies for age-related macular degeneration. 2009 , 14, 341-62	8
852	Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. 2009 , 52, 425-32	103
851	Molecular Imaging in Cardiology. 2009 , 299-323	1
850	Micro and Nano Technologies in Bioanalysis. 2009 ,	4
849	The Structure, Function, and Evaluation of the Female Reproductive Tract. 2009 , 191-233	1
848	PET Imaging of Angiogenesis. 2009 , 4, 17-38	45
847	Angiogenesis in rheumatoid arthritis. 2009 , 42, 563-73	83
846	Self-regulated multifunctional collaboration of targeted nanocarriers for enhanced tumor therapy. 2014 , 15, 3634-42	44
845	Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors. 2014 , 35, 3416-26	101
844	The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. 2014 , 133, 855-62	24
843	Non-collagenous ECM proteins in blood vessel morphogenesis and cancer. 2014 , 1840, 2403-13	25
842	Recent advances in molecular, multimodal and theranostic ultrasound imaging. 2014 , 72, 15-27	147
841	Vimentin as an integral regulator of cell adhesion and endothelial sprouting. 2014 , 21, 333-44	104
840	Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). 2014 , 11, 1687-95	42
839	Brain metastasis: new opportunities to tackle therapeutic resistance. 2014 , 8, 1120-31	28
838	Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. 2014 , 173, 51-8	40
837	Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. 2014 , 44, 1394-400	6
836	Metal Particles for Photoacoustic Imaging. 2014 , 345-384	

- 835 C/EBP β promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma. **2015**, 136, 2524-34 19
- 834 The Tumor Microenvironment as a Target for Therapeutic Intervention. **2015**, 47-63
- 833 In vivo imaging study of angiogenesis in a channelized porous scaffold. **2015**, 14, 6
- 832 Segregation versus colocalization: orthogonally functionalized binary micropatterned substrates regulate the molecular distribution in focal adhesions. **2015**, 27, 3737-47 31
- 831 Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging. **2015**, 5, 71 43
- 830 HepG2 Cell Resistance against Camptothecin from a Lysosomal Drug Delivery. **2015**, 10, 2695-700 2
- 829 Study of novel molecular probe ^{99m}Tc -3PRGD2 in the diagnosis of rheumatoid arthritis. **2015**, 36, 1208-14 9
- 828 Multicenter Reproducibility of ^{18}F -Fluciclatide PET Imaging in Subjects with Solid Tumors. **2015**, 56, 1855-61 19
- 827 Exploration of peptide T7 and its derivative as integrin $\alpha\beta$ -targeted imaging agents. **2015**, 8, 1483-91 1
- 826 Biological production of an integrin $\alpha\beta$ targeting imaging probe and functional verification. **2015**, 2015, 681012 2
- 825 Pilot Prospective Evaluation of (^{18}F) -Alfatide II for Detection of Skeletal Metastases. **2015**, 5, 1115-21 40
- 824 $\alpha\text{V}\beta\text{3}$ -targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment. **2015**, 5, 124-33 46
- 823 . **2015**, 2
- 822 Pathological functions of hypoxia in endometriosis. **2015**, 7, 352-366 1
- 821 MFG-E8 inhibits neutrophil migration through $\alpha\text{5}\beta\text{1}$ Integrin-dependent MAP kinase activation. **2015**, 36, 18-28 16
- 820 Integrins and haptoglobin: Molecules overexpressed in ovarian cancer. **2015**, 211, 973-81 15
- 819 Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis. **2015**, 104, 2600-10 33
- 818 ^{177}Lu -Labeled RGD-BBN Peptide for Targeting Prostate Cancer. **2015**, 93-98

817	One-step (18)F labeling of non-peptidic bivalent integrin $\alpha_5\beta_1$ antagonist for cancer imaging. 2015 , 26, 24-8	9
816	Integrin-mediated adhesion and mechano-sensing in cutaneous wound healing. 2015 , 360, 571-82	38
815	Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. 2015 , 75, 1356-65	56
814	PKD1 regulates focal adhesion disassembly by modulating endocytosis of $\alpha_5\beta_1$ integrin. 2015 , 128, 863-77	15
813	Inhibition of tumor-associated $\alpha_5\beta_1$ integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo. 2015 , 18, 31-46	19
812	Tumour but not stromal expression of β_1 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer. 2015 , 235, 760-72	24
811	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 2015 , 75, 343-52	4
810	Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. 2015 , 2, 173-185	15
809	RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of $\alpha_5\beta_1$ integrin-overexpressing breast cancer cells. 2015 , 5, 15-26	55
808	Bacteria-mimicking nanoparticle surface functionalization with targeting motifs. 2015 , 7, 6737-44	11
807	Angiogenesis and airway reactivity in asthmatic Brown Norway rats. 2015 , 18, 1-11	16
806	A novel PET tracer for targeted imaging of atherosclerosis. 2015 , 22, 1191-4	3
805	Dendrimer-entrapped gold nanoparticles modified with RGD peptide and alpha-tocopheryl succinate enable targeted theranostics of cancer cells. 2015 , 133, 36-42	58
804	Pivotal role for decorin in angiogenesis. 2015 , 43, 15-26	109
803	Antibody-Drug Conjugate (ADC) Research in Ophthalmology--a Review. 2015 , 32, 3572-6	1
802	PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy. 2015 , 10, 495-505	5
801	Molecular and Multimodality Imaging in Cardiovascular Disease. 2015 ,	
800	Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis. 2015 , 9, 8012-21	91

799	A Lipopeptide-Based $\alpha_5\beta_1$ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis. 2015 , 41, 2765-73	25
798	Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously. 2015 , 26, 1561-70	15
797	Gene Therapy of Solid Cancers. 2015 ,	1
796	Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. 2015 , 22, 146-54	20
795	Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. 2015 , 93, 991-1001	55
794	Tc-3P-RGD2 molecular imaging targeting integrin in head and neck squamous cancer xenograft. 2015 , 304, 1171-1177	6
793	Peptide receptor radionuclide therapy: an overview. 2015 , 30, 47-71	71
792	New trends in guided nanotherapies for digestive cancers: A systematic review. 2015 , 209, 288-307	68
791	Radiotracer imaging of peripheral vascular disease. 2013 , 54, 2104-10	18
790	Role of Multimodality Imaging in Atherosclerotic Plaque Burden and Metabolism. 2015 , 153-174	
789	Copper-Free Click Chemistry Modification of Nanovectors for Integrin-Targeted Cancer Therapy. 2015 , 35-49	
788	Cell Adhesion Mediated by VCAM-ITG β Interactions Enables Lymphatic Development. 2015 , 35, 1179-89	8
787	Biodistribution of the ^{18}F -FPPRGD β -PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. 2015 , 42, 1850-8	34
786	Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. 2015 , 218, 13-21	94
785	Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes. 2015 , 56, 1637-41	15
784	PDK1: A signaling hub for cell migration and tumor invasion. 2015 , 1856, 178-88	48
783	Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor. 2015 , 34, 1227-36	7
782	Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR. 2015 , 12, 3749-58	11

781	RGD-conjugated two-photon absorbing near-IR emitting fluorescent probes for tumor vasculature imaging. 2015 , 13, 10716-25		15
780	The anti-tumour activity of rLj-RGD4, an RGD toxin protein from <i>Lampetra japonica</i> , on human laryngeal squamous carcinoma Hep-2 cells in nude mice. 2015 , 119, 183-91		5
779	Early recognition of lung cancer by integrin targeted imaging in K-ras mouse model. 2015 , 137, 1107-18		8
778	Light-triggered in vivo activation of adhesive peptides regulates cell adhesion, inflammation and vascularization of biomaterials. 2015 , 14, 352-60		319
777	A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation. 2015 , 137, 6-9		60
776	Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation. 2015 , 198, 35-54		79
775	Asthma is not only an airway disease, but also a vascular disease. 2015 , 148, 17-33		42
774	Angiogenic effects of ionic dissolution products released from a boron-doped 45S5 bioactive glass. 2015 , 3, 1142-1148		66
773	The Conquest of Cancer. 2015 ,		
772	SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. <i>Oncogene</i> , 2015 , 34, 878-89	9.2	18
771	Diabetes Mellitus. 2015 , 527-553.e7		2
770	Autophagy in Ocular Pathophysiology. 2016 ,		1
769	Fluorescence and Cerenkov luminescence imaging. 2016 , 55, 63-70		4
768	Nanoformulations: A lucrative tool for protein delivery in cancer therapy. 2016 , 307-330		
767	Image-enhanced bronchoscopic evaluation of bronchial mucosal microvasculature in COPD. 2016 , 11, 2447-2455		5
766	Design of Nanoparticle-Based Carriers for Targeted Drug Delivery. 2016 , 2016,		138
765	Active-target T1-weighted MR Imaging of Tiny Hepatic Tumor via RGD Modified Ultra-small Fe ₃ O ₄ Nanoprobes. 2016 , 6, 1780-91		46
764	Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles. 2016 , 11, 5671-5682		16

763	Tension in Cancer. 2016 , 17,	12
762	Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular Pathology. 2016 , 5,	13
761	Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and $\alpha_5\beta_1$ Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells. 2016 , 11, e0158592	9
760	Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin. 2016 , 11, e0163732	21
759	Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. 2016 , 11, e0168366	10
758	Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. 2016 , 128, 10048-10051	4
757	A Combined NMR and Computational Approach to Determine the RGD $\alpha_5\beta_1$ Integrin Recognition Mode in Isolated Cell Membranes. 2016 , 22, 681-93	19
756	Crossing the barrier: treatment of brain tumors using nanochain particles. 2016 , 8, 678-95	21
755	Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. 2016 , 104, 889-900	66
754	Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy. 2016 , 26, 4192-4200	65
753	Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity. 2016 , 5, 1310-25	38
752	$\alpha_5\beta_1$ - or $\alpha_1\beta_1$ -Integrin-Selective Peptidomimetics for Surface Coating. 2016 , 55, 7048-67	76
751	Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. 2016 , 55, 9894-7	42
750	$\alpha_5\beta_1$ - oder $\alpha_1\beta_1$ -Integrin-selektive Peptidmimetika für die Oberflächenbeschichtung. 2016 , 128, 7162-7183	14
749	Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. 2016 , 6, 34523	13
748	A cytosensor based on NiO nanoparticle-enhanced surface plasmon resonance for detection of the breast cancer cell line MCF-7. 2016 , 183, 683-688	31
747	Antagonizing Integrin β Increases Immunosuppression in Cancer. 2016 , 76, 3484-95	45
746	Synergistic active targeting of dually integrin $\alpha_5\beta_1$ /CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. 2016 , 235, 1-13	57

745	Molecular Basis of the Ligand Binding Specificity of $\alpha_5\beta_1$ Integrin. 2016 , 291, 11551-65	30
744	The disintegrin tzbacanin inhibits adhesion and migration in melanoma and lung cancer cells. 2016 , 88, 457-64	27
743	Design, preparation and characterization of cyclic RGDfK peptide modified poly(ethylene glycol)-block-poly(lactic acid) micelle for targeted delivery. 2016 , 64, 303-309	19
742	Tailoring Fluorescent Dyes To Optimize a Hybrid RGD-Tracer. 2016 , 27, 1253-8	46
741	Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. 2016 , 163, 94-108	441
740	Extracellular Matrix and Tissue Regeneration. 2016 , 1-55	2
739	A review on evaluation of technetium-99m labeled radiopharmaceuticals. 2016 , 310, 477-493	25
738	Targeted Dendrimers for Cancer Diagnosis and Therapy. 2016 , 61-86	1
737	Endothelial Cells Require CD98 for Efficient Angiogenesis-Brief Report. 2016 , 36, 2163-2166	8
736	$\alpha_5\beta_1$ Integrin and tumour blood vessels-learning from the past to shape the future. 2016 , 42, 121-127	65
735	Imaging Angiogenesis. 2016 , 549-567	
734	Antiendothelial $\alpha_5\beta_1$ Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. 2016 , 36, 1517-24	56
733	In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT-116 xenograft model in nude mice. 2016 , 36, 2951-2959	5
732	Comparison of the accuracy of Tc-3P-RGD SPECT and CT in diagnosing solitary pulmonary nodules. 2016 , 12, 2517-2523	1
731	In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs. 2016 , 513, 211-217	18
730	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. 2016 , 111, 577-591	26
729	Microvessels-on-a-Chip to Assess Targeted Ultrasound-Assisted Drug Delivery. 2016 , 8, 31541-31549	17
728	Rational design of a protein that binds integrin $\alpha_5\beta_1$ outside the ligand binding site. 2016 , 7, 11675	18

727	NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase. 2016 , 6, 36210	14
726	A Multifunctional Platform for Tumor Angiogenesis-Targeted Chemo-Thermal Therapy Using Polydopamine-Coated Gold Nanorods. 2016 , 10, 10404-10417	154
725	Molecular Radio-Oncology. 2016 ,	1
724	Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology. 2016 , 198, 89-106	7
723	Quantification of Endothelial α_1 Expression with High-Frequency Ultrasound and Targeted Microbubbles: In Vitro and In Vivo Studies. 2016 , 42, 2283-93	18
722	Inhibition of angiopoietin-1 (ANGPT1) affects vascular integrity in ovarian hyperstimulation syndrome (OHSS). 2016 , 28, 690-9	10
721	Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis. 2016 , 44, 1983-92	8
720	Safety of targeting tumor endothelial cell antigens. 2016 , 14, 90	5
719	SPECT Imaging of 2-D and 3-D Distributed Sources with Near-Field Coded Aperture Collimation: Computer Simulation and Real Data Validation. 2016 , 36, 32-43	4
718	Long Term Follow-Up of Dental Implants Placed in Autologous Onlay Bone Graft. 2016 , 18, 449-61	17
717	Advances in Nanotheranostics II. 2016 ,	3
716	Molecular Imaging of Tumor Angiogenesis with Magnetic Nanoprobes. 2016 , 75-104	
715	Next-Generation Ultrasonic Theranostic Agents for Molecular Imaging and Therapy: Design, Preparation, and Biomedical Application. 2016 , 153-188	1
714	Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases. 2016 , 25, 319-34	12
713	Preparation and bioevaluation of [99mTcN]2+-labeled tetrameric complex of E-c(RGDfK)2 as a radiotracer for imaging α_1 integrins in tumors. 2016 , 309, 923	5
712	Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. 2016 , 12, 269-86	75
711	Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway. 2016 , 291, 2731-50	16
710	MART-10, the new brand of 1 β 25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro. 2016 , 155, 26-34	7

709	Anti-angiogenic alternatives to VEGF blockade. 2016 , 33, 197-210	23
708	Targeting of proangiogenic signalling pathways in chronic inflammation. 2016 , 12, 111-22	62
707	Complementary, Selective PET Imaging of Integrin Subtypes α_1 and α_3 Using ^{68}Ga -Aquibepirin and ^{68}Ga -Avebetrin. 2016 , 57, 460-6	27
706	The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis. 2016 , 57 Suppl 1, 89S-95S	22
705	Adhesion molecules and the extracellular matrix as drug targets for glioma. 2016 , 33, 97-106	23
704	Serum amyloid A1: Structure, function and gene polymorphism. 2016 , 583, 48-57	99
703	Switchable two-photon imaging of RGD-functionalized polynorbornenes with enhanced cellular uptake in living cells. 2016 , 40, 3252-3260	6
702	Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery. 2016 , 40, 263-272	21
701	Integrin α_3 and RGD-based radiopharmaceuticals. 2016 , 40, 41-54	4
700	A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours. 2016 , 24, 590-602	31
699	RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. 2016 , 12, 1627-39	88
698	A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging. 2016 , 85, 168-79	44
697	Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges. 2016 , 12, 287-307	112
696	Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis. 2016 , 80, 67-74	11
695	Pilot prospective evaluation of $(^{18}\text{F})\text{-FPPRGD2}$ PET/CT in patients with cervical and ovarian cancer. 2016 , 43, 1047-55	17
694	Listening to the Brain With Photoacoustics. 2016 , 22, 117-126	28
693	JunB regulates angiogenesis and neurovascular parallel alignment in mouse embryonic skin. 2017 , 130, 916-926	14
692	A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors. 2017 , 25, 92-101	53

691	Comparison of Tc-99m maraciclalide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. 2017 , 7, 5	10
690	Molecular Imaging of Abdominal Aortic Aneurysms. 2017 , 23, 150-164	19
689	Nonconventional trans-Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytotoxicity Studies. 2017 , 2017, 1835-1840	9
688	Next generation NIR fluorophores for tumor imaging and fluorescence-guided surgery: A review. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 2017-2034	3-4 125
687	Nanotherapeutics relieve rheumatoid arthritis. 2017 , 252, 108-124	118
686	Integrin signaling in atherosclerosis. 2017 , 74, 2263-2282	53
685	Controlled PEGylation Crowdedness for Polymeric Micelles To Pursue Ligand-Specified Privileges as Nucleic Acid Delivery Vehicles. 2017 , 9, 8455-8459	4
684	Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel F-Labeled Cyclic RGD Analogues. 2017 , 14, 1169-1180	6
683	Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. 2017 , 12, 1075-1086	27
682	Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary-like tube formation. 2017 , 41, 769-778	18
681	In-Cell Dual Drug Synthesis by Cancer-Targeting Palladium Catalysts. 2017 , 129, 6968-6972	21
680	Modulating angiogenesis with integrin-targeted nanomedicines. 2017 , 119, 101-119	46
679	Evaluation of Tc-3PRGD integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with F-FDG metabolic imaging. 2017 , 31, 486-494	3
678	In-Cell Dual Drug Synthesis by Cancer-Targeting Palladium Catalysts. 2017 , 56, 6864-6868	70
677	First plasma and tissue pharmacokinetic study of the YSNSG cyclopeptide, a new integrin antagonist, using microdialysis. 2017 , 105, 178-187	1
676	Anti-human platelet antigen (HPA)-1a antibodies may affect trophoblast functions crucial for placental development: a laboratory study using an in vitro model. 2017 , 15, 28	12
675	Extracellular matrix protein laminin enhances mesenchymal stem cell (MSC) paracrine function through $\alpha 5 \beta 1$ /CD61 integrin to reduce cardiomyocyte apoptosis. 2017 , 21, 1572-1583	22
674	High-Affinity "Click" RGD Peptidomimetics as Radiolabeled Probes for Imaging $\alpha 5 \beta 1$ Integrin. 2017 , 12, 1142-1151	8

673	Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin β recycling, cell migration and cancer metastasis. <i>Oncogene</i> , 2017 , 36, 5757-5767	9.2	19
672	Low levels of physiological interstitial flow eliminate morphogen gradients and guide angiogenesis. 2017 , 20, 493-504		59
671	Thrombospondin-1-Derived Peptide RFYVVMWK Improves the Adhesive Phenotype of CD34 Cells From Atherosclerotic Patients With Type 2 Diabetes. 2017 , 26, 327-337		5
670	Activation mechanisms of $\alpha 5 \beta 1$ integrin by binding to fibronectin: A computational study. 2017 , 26, 1124-1137		16
669	Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. 2017 , 25, 534-546		14
668	The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. 2017 , 37,		17
667	The anti-tumor effects of the recombinant toxin protein rLj-RGD3 from <i>Lampetra japonica</i> on pancreatic carcinoma Panc-1 cells in nude mice. 2017 , 88, 8-17		5
666	Genetically tailored magnetosomes used as MRI probe for molecular imaging of brain tumor. 2017 , 121, 167-178		67
665	Next generation ultrasound platforms for theranostics. <i>Journal of Colloid and Interface Science</i> , 2017 , 491, 151-160	9.3	20
664	<i>Davallia bilabiata</i> exhibits anti-angiogenic effect with modified MMP-2/TIMP-2 secretion and inhibited VEGF ligand/receptors expression in vascular endothelial cells. 2017 , 196, 213-224		9
663	Vascular inter-regulation of inflammation: molecular and cellular targets for CNS therapy. 2017 , 140, 692-702		9
662	Integrin Antagonists and Angiogenesis. 2017 , 99-123		1
661	Melanoma topology reveals a stem-like phenotype that promotes angiogenesis. 2017 , 3, e1701350		18
660	Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. 2017 , 532, 581-594		22
659	Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. 2017 , 268, 49-56		4
658	miR-200b downregulates Kruppel Like Factor 2 (KLF2) during acute hypoxia in human endothelial cells. 2017 , 96, 758-766		28
657	Imaging of Integrin β Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer Tc-IDA-D-[c(RGDfK)]. 2017 , 32, 288-296		6
656	Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/ β -catenin pathway in gliomas. 2018 , 29, 71-91		66

655	Bone-Induced Expression of Integrin β Enables Targeted Nanotherapy of Breast Cancer Metastases. 2017 , 77, 6299-6312	42
654	Insufficient Angiogenesis: Cause of Abnormally Thin Endometrium in Subfertile Patients?. 2017 , 77, 756-764	23
653	Endothelial cells: From innocent bystanders to active participants in immune responses. 2017 , 16, 951-962	80
652	A salt-bridge switch in the molecular recognition between RS receptor and RGD ligand from the ABEEM Γ molecular dynamics simulations. 2017 , 43, 1045-1055	0
651	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. 2017 , 31, 43-51	31
650	Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability. 2017 , 16, 953-961	115
649	Platelet-targeted pharmacologic treatments as anti-cancer therapy. 2017 , 36, 331-355	27
648	Photothermal, Targeting, Theranostic Near-Infrared Nanoagent with SN38 against Colorectal Cancer for Chemothermal Therapy. 2017 , 14, 2766-2780	16
647	Imaging of β Integrin expression in experimental myocardial ischemia with [Ga]NODAGA-RGD positron emission tomography. 2017 , 15, 144	15
646	Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. 2017 , 9, e1439	41
645	Evaluation of a Flexible NOTA-RGD Kit Solution Using Gallium-68 from Different Ge/Ga-Generators: Pharmacokinetics and Biodistribution in Nonhuman Primates and Demonstration of Solitary Pulmonary Nodule Imaging in Humans. 2017 , 19, 469-482	13
644	Von Willebrand factor and angiogenesis: basic and applied issues. 2017 , 15, 13-20	105
643	The Extracellular Matrix in Development. 2017 , 49-54.e2	
642	Molecular Regulation of Sprouting Angiogenesis. 2017 , 8, 153-235	29
641	Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. 2017 , 117, 595-605	1
640	Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis. 2017 , 34, 283-316	7
639	Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes. 2017 , 8, 32741-32751	33
638	β binding to a fibrinogen fragment lacking the β chain dodecapeptide is activation dependent and EDTA inducible. 2017 , 1, 417-428	8

637 Cell Recruitment and Angiogenesis. **2017**, 384-395.e5

636 Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. **2017**, 8, 52193-52210 18

635 RGD-Binding Integrins in Head and Neck Cancers. **2017**, 9, 19

634 4.9 Integrin-Activated Reactions to Metallic Implant Surfaces ?. **2017**, 130-151

633 In vitro and in vivo effects of PDGF-BB delivery strategies on tendon healing: a review. **2017**, 34, 15-39 37

632 Talin Modulation by a Synthetic N-Acylurea Derivative Reduces Angiogenesis in Human Endothelial Cells. **2017**, 18, 5

631 Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. **2017**, 6, 39-49 17

630 Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides. **2017**, 12, 1517-1537 49

629 Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line. **2017**, 15, 495-501 12

628 Molecular imaging of integrins in oncology. **2017**, Volume 10, 17-30 7

627 Association of aquaporin-1 with tumor migration, invasion and vasculogenic mimicry in glioblastoma multiforme. **2018**, 17, 3206-3211 10

626 Therapeutic Radiopharmaceuticals Targeting Integrin $\alpha_5\beta_1$. **2018**, 3, 2428-2436 15

625 Tropoelastin Implants That Accelerate Wound Repair. **2018**, 7, e1701206 21

624 Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. **2018**, 129, 37-53 81

623 Biomaterials for revascularization and immunomodulation after spinal cord injury. **2018**, 13, 044105 33

622 Mid-size Drugs Based on Peptides and Peptidomimetics. **2018**, 2

621 "NOTA-PRGD and NODAGA-PRGD : Bioconjugation, characterization, radiolabelling, and design space". **2018**, 61, 487-500 1

620 Endothelial lineage-specific interaction of Mycobacterium tuberculosis with the blood and lymphatic systems. **2018**, 111, 1-7 3

619	F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. 2018 , 59, 1809-1816	21
618	Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step Förster resonance energy transfer imaging. 2018 , 8, 261-271	24
617	Novel Cu Labeled RGD-BBN Heterotrimers for PET Imaging of Prostate Cancer. 2018 , 29, 1595-1604	19
616	Bleeding or no bleeding? Anti-endothelial $\alpha V\beta 3$ antibodies as a major cause of intracranial haemorrhage in fetal/neonatal alloimmune thrombocytopenia. 2018 , 13, 59-69	2
615	$\alpha 3\beta 1$ and $\alpha 5\beta 1$ integrin-specific ligands: From tumor angiogenesis inhibitors to vascularization promoters in regenerative medicine?. 2018 , 36, 208-227	31
614	Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation. 2018 , 9, 9951-9962	3
613	Cardiac fibrosis in regenerative medicine: destroy to rebuild. 2018 , 10, S2376-S2389	13
612	Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment. 2018 , 23,	24
611	Promoted Angiogenesis Associated With Modified MMP-2/TIMP-2 Balance and Activation of VEGF Ligand/Receptors Expression. 2018 , 9, 979	10
610	Peptide-based targeted therapeutics: Focus on cancer treatment. 2018 , 292, 141-162	66
609	Integrin-Mediated Delivery of Drugs and Nucleic Acids for Anti-Angiogenic Cancer Therapy: Current Landscape and Remaining Challenges. 2018 , 5,	14
608	Mechanical Forces in Tumor Angiogenesis. 2018 , 1092, 91-112	52
607	Physiology and Pathophysiology of Wound Healing in Diabetes. 2018 , 109-130	0
606	isoDGR-Peptides for Integrin Targeting: Is the Time Up for RGD?. 2018 , 61, 7471-7473	8
605	The $\beta 1$ -integrin endothelial adhesome regulates microtubule-dependent cell migration. 2018 , 19,	9
604	The interface between the EGF1 and EGF2 domains is critical in integrin affinity regulation. 2018 , 119, 7264-7273	5
603	Integrin Targeting Systems for Tumor Diagnosis and Therapy. 2018 ,	
602	Recombinant Spider Silk Functionalized Silkworm Silk Matrices as Potential Bioactive Wound Dressings and Skin Grafts. 2018 , 10, 23560-23572	40

601 Progranulin. **2018**,

- 600 Methods to Investigate the Roles of Progranulin in Angiogenesis Using In Vitro Strategies and Transgenic Mouse Models. **2018**, 1806, 329-360 2
- 599 Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention. **2018**, 41, 711-724 32
- 598 Immunomodulatory and enhanced antitumor activity of a modified thymosin α 1 in melanoma and lung cancer. **2018**, 547, 611-620 9
- 597 Intrauterine growth restriction decreases NF- κ B signaling in fetal pulmonary artery endothelial cells of fetal sheep. **2018**, 315, L348-L359 10
- 596 Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis. **2018**, 11, 1787-1799 32
- 595 An optimized LC-MS/MS method for determination of HYNIC-3PRGD, a new promising imaging agent for tumor targeting, in rat plasma and its application. **2018**, 1095, 142-148 0
- 594 Type IV Secretion System and Its Adhesin Subunit, CagL, Mediate Potent Inflammatory Responses in Primary Human Endothelial Cells. **2018**, 8, 22 18
- 593 Peptides derived from the integrin α 5 cytoplasmic tails inhibit angiogenesis. **2018**, 16, 38 7
- 592 Angiogenesis PET Tracer Uptake (68 Ga-NODAGA-E[(cRGDyK)] α 5 in Induced Myocardial Infarction and Stromal Cell Treatment in Minipigs. **2018**, 8, 3
- 591 Imaging the Vascular Bone Marrow Niche During Inflammatory Stress. **2018**, 123, 415-427 31
- 590 Platelet-Activation Mechanisms and Vascular Remodeling. **2018**, 8, 1117-1156 16
- 589 Multifaced Roles of the α 5 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts. **2018**, 19, 14
- 588 Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells. **2018**, 23, 25
- 587 Comparison of Radioiodine- or Radiobromine-Labeled RGD Peptides between Direct and Indirect Labeling Methods. **2018**, 66, 651-659 16
- 586 Synergistic Active Targeting to B16F10 Tumors by α 5/CD44-Targeted Nanoparticles Loaded with Docetaxel. **2018**, 207-223
- 585 CAR T cells targeting α 5 Integrin are effective against advanced cancer in preclinical models. **2018**, 1, e11 28
- 584 Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15. **2018**, 3, 21 4

583	Porphyrinoid biohybrid materials as an emerging toolbox for biomedical light management. 2018 , 47, 7369-7400	112
582	Biodistribution and Internal Radiation Dosimetry of Tc-IDA-D-[c(RGDfK)] (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin Expression. 2018 , 33, 396-402	6
581	Dendrimer-based magnetic resonance imaging agents for brain cancer. 2018 , 61, 1420-1443	6
580	Photostable and Biocompatible Fluorescent Silicon Nanoparticles-Based Theranostic Probes for Simultaneous Imaging and Treatment of Ocular Neovascularization. 2018 , 90, 8188-8195	27
579	EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. 2018 , 233, 8526-8537	25
578	Structure, Function, and Evaluation of the Female Reproductive Tract. 2019 , 206-247.e13	13
577	Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression. 2019 , 79, 5048-5059	12
576	Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. 2019 , 60, 1743-1749	73
575	Patrolling the vascular borders: platelets in immunity to infection and cancer. 2019 , 19, 747-760	54
574	The uPAR System as a Potential Therapeutic Target in the Diseased Eye. 2019 , 8,	7
573	The Scope of Application of Macrocyclic Polyamines Beyond Metal Chelation. 2019 , 2019, 6146-6157	10
572	Design, synthesis and biological evaluation of peptide-NSAID conjugates for targeted cancer therapy. 2019 , 352, e1800379	6
571	Frontiers in positron emission tomography imaging of the vulnerable atherosclerotic plaque. 2019 , 115, 1952-1962	12
570	Cell Adhesion by Integrins. 2019 , 99, 1655-1699	113
569	Basic fibroblast growth factor promotes prehierarchical follicle growth and yolk deposition in the chicken. 2019 , 139, 90-97	11
568	Nanomedicine - advantages for their use in rheumatoid arthritis theranostics. 2019 , 316, 302-316	38
567	Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme. 2019 , 30, 3087-3097	17
566	Integrin-dependent regulation of the endothelial barrier. 2019 , 7, 1685844	11

565	Comparison of Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. 2019 , 78-79, 1-10	9
564	Potential of targeted drug delivery systems in treatment of rheumatoid arthritis. 2019 , 53, 101217	2
563	Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease. 2019 , 249, 523-535	2
562	3D printed HUVECs/MSCs cocultures impact cellular interactions and angiogenesis depending on cell-cell distance. 2019 , 222, 119423	37
561	In Vivo Biodistribution of Engineered Lipid Microbubbles in Rodents. 2019 , 4, 13371-13381	4
560	Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin $\alpha_5\beta_1$ -Specific Apoptotic Peptide and Therapeutic Nitric Oxide. 2019 , 11, 34663-34675	9
559	Targeted Delivery of Camptothecin-Encapsulated Carbon Nanotube-Cyclic RGD in 2D and 3D Cancer Cell Culture. 2019 , 108, 3704-3712	7
558	Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling. 2019 , 203, 1383-1391	13
557	Gold Nanoparticle Aggregates Functionalized with Cyclic RGD Peptides for Targeting and Imaging of Colorectal Cancer Cells. 2019 , 2, 6436-6444	23
556	Recent Advances in Imaging Inflammation Post-Myocardial Infarction Using Positron Emission Tomography. 2019 , 12, 1	
555	Hypercholesterolemia-induced increase in plasma oxidized LDL abrogated pro angiogenic response in kidney grafts. 2019 , 17, 26	3
554	Bone as a Preferential Site for Metastasis. 2019 , 3, e10126	22
553	Photoacoustic Therapy for Precise Eradication of Glioblastoma with a Tumor Site Blood-Brain Barrier Permeability Upregulating Nanoparticle. 2019 , 29, 1808601	21
552	Molecular Imaging in Ischemic Heart Disease. 2019 , 12, 31	2
551	Bush-like integrin filament networks associated with hyaloid vasculature in murine neonate eyes. 2019 , 40, 79-85	
550	Tumor Chemo-Radiotherapy with Rod-Shaped and Spherical Gold Nano Probes: Shape and Active Targeting Both Matter. 2019 , 9, 1893-1908	39
549	Radiotheranostics Coupled between an At-211-Labeled RGD Peptide and the Corresponding Radioiodine-Labeled RGD Peptide. 2019 , 4, 4584-4591	18
548	The Role of Platelets in Atherothrombosis. 2019 , 459-467	4

547	Alloimmune Thrombocytopenia. 2019 , 833-848	1
546	Roles of EphA1/A2 and ephrin-A1 in cancer. 2019 , 110, 841-848	28
545	Platelet physiology and immunology: pathogenesis and treatment of classical and non-classical fetal and neonatal alloimmune thrombocytopenia. 2019 , 4, 29-29	4
544	Systems-wide analysis unravels the new roles of CCM signal complex (CSC). 2019 , 5, e02899	10
543	Pretreatment PET/CT imaging of angiogenesis based on F-RGD tracer uptake may predict antiangiogenic response. 2019 , 46, 940-947	17
542	RGD-modified PEGylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability. 2019 , 556, 217-225	33
541	Cancer-targeted and glutathione-responsive micellar carriers for controlled delivery of cabazitaxel. 2019 , 30, 055601	4
540	Preclinical SPECT Imaging of Choroidal Neovascularization in Mice Using Integrin-Binding [Tc]IDA-D-[c(RGDfK)]. 2019 , 21, 644-653	1
539	Hypoxia: The force of endometriosis. 2019 , 45, 532-541	28
538	Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications. 2019 , 383, 104-131	19
537	Genetic Variants of and Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. 2019 , 79, 231-241	9
536	Dual-functional gelatin-capped silver nanoparticles for antibacterial and antiangiogenic treatment of bacterial keratitis. <i>Journal of Colloid and Interface Science</i> , 2019 , 536, 112-126	9.3 33
535	Tenascin-C Produced by Intestinal Myofibroblasts Promotes Colitis-associated Cancer Development Through Angiogenesis. 2019 , 25, 732-741	12
534	RGD peptide-based non-viral gene delivery vectors targeting integrin β for cancer therapy. 2019 , 27, 1-11	49
533	Therapeutic Antibodies and Immunologic Conjugates. 2020 , 486-499.e8	1
532	Emerging roles of ECM remodeling processes in cancer. 2020 , 62, 192-200	63
531	Surface markers: An identity card of endothelial cells. 2020 , 27, e12587	11
530	Crucial Role for Endothelial Cell α 1 Integrin Receptor Clustering in Collagen-Induced Angiogenesis. 2020 , 303, 1604-1618	7

529	Boron agents for neutron capture therapy. 2020 , 405, 213139		56
528	Synthesis and characterization of Cu- and Cy5.5-labeled tetraiodothyroacetic acid derivatives for tumor angiogenesis imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2020 , 28, 115212	3-4	1
527	Immune-Mediated Cytopenia in the Pediatric Setting. 2020 , 167-181		
526	Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer. 2020 , 15, 6791-6811		4
525	The role of integrins in inflammation and angiogenesis. 2021 , 89, 1619-1626		39
524	Molecular Ultrasound Imaging. 2020 , 10,		15
523	Anti-integrin therapy for retinovascular diseases. 2020 , 29, 935-945		13
522	Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions. 2020 , 10,		7
521	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease. 2020 , 18, 2721-2731		3
520	Altered Protein Function Caused by AMD-associated Variant rs704 Links Vitronectin to Disease Pathology. 2020 , 61, 2		3
519	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. 2020 , 12,		9
518	Vascularisation of Skeletal Muscle. 2020 ,		
517	Temporal changes guided by mesenchymal stem cells on a 3D microgel platform enhance angiogenesis in vivo at a low-cell dose. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 19033-19044	11.5	19
516	Anticoagulant and signaling functions of antithrombin. 2020 , 18, 3142-3153		13
515	Noninvasive Molecular Imaging of the Enhanced Permeability and Retention Effect by Cu-Liposomes: In vivo Correlations with Ga-RGD, Fluid Pressure, Diffusivity and F-FDG. 2020 , 15, 8571-8581		7
514	Integrin-Ligand Interactions in Inflammation, Cancer, and Metabolic Disease: Insights Into the Multifaceted Roles of an Emerging Ligand Irisin. 2020 , 8, 588066		19
513	Biomaterials for Bioprinting Microvasculature. 2020 , 120, 10887-10949		25
512	Cyclic RGD-Functionalized -Dodecaborate Albumin Conjugates as Integrin Targeting Boron Carriers for Neutron Capture Therapy. 2020 , 17, 3740-3747		12

511	Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines. 2020 , 10, 14505	9
510	Review of Integrin-Targeting Biomaterials in Tissue Engineering. 2020 , 9, e2000795	16
509	3D monitoring of tumor volume in an in vivo model. 2020 , 76, 123-131	6
508	Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin β Levels and Is Dependent on STAT3. 2020 , 94,	5
507	Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions. 2020 , 7, 1902933	15
506	PKC (Protein Kinase C)-Modulates AT (Antithrombin) Signaling in Vascular Endothelial Cells. 2020 , 40, 1748-1762	3
505	Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. 2020 , 154-155, 245-273	12
504	Cancer Burden Is Controlled by Mural Cell- β -Integrin Regulated Crosstalk with Tumor Cells. 2020 , 181, 1346-1363.e21	20
503	Engineering nanoparticles to tackle tumor barriers. 2020 , 8, 6686-6696	4
502	Nanoparticle-based co-delivery of siRNA and paclitaxel for dual-targeting of glioblastoma. 2020 , 15, 1391-1409	14
501	Small extracellular vesicles modulated by α β integrin induce neuroendocrine differentiation in recipient cancer cells. 2020 , 9, 1761072	15
500	NRP2 as an Emerging Angiogenic Player; Promoting Endothelial Cell Adhesion and Migration by Regulating Recycling of β Integrin. 2020 , 8, 395	9
499	CASIN and AMD3100 enhance endothelial cell proliferation, tube formation and sprouting. 2020 , 130, 104001	5
498	High Density Display of an Anti-Angiogenic Peptide on Micelle Surfaces Enhances Their Inhibition of α β Integrin-Mediated Neovascularization In Vitro. 2020 , 10,	6
497	Prognosis Evaluation Using F-Alfatide II PET in a Rat Model of Spinal Cord Injury Treated With Estrogen. 2020 , 19, 1536012120909199	0
496	Engineering bacterial outer membrane vesicles as transdermal nanoplatfoms for photo-TRAIL-programmed therapy against melanoma. 2020 , 6, eaba2735	33
495	MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy. 2020 , 7, 1902746	11
494	Bioinspired Biomaterials. 2020 ,	1

493	Isolation of an Anti-Tumour Disintegrin: Dabmaurin-1, a Peptide Lebein-1-Like, from Venom. 2020 , 12,	3
492	Infection and Inflammation Imaging: Beyond FDG. 2020 , 15, 215-229	5
491	Angiogenic Networks in Tumors-Insights via Mathematical Modeling. 2020 , 8, 43215-43228	5
490	[F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. 2020 , 47, 1239-1251	7
489	An octopus-mimic PEGylated peptide as a specific integrin $\alpha 3$ inhibitor for preventing tumor progression. 2020 , 56, 2178-2181	3
488	Temperature-Responsive Multifunctional Protein Hydrogels with Elastin-like Polypeptides for 3-D Angiogenesis. 2020 , 21, 1126-1135	14
487	Multifunctional coatings combining bioactive peptides and affinity-based cytokine delivery for enhanced integration of degradable vascular grafts. 2020 , 8, 1734-1747	10
486	Wound repair: basic biology to tissue engineering. 2020 , 1309-1329	3
485	The dynamics of cell-extracellular matrix interactions, with implications for tissue engineering. 2020 , 93-117	2
484	Opening of endothelial cell-cell contacts due to sonoporation. 2020 , 322, 426-438	18
483	Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer. 2021 , 22, 1151-1160	11
482	An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism. 2021 , 191, 527-544	1
481	Two sides of the same coin: Insights into the myoepithelial cells in carcinoma ex pleomorphic adenoma development. 2021 , 157, 103195	1
480	Engineering a Chemically Defined Hydrogel Bioink for Direct Bioprinting of Microvasculature. 2021 , 22, 275-288	7
479	RGD peptide-mediated liposomal curcumin targeted delivery to breast cancer cells. 2021 , 35, 743-753	22
478	Atherosclerosis imaging using PET: Insights and applications. 2021 , 178, 2186-2203	6
477	Congestive Heart Failure. 2021 , 1167-1191	
476	Influence of integrins on thrombus formation: a road leading to the unravelling of DVT. 2021 , 476, 1489-1504	1

475	Chloroalkene dipeptide isosteres as peptidomimetics. 2021 , 656, 191-239	0
474	RGD-binding integrins and TGF- β in SARS-CoV-2 infections - novel targets to treat COVID-19 patients?. 2021 , 10, e1240	12
473	Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. 2021 , 11, 6507-6521	20
472	SAA1 knockdown promotes the apoptosis of glioblastoma cells via downregulation of AKT signaling. 2021 , 12, 2756-2767	2
471	Tumor Vasculature. 2021 , 831-867	0
470	Natural Polysaccharides on Wound Healing. 2021 , 1-16	
469	Organometallic Chemistry of Drugs Based on Technetium and Rhenium. 2021 ,	
468	A Global Review on Short Peptides: Frontiers and Perspectives. 2021 , 26,	37
467	Targeted brain tumor imaging by using discrete biopolymer-coated nanodiamonds across the blood-brain barrier. 2021 , 13, 3184-3193	1
466	Antagonizing $\alpha_5\beta_1$ Integrin Improves Ischemia-Mediated Vascular Normalization and Blood Perfusion by Altering Macrophages. 2021 , 12, 585778	1
465	Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. 2021 , 218,	6
464	Molecular mediators of breast cancer metastasis. 2021 , 14, 275-289	3
463	Vitronectin-activated $\alpha_5\beta_1$ and $\alpha_5\beta_3$ integrin signalling specifies haematopoietic fate in human pluripotent stem cells. 2021 , 54, e13012	3
462	Emerging methods for the characterization of ischemic heart disease: ultrafast Doppler angiography, micro-CT, photon-counting CT, novel MRI and PET techniques, and artificial intelligence. 2021 , 5, 12	5
461	Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. 2021 , 85, 100966	5
460	Transforming Growth Factor-induced Protein Promotes NF- κ B-mediated Angiogenesis during Postnatal Lung Development. 2021 , 64, 318-330	2
459	Angiogenesis Inhibitors. 1-66	
458	New Thyrointegrin β Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. 2021 , 64, 6300-6309	3

- 457 A Programmable Toolkit to Dynamically Signal Cells Using Peptide Strand Displacement. **2021**, 13, 21018-21029
- 456 Long-Term Imaging of Wound Angiogenesis with Large Scale Optoacoustic Microscopy. **2021**, 8, 2004226 9
- 455 Non-productive angiogenesis disassembles A β plaque-associated blood vessels. **2021**, 12, 3098 8
- 454 Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. **2021**, 22, 6
- 453 Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA-Modified Peptidic Radioligands Targeting Both Integrin $\alpha_5\beta_1$ and the MC1 Receptor-Suitable for the Specific Visualization of Melanomas?. **2021**, 14, 3
- 452 Proangiogenic Collagen-Binding Glycan Therapeutic Promotes Endothelial Cell Angiogenesis. **2021**, 7, 3281-3292 2
- 451 Synthetic extracellular matrices with tailored adhesiveness and degradability support lumen formation during angiogenic sprouting. **2021**, 12, 3402 5
- 450 Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction. **2021**, 13, 1
- 449 Nanoformulation Shows Cytotoxicity against Glioblastoma Cell Lines and Antiangiogenic Activity in Chicken Chorioallantoic Membrane. *Pharmaceutics*, **2021**, 13, 6.4 1
- 448 Exploring Single Nucleotide Polymorphisms in ITGAV for Gastric, Pancreatic and Liver Malignancies: An Approach Towards the Discovery of Biomarker. **2021**, 24, 860-873 0
- 447 Association between [Ga]NODAGA-RGDyK uptake and dynamics of angiogenesis in a human cell-based 3D model. **2021**, 48, 5347-5353 1
- 446 Frischer Wind f β Integrine. **2021**, 44, 152-159
- 445 In Vivo Imaging of Biodegradable Implants and Related Tissue Biomarkers. **2021**, 13, 1
- 444 Integrins Within the Tumor Microenvironment: Biological Functions, Importance for Molecular Targeting, and Cancer Therapeutics Innovation. **2021**, 25, 417-430 1
- 443 RGD-modified multifunctional nanoparticles encapsulating salvianolic acid A for targeted treatment of choroidal neovascularization. **2021**, 19, 196 4
- 442 Evaluation of Integrin $\alpha_5\beta_1$ Expression in Murine Xenograft Models: [Ga]Ga-DOTA-C(RGDfK) PET Study with Immunohistochemical Confirmation. **2021**, 11, 1
- 441 Improvement of wound healing by the development of ECM-inspired biomaterial coatings and controlled protein release. **2021**, 402, 1271-1288 2
- 440 Assessment of breast cancer primary tumor material in a 3D in vivo model. **2021**, 79, 157-166 1

439	Molecular magnetic resonance imaging of Alpha-v-Beta-3 integrin expression in tumors with ultrasound microbubbles. 2021 , 275, 120896	5
438	Activatable luminescent probes for imaging brain diseases. 2021 , 39, 101239	1
437	Endothelial connexin-integrin crosstalk in vascular inflammation. 2021 , 1867, 166168	1
436	HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma. 2021 , 167, 106017	1
435	Extracellular PKM2 facilitates organ-tissue fibrosis progression. 2021 , 24, 103165	0
434	PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" $\alpha_5\beta_1$ with Ga-68-Trivehexin. 2021 , 1	3
433	Pericytes cross-talks within the tumor microenvironment. 2021 , 1876, 188608	6
432	RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy multiple tumorous targeting. 2021 , 11, 3301-3316	12
431	Treatment of rheumatoid arthritis by phototherapy: advances and perspectives. 2021 , 13, 14591-14608	3
430	An Injectable Nano-Enabled Thermogel to Attain Controlled Delivery of p11 Peptide for the Potential Treatment of Ocular Angiogenic Disorders of the Posterior Segment. <i>Pharmaceutics</i> , 2021 , 13, 13, 6.4	3
429	Recent progress in functional peptides designed for tumor-targeted imaging and therapy. 2021 , 9, 3749-3772	2
428	Impact of the protein corona on nanomaterial immune response and targeting ability. 2020 , 12, e1615	15
427	Imaging of Angiogenesis. 2007 , 394-411	1
426	Fibroblast Growth Factor-2 in Angiogenesis. 2008 , 77-88	2
425	Vitronectin-Binding Integrins in Cancer. 2010 , 137-170	1
424	Metastasis and angiogenesis. 2004 , 117, 285-304	44
423	Angiogenesis and Vasculogenesis in Pregnancy and in Tumor Development. 2001 , 251-266	1
422	The Role of Angiogenesis in the Development of Psoriasis. 2017 , 41-66	2

421	Vascularization of the Placenta. 2002 , 239-273	3
420	The Role of Cell Adhesion Receptors in Vascular Development: An Overview. 2002 , 97-110	3
419	Growth Factors and Angiogenesis in Wound Healing. 1997 , 8-26	5
418	The Morphogenesis of Primordial Vascular Networks. 1996 , 3-19	4
417	On the Possible Role of Endothelial Cell Heterogeneity in Angiogenesis. 1996 , 1-17	3
416	Angiogenesis in Cancer. 2013 , 335-356	4
415	Development of the Pulmonary Vasculature. 1999 , 152-195	2
414	Cancer Cell Respiration: Hypoxia and pH in Solid Tumors. 2013 , 183-206	1
413	Progresses in synthetic vascular prostheses: toward the endothelialization. 2003 , 534, 165-77	1
412	Restorative Potential of Angiogenesis after Ischemic Stroke. 2003 , 75-94	2
411	Structural and functional aspects of three major glycoproteins of the human milk fat globule membrane. 2001 , 501, 179-87	31
410	Targeting Integrins $\alpha_5\beta_1$ and $\alpha_v\beta_3$ for Blocking Tumor-Induced Angiogenesis. 2000 , 169-180	34
409	Signal transduction and transcriptional regulation of angiogenesis. 2000 , 476, 109-15	41
408	Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. 1999 , 469, 623-30	14
407	Angiogenesis and metastasis. 2002 , 107, 353-81	12
406	Immunopathogenesis of Kaposi's Sarcoma. 1996 , 437-450	3
405	Role of 12-lipoxygenase and protein kinase C in modulating the activation state of the integrin $\alpha_{IIb}\beta_3$ on human tumor cells. 1997 , 407, 55-60	5
404	Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma. 2015 , 1317, 359-64	1

403	Diagnostic and Prognostic Significance of Tumor Angiogenesis. 2002 , 151-176	1
402	Contact-Guided Angiogenesis and Tissue Engineering. 2002 , 295-313	1
401	Angiogenesis. 1999 , 29-49	4
400	Thalidomide and Analogs. 1999 , 263-274	1
399	Potential of Cytotoxic Cancer Therapies by Antiangiogenic Agents. 1999 , 277-316	5
398	Thalidomide. 1999 , 407-422	1
397	Fibroblast Growth Factors in Tumor Progression and Angiogenesis. 1999 , 93-118	4
396	C-X-C Chemokines and Lung Cancer Angiogenesis. 1999 , 143-167	1
395	Discovery of TNP-470 and Other Angiogenesis Inhibitors. 1997 , 283-298	1
394	Angiogenesis and Ocular Tumorigenesis. 2006 , 161-171	1
393	Angiogenesis Switch Pathways. 2008 , 239-256	3
392	MicroPET, MicroSPECT, and NIR fluorescence imaging of biomolecules in vivo. 2009 , 544, 461-81	2
391	Adhesion molecules: potential therapeutic and diagnostic implications. 2010 , 663, 261-76	8
390	Overview: studying integrins in vivo. 2012 , 757, 369-97	72
389	Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation. 2020 , 1221, 97-135	16
388	The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. 1997 , 79, 361-90	43
387	Tumor angiogenesis: functional similarities with tumor invasion. 1997 , 79, 413-8	17
386	Regulation of angiogenesis in malignant gliomas. 1997 , 79, 47-64	10

385	Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. 1997 , 79, 113-56	20
384	Sex and Sex Hormones Mediate Wound Healing. 2015 , 31-48	4
383	Fibronectin and Other Adhesive Glycoproteins. 2011 , 41-75	24
382	(68)Ga-labeled bombesin analogs for receptor-mediated imaging. 2013 , 194, 221-56	6
381	Cloning of JAM-2 and JAM-3: an emerging junctional adhesion molecular family?. 2000 , 251, 91-8	59
380	Extracellular Matrix and Tissue Regeneration. 2011 , 21-80	22
379	The Discovery of Disintegrins. 2010 , 269-284	1
378	Our Current Knowledge. 2015 , 35-67	1
377	Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer.	2
376	Retinal and Choroidal Blood Flow in Health and Disease. 2006 , 83-102	10
375	Intraocular Neovascularization. 2006 , 2403-2411	1
374	DYNAMICS OF CELL-ECM INTERACTIONS. 2000 , 33-55	13
373	MATRIX EFFECTS. 2000 , 237-250	7
372	Cryopreserved Dermal Implants. 2002 , 1157-II	2
371	Integrin Antagonists as Cancer Therapeutics. 2002 , 379-396	1
370	Vasculogenesis and Angiogenesis. 2002 , 211-233	10
369	CXC Chemokines in Angiogenesis. 2002 , 129-148	4
368	Cell Recruitment and Angiogenesis. 2013 , 358-368.e5	2

367	Isolation of a Sponge-derived Extracellular Matrix Adhesion Protein. 1996 , 271, 16119-16125	12
366	Sugar amino acids and carbohydrates as scaffolds and peptidomimetics. 1999 , 263-292	19
365	Tumor-Targeted Anti-VEGF RNAi Capable of Sequentially Responding to Intracellular Microenvironments for Potent Systemic Tumor Suppression.. 2020 , 3, 9145-9155	3
364	The role of alpha(v)beta(3) in prostate cancer progression. 2002 , 4, 191-4	92
363	Angiogenesis and angiogenic mediators in haematological malignancies. 2000 , 111, 43-51	74
362	CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6355-60	11.5 377
361	Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. 2001 , 15, 1021-1027	16
360	Alphavbeta3 integrin binding affinity and specificity of SM256 in various species. 1999 , 33, 641-6	26
359	Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. 2000 , 36, 498-502	19
358	Integrins and the kidney: biology and pathobiology. 1999 , 8, 9-14	19
357	Clinical evaluation of kit based Tc-99m-HYNIC-RGD2 for imaging angiogenesis in breast carcinoma patients. 2020 , 41, 1250-1256	1
356	Systems-wide analysis unravels the new roles of CCM signal complex (CSC).	2
355	NRP2 as an emerging angiogenic player; promoting endothelial cell adhesion and migration by regulating recycling of β integrin.	1
354	The diverse roles of integrins and their ligands in angiogenesis. 2002 , 67, 143-53	95
353	Profiling the molecular diversity of blood vessels. 2002 , 67, 223-5	14
352	A genetic approach to understanding tumor angiogenesis. 2002 , 67, 249-54	2
351	Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. 1997 , 136, 859-865	60
350	ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands. 2002 , 2002, pe7-pe7	7

349	Foot-and-Mouth Disease Virus-Receptor Interactions: Role in Pathogenesis and Tissue Culture Adaptation. 115-123	4
348	Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of lyme disease spirochetes to human cells. 1998 , 66, 1946-52	93
347	Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. 1996 , 70, 6831-8	240
346	Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. 1997 , 71, 8221-9	389
345	Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. 1998 , 72, 3587-94	165
344	Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. 1997 , 96, 1809-18	127
343	Ligation of endothelial alpha v beta 3 integrin increases capillary hydraulic conductivity of rat lung. 1995 , 77, 651-9	46
342	Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. 1995 , 77, 665-72	121
341	Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. 1995 , 77, 1129-35	157
340	Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. 1999 , 85, 1040-5	52
339	Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. 2004 , 3, 125-34	98
338	Inhibition of endothelial cell survival and angiogenesis by protein kinase A. 2002 , 110, 933-941	130
337	Endothelial integrins and angiogenesis: not so simple anymore. 2002 , 110, 913-914	22
336	Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. 1995 , 95, 1723-34	127
335	Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. 1995 , 95, 2096-103	64
334	Starve a tumor: therapeutic advice for breast cancer?. 1995 , 96, 1696-7	2
333	Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. 1995 , 96, 1815-22	650
332	Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. 1996 , 98, 426-33	297

331	Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. 1998 , 101, 1551-6	221
330	Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. 2003 , 112, 1142-51	218
329	Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. 2003 , 112, 1142-1151	372
328	Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. 2004 , 113, 1684-1691	189
327	Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. 2004 , 113, 1684-91	119
326	Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. 2006 , 116, 1596-605	68
325	Fibrosis and diseases of the eye. 2007 , 117, 576-86	171
324	Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. 1999 , 103, 47-54	246
323	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. 1999 , 103, 159-65	913
322	Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. 1999 , 103, 3-4	126
321	The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. 1999 , 103, 1227-30	501
320	Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. 1999 , 104, 1469-80	67
319	Maternal anti-platelet β integrins impair angiogenesis and cause intracranial hemorrhage. 2015 , 125, 1545-56	66
318	Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. 1998 , 101, 1401-13	327
317	Multiple Myeloma: New Insights and Therapeutic Approaches. 2000 , 2000, 147-165	6
316	Accutin, a New Disintegrin, Inhibits Angiogenesis In Vitro and In Vivo by Acting as Integrin α 5 β Antagonist and Inducing Apoptosis. 1998 , 92, 3268-3276	3
315	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. 1999 , 94, 4143-4155	14
314	Integrin Regulation in Wound Repair. 2000 , 63-97	2

313	Integrins and Pulmonary Fibrosis. 2003 , 359-378	1
312	Changes in endothelial cell and smooth muscle cell integrin expression during closure of the ductus arteriosus: an immunohistochemical comparison of the fetal, preterm newborn, and full-term newborn rhesus monkey ductus. 1996 , 40, 198-208	27
311	A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. 1998 , 125, 1591-1598	868
310	Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. 2002 , 129, 1397-1410	185
309	Transcriptional activation of endothelial cell integrin alpha v by protein kinase C activator 12(S)-HETE. 1995 , 108, 2629-2644	48
308	An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. 1995 , 108, 2655-2661	233
307	An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. 1995 , 108, 2825-2838	106
306	Cell adhesion in sponges: potentiation by a cell surface 68 kDa proteoglycan-binding protein. 1995 , 108, 3119-3126	14
305	Regulation of cell migration by the integrin beta subunit ectodomain. 1996 , 109, 1615-1622	29
304	The synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration. 1998 , 111, 469-478	134
303	The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. 1999 , 112, 1599-1609	50
302	Homophilic PECAM-1(CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration. 1999 , 112, 1989-1997	65
301	In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. 1999 , 112, 4213-4221	49
300	Adhesion and migration of avian neural crest cells on fibronectin require the cooperating activities of multiple integrins of the (beta)1 and (beta)3 families. 1999 , 112, 4715-4728	54
299	Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. 1999 , 112, 569-578	59
298	VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. 2000 , 113, 1525-1534	58
297	Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. 2001 , 114, 917-930	166
296	Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. 2002 , 115, 3073-3081	115

295	Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). 2002 , 115, 3427-3438	177
294	The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. 2002 , 115, 1123-1136	188
293	Vascular endothelial cells that express dystroglycan are involved in angiogenesis. 2002 , 115, 1487-1496	33
292	Knockdown of the KINDLIN-2 Gene and Reduced Expression of Kindlin-2 Affects Vascular Permeability in Angiogenesis in a Mouse Model of Wound Healing. 2018 , 24, 5376-5383	6
291	Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. 2009 , 4, e6913	46
290	Regulated expression of ADAMTS-12 in human trophoblastic cells: a role for ADAMTS-12 in epithelial cell invasion?. 2011 , 6, e18473	42
289	Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. 2011 , 6, e18864	23
288	Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects. 2013 , 8, e84493	10
287	RGDechi-hCit: BB selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells. 2014 , 9, e106441	22
286	Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications. 2014 , 9, e108071	16
285	Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. 2014 , 9, e111221	20
284	Proteolytic Enzymes Clustered in Specialized Plasma-Membrane Domains Drive Endothelial Cells' Migration. 2016 , 11, e0154709	12
283	Human umbilical mesenchymal stem cells conditioned medium promote primary wound healing regeneration. 2016 , 9, 605-10	24
282	Tetrac as an anti-angiogenic agent in cancer. 2019 , 26, R287-R304	6
281	Expression of angiopoietin-1, angiopoietin-2, and the Tie-2 receptor tyrosine kinase during mouse kidney maturation. 1999 , 10, 1722-36	72
280	A Novel Small-Molecule Integrin Antagonist Inhibits Cells Adhesion Followed By Anoikis in Endothelial Cells - A Comparative Analysis with Cilengitide. 009-018	1
279	Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. 2016 , 7, 82458-82472	13
278	The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing β integrin in chick embryo and nude mouse models. 2016 , 7, 87031-87036	7

277	Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF- β signaling and malignant features and. 2017 , 8, 114856-114876	24
276	Comparison and evaluation of two RGD peptides labelled with Ga or F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. 2018 , 9, 19307-19316	10
275	Suppression of focal adhesion formation may account for the suppression of cell migration, invasion and growth of non-small cell lung cancer cells following treatment with polyisoprenylated cysteinyl amide inhibitors. 2018 , 9, 25781-25795	7
274	Optical imaging detection of preclinical models of gut tumors through the expression of integrin α 5 β 1. 2018 , 9, 31380-31396	2
273	Palmitate up-regulates laminin expression via ROS/integrin α 5 β 1 pathway in HLSECs. 2019 , 10, 4083-4090	1
272	A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. 2015 , 6, 32681-700	29
271	Novel leptin OB3 peptide-induced signaling and progression in thyroid cancers: Comparison with leptin. 2016 , 7, 27641-54	10
270	Sulfatide interacts with and activates integrin α 5 β 1 in human hepatocellular carcinoma cells. 2016 , 7, 36563-36576	4
269	Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer. 2016 , 5, S951-S963	7
268	Pathophysiology of tumor neovascularization. 2005 , 1, 277-90	37
267	Transition Metal-Based Prodrugs for Anticancer Drug Delivery. 2019 , 26, 7476-7519	3
266	Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. 2010 , 11, 1000-17	231
265	Fisiologie de la cicatrizaciune cutanea. 2010 , 2, 69-78	1
264	FAM83A exerts tumor-suppressive roles in cervical cancer by regulating integrins. 2020 , 57, 509-521	4
263	Angiogenesis in cancer: Anti-VEGF escape mechanisms. 2012 , 1, 14-25	56
262	Antiangiogenic mechanisms and factors in breast cancer treatment. 2016 , 15, 1	30
261	Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis. 2019 , 14, 471-487	4
260	Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme. 2018 , 13, 546-554	8

- 259 Importance of integrin receptors in the field of pharmaceutical & medical science. **2013**, 03, 224-252 12
- 258 Non-invasive detection of vulnerable coronary plaque. **2011**, 3, 219-29 7
- 257 Molecular Imaging of Atherosclerosis. **2009**, 52, 143 2
- 256 Saxatilin suppresses tumor-induced angiogenesis by regulating VEGF expression in NCI-H460 human lung cancer cells. **2007**, 40, 439-43 22
- 255 Investigation of ICAM-1 and β integrin gene variations in patients with brain tumors. **2013**, 14, 5929-34 8
- 254 There is a world beyond $\alpha\beta$ -integrin: Multimeric ligands for imaging of the integrin subtypes $\alpha\beta$, $\alpha8$, $\alpha9$, and $\alpha11$ by positron emission tomography. **2021**, 11, 106 0
- 253 Literaturverzeichnis. **2000**, 63-75
- 252 F. **2000**, 90-143
- 251 The Uteroplacental Circulation: Extravillous Trophoblast. **2000**, 89-129 1
- 250 The role of eicosanoids in tumor growth and metastasis. **2000**, 201-17 4
- 249 Cytokines, Viruses, Angiogenesis. **2000**, 169-194
- 248 Tryptase inhibitors. **2000**, 101-121
- 247 Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. **2000**, 95, 2304-2311 3
- 246 Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. **2000**, 96, 176-181
- 245 The transforming growth factor family and the endothelium. **2001**, 41-64
- 244 Pathobiology of Vascular Disease. **2001**, 987-1004
- 243 Tumormetastasierung. **2001**, 77-85
- 242 Trophoblast Implantation Versus Tumor Invasion. **2001**, 267-276

241 Imaging of Angiogenesis. **2001**, 200-214

240 Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. **2001**, 311-326

239 Molecular and Cellular Angiogenesis. **2002**, 273-287

238 Inhibitors of Angiogenesis. **2002**, 261-292

237 Therapeutic Angiogenesis for the Treatment of Cardiovascular Disease. **2002**, 249-277

236 Molecular Vascular Embryology. **2002**, 18-35

1

235 Ligand-Directed Destruction of Tumor Vasculature. **2002**, 229-248

234 Control of Angiogenesis by Microbial Products. **2002**, 329-355

233 Antibody Targeting of Tumor Vasculature. **2002**, 475-489

232 Integrin Receptors and the Regulation of Angiogenesis. **2002**, 67-79

231 Angiogenesis: A Promising Target for Cancer Prevention. **2003**, 169-185

230 Controlled Drug Delivery In Photodynamic Therapy And Fluorescence-based Diagnosis Of Cancer. **2003**,

229 Angiogenesis Switch Pathways. **2004**, 411-441

228 The Extracellular Matrix in Development. **2004**, 52-57

227 Chick Chorioallantoic Membrane Assay: Growth Factor and Tumor-induced Angiogenesis and Lymphangiogenesis. **2004**, 247-261

1

226 Zellinvasion und Metastasierung. **2004**, 325-354

225 Molecular Aspects of Foot-and-Mouth Disease Virus Virulence and Host Range. **2004**, 146-172

1

224 Modeling Blood Vessel Formation in the Mouse.

223 Regulation of Postangiogenic Vascular Regression. **2006**, 79-95

222 Pharmacotherapy of Age-Related Macular Degeneration. **2006**, 1211-1239

1

221 Angiogenesis in Inflammatory Arthritis. **2007**, 403-440

220 Endothelial Cell Propagation Targeting. **2007**, 269-294

219 Malignant Melanoma. **2008**, 491-497

0

218 Integrins in Angiogenesis. **2008**, 63-73

1

217 Tumor Endothelial Markers. **2008**, 333-342

216 Therapeutic Antibodies and Immunologic Conjugates. **2008**, 531-544

215 Fractal Binding and Dissociation Kinetics of Disease-Related Compounds on Biosensor Surfaces. **2008**, 89-121

214 Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. 311-326

0

213 Erythropoietin-producing Human Hepatocellular Carcinoma Receptor B1 Polymorphisms are Associated with HBV-infected Chronic Liver Disease and Hepatocellular Carcinoma in a Korean Population. **2008**, 6, 192-201

212 Diabetes Mellitus. **2009**, 595-624

211 Molecular Imaging of Angiogenesis. **2009**, 52, 135

210 Cell Recruitment and Angiogenesis. **2009**, 357-365

209 Fibronectins and Their Receptors in Cancer. **2010**, 111-136

208 The Discovery and Characterisation of Tumour Endothelial Markers. **2010**, 31-48

207 Degeneration. **2010**, 513-614

206 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275

- 205 Tratamiento combinado farmacológico en la DMAE exudativa: Más allá de la monoterapia antiangiogénica. **2010**, 173-180
- 204 Cooperative Interactions Between Integrins and Growth Factor Signaling in Pathological Angiogenesis. **2010**, 673-693
- 203 Contrast Ultrasound in Imaging Tumor Angiogenesis. **2010**, 165-179
- 202 Novel Imaging Agents for Molecular MR Imaging of Cancer.
- 201 From In Vivo Ultrasound and MRI Imaging to Therapy: Contrast Agents Based on Target-Specific Nanoparticles. 17
- 200 The Extracellular Matrix in Development. **2011**, 59-64
- 199 The Interstitium and Lymphatics have an Important Role in Edema Generation during Sepsis. **2011**, 297-306
- 198 Angiogenesis in rheumatoid arthritis. **2011**, 905-909.e1
- 197 Molecular Regulation of Skin Wound Healing. **2012**, 1-23 O
- 196 Cell-Based Models of Tumor Angiogenesis. **2012**, 135-150 1
- 195 Integrin Antagonists and Angiogenesis. **2013**, 119-141
- 194 RGD-Based Molecular Probes for Integrin $\alpha_5\beta_1$ Imaging. **2013**, 513-538
- 193 Cancer-Specific Ligand-Receptor Interactions. **2013**, 461-507
- 192 Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics. 438-469
- 191 The cellular microenvironment modulates the role of PAI-1 and vitronectin in mediating cell-matrix interactions. **2013**, 03, 114-132
- 190 Integrin-Functionalized Artificial Membranes as Test Platforms for Monitoring Small Integrin Ligand Binding by Surface Plasmon-Enhanced Fluorescence Spectroscopy. **2013**, 705-745
- 189 Molecular Imaging of Inflammation and Intraplaque Vasa Vasorum. **2014**, 299-316
- 188 Stem Cell-Based Antiangiogenic Therapies for Brain Tumors. 87-101

187 Imaging in Drug Development. **2014**, 731-746

186 Therapeutic Antibodies and Immunologic Conjugates. **2014**, 508-518.e7

0

185 Human Retroviruses in the Second Decade: Some Pathogenic Mechanisms and Approaches to Their Control. 245-269

184 Angiogenesis. **1988**, 355-371

1

183 V. **1990**, 321-372

182 A Method for the in Vivo Quantitation of Angiogenesis in the Rabbit Corneal Model. **1996**, 241-253

181 The Rat Aorta Model of Angiogenesis and Its Applications. **1996**, 111-129

1

180 Adhäsionsmoleküle: Bedeutung für die Pathophysiologie chirurgischer Erkrankungen. **1997**, 297-306

179 Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. **1997**, 157, 306-10

10

178 The Role of Integrin $\alpha_5\beta_1$ in Cell Survival and Angiogenesis. **1997**, 35-42

177 Embryogenesis and Angiogenesis. **1997**, 5-8

176 References. **1997**, 215-326

175 Angiogenesis and Metastasis. **1997**, 40-53

174 #513 Integrin $\alpha_v\beta_3$ is expressed on angiogenic endothelial cells in malignant pediatric brain tumors. **1997**, 19, 366

173 Early Markers of Cardiovascular Damage. **1998**, 103-122

172 Clinical significance of angiogenic factors in breast cancer. **1998**, 249-263

171 Mechanismen der Angiogenese. **1998**, 308-321

170 Role of Endothelial Plasminogen Activators in Fibrinolysis and Repair-Associated Angiogenesis. **1998**, 77-97

169 Adhesion Molecules, Angiogenesis and Malignant Gliomas: Implications for Tumorigenesis. **1998**, 405-429

168 Adhesion and Apoptosis. **1998**, 143-165

1

167 Molecular Biology of Cerebrovascular Diseases. **1998**, 163-173

166 Integrins and Angiogenesis. **1999**, 23-39

165 Cancer Immunotherapy. **1999**, 170-204

164 The Role of CXC Chemokines in the Regulation of Angiogenesis in Association with Non-Small-Cell Lung Cancer. **1999**, 171-189

163 Antiangiogenetische Therapie von Tumoren durch Inhibition des Integrins $\alpha 3$ mit einem zyklischen Peptid. **1999**, 349-353

162 Dieckol Suppresses CoCl₂-induced Angiogenesis in Endothelial Cells. **2014**, 17, 305-311

1

161 Integrins. **2015**, 26, 3-9

160 Tumour Angiogenesis. **2015**, 47-62

159 Anticancer Agents: Drug Carrier Systems. 228-241

158 Antiangiogenic Gene Therapy. **2016**, 1-14

157 Immunotherapy and Vaccines. **2016**, 441-464

156 Conjugates: BiosyntheticSynthetic Polymer Based. 2039-2060

155 Antiangiogenic Gene Therapy. **2017**, 1623-1636

154 Endogenous Proteases in Tumoral Progression. **2017**, 119-145

153 Conjugates: BiosyntheticSynthetic Polymer Based. **2017**, 340-361

152 The role of integrins in acute leukemias and potential as targets for therapy. **2018**, 1, 63

- 151 Chloroalkene Dipeptide Isosteres as Peptidomimetics. **2018**, 17-47
- 150 Tumour Angiogenesis. **2019**, 55-76
- 149 Nanomaterials in Gene Therapy Technology. 63-107
- 148 The clinical translation of novel near-infrared fluorophores for fluorescence guided surgery. **2019**,
- 147 Antitumor activity of integrin $\alpha_5\beta_1$ antibody conjugated-cationic microbubbles in liver cancer.. **2019**, 8, 899-908 1
- 146 Developmental Expression of Transforming Growth Factor Induced Protein Promotes NF-Kappa-B Mediated Angiogenesis During Postnatal Lung Development.
- 145 Temporal Changes Guided by Mesenchymal Stem Cells on a 3D Microgel Platform Enhances Angiogenesis In Vivo at a Low-Cell Dose.
- 144 RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. **2021**, 340, 221-242 20
- 143 Protein-Based Drug Delivery in Brain Tumor Therapy. **2020**, 1249, 203-221 0
- 142 Preparation of nanoparticles of β -cyclodextrin-loaded scutellarein anti-tumor activity research by targeting integrin $\alpha_5\beta_1$. **2021**, 12, 1
- 141 Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics.. **2022**, 13, 179-190 2
- 140 The Role of Integrin-Mediated Processes in the Biology of Metastasis. **2000**, 19-54
- 139 Mechanical Signaling and the Cardiac Renin-angiotensin. **2006**, 111-127
- 138 Type-II transmembrane prolyl dipeptidases and matrix metalloproteinases in membrane vesicles of active endothelial cells. **2006**, 575, 207-12
- 137 Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. **2005**, 345-367
- 136 Tumormetastasierung. **2006**, 63-71
- 135 Novel Therapeutic Strategies For Posterior Segment Neovascularization. **2008**, 445-526
- 134 Inhibition of endothelial cell survival and angiogenesis by protein kinase A. **2002**, 110, 933-41 60

133	Endothelial integrins and angiogenesis: not so simple anymore. 2002 , 110, 913-4	13
132	Antimetastatic Gene Therapy. 2005 , 299-319	
131	Therapeutic Angiogenesis for Ischemic Vascular Disease. 2005 , 369-385	
130	Integrins in Ocular Angiogenesis. 2006 , 279-289	
129	The Role of Integrins in Tumor Angiogenesis. 2008 , 49-71	
128	Gene Therapy Targeted at Angiogenesis and Lymphangiogenesis for Cancer Treatment. 2007 , 301-330	
127	Magnetic Resonance Probes for Tumor Imaging. 2007 , 259-280	
126	Integrins: Targets for Anti-Angiogenic Therapy. 2008 , 761-777	1
125	Applications of Molecular Imaging with MR. 2009 , 363-393	
124	Extracellular matrix and integrin signalling: the shape of things to come. 1999 , 339 (Pt 3), 481-8	138
123	Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. 2000 , 346 Pt 1, 133-8	35
122	Involvement of endothelial PECAM-1/CD31 in angiogenesis. 1997 , 151, 671-7	341
121	Expression and function of endothelial cell alpha v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. 1997 , 151, 975-83	42
120	Focally regulated endothelial proliferation and cell death in human synovium. 1998 , 152, 691-702	85
119	Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. 1998 , 152, 1607-16	33
118	Cellular adhesion molecules. Newly identified mediators of angiogenesis. 1996 , 148, 1023-9	55
117	Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. 1996 , 148, 1407-21	148
116	Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro. 1996 , 148, 749-61	23

115	Mesenchymal cell activation is the rate-limiting step of granulation tissue induction. 1996 , 149, 1257-70	84
114	Biochemical and morphological characterization of vascular and lymphocytic interleukin-4 receptors. 1996 , 149, 1369-79	9
113	Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. 1996 , 149, 293-305	404
112	Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischemia. 1996 , 149, 37-44	88
111	Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. 1996 , 149, 1-7	100
110	Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. 1996 , 149, 59-71	161
109	Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. 1996 , 149, 1707-17	39
108	Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. 1995 , 147, 339-51	130
107	Angiogenic growth factors in neural embryogenesis and neoplasia. 1995 , 146, 293-309	64
106	Altered vascular endothelium integrin expression in psoriasis. 1995 , 147, 1661-7	34
105	Between molecules and morphology. Extracellular matrix and creation of vascular form. 1995 , 147, 873-83	138
104	The role of alphav integrins during angiogenesis. 1998 , 4, 741-50	22
103	RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. 2007 , 2, 191-9	36
102	Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. 2007 , 2, 515-26	59
101	The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. 2008 , 2, 57-73	25
100	Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. 2009 , 8, 101-10	29
99	Preclinical molecular imaging of tumor angiogenesis. 2010 , 54, 291-308	27
98	Targeted molecular imaging of angiogenesis in PET and SPECT: a review. 2012 , 85, 75-86	43

97	(68)Ga-Labeling of RGD peptides and biodistribution. 2012 , 5, 165-72	17
96	Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. 2010 , 9, 21-9	21
95	Mechanism for laser-induced neovascularization in rat choroid: accumulation of integrin β chain-positive cells and their ligands. 2014 , 20, 864-71	7
94	Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. 2000 , 60, 722-7	627
93	Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice. 2016 , 15, 762-72	9
92	Small molecular peptide-ScFv $\alpha\beta$ conjugates specifically inhibit lung cancer cell growth and. 2016 , 6, 2846-2858	
91	Design, Synthesis and Biological Evaluation of Ketoprofen Conjugated To RGD/NGR for Targeted Cancer Therapy. 2018 , 17, 1297-1305	4
90	RGD-human serum albumin conjugates as efficient tumor targeting probes. 2009 , 8, 65-73	18
89	Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer. 2021 ,	3
88	The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma Determines Cancer Associated Fibroblast Growth. 2021 , 13,	4
87	Feasibility of I-RGD uptake as a marker of angiogenesis after myocardial infarction. 2021 , 1	
86	Simultaneous delivery of immune stimulatory gene and checkpoint blocker via targeted nanoparticles to strengthen anti-tumor immunity. 2021 , 100151	0
85	It's Time to Shift the Paradigm: Translation and Clinical Application of Non- $\alpha\beta$ Integrin Targeting Radiopharmaceuticals. 2021 , 13,	1
84	Theranostic Microbubbles with Homogeneous Ligand Distribution for Higher Binding Efficacy.. <i>Pharmaceutics</i> , 2022 , 14,	6.4 0
83	Resistance to antiangiogenic treatments: A review. 2022 , 147-197	
82	Pre-treatment F-RGD Uptake may Predict Adverse Events during Apatinib Antiangiogenic Therapy.. 2022 ,	1
81	Tissue engineering of the vascular system: from capillaries to larger blood vessels. 2000 , 38, 232-40	9
80	Natural Polysaccharides on Wound Healing. 2022 , 1117-1132	

- 79 Molecular Imaging in Infection and Inflammation. **2022**, 45-52
- 78 Targeting of the alpha beta integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma.. **2022**, 10, 3
- 77 Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer.. **2022**, 1 1
- 76 Convergent Arrangement of sgRNA and Cas9 in CRISPRsome for Transcellular Trafficking. **2022**, 4, 505-510 1
- 75 Synthetic hydrogels engineered to promote collecting lymphatic vessel sprouting.. **2022**, 284, 121483 1
- 74 A novel porous granular scaffold for the promotion of trabecular bone repair by time-dependent alteration of morphology. **2022**, 212777 0
- 73 Applications of Polymer Bioconjugates. 1-47
- 72 Expression Profile of CD157 Reveals Functional Heterogeneity of Capillaries in Human Dermal Skin.. **2022**, 10, 0
- 71 Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.. **2022**, 12, 837952 2
- 70 Blutgefäß aus dem Labor [neue Matriceigenschaften zur Gefäßbildung]. **2022**, 28, 149-151
- 69 Applications of nanoparticles in cardiovascular imaging and therapeutics.. **2022**, 2184923221087003 1
- 68 Study on the Preparation and Properties of Highly Stable Micelles Sealed by Hydrogen Bonds. **2021**, 63, 769-778 1
- 67 Evaluation of [Ga]Ga-NODAGA-RGD for PET Imaging of Rat Autoimmune Myocarditis.. *Frontiers in Medicine*, **2021**, 8, 783596 4.9 1
- 66 Microvascular remodeling and altered angiogenic signaling in human kidneys distal to occlusive atherosclerotic renal artery stenosis.. **2022**,
- 65 Targeting Angiogenic Factors for the Treatment of Medulloblastoma.. **2022**, 23, 864
- 64 Image1.PDF. **2018**,
- 63 Image_1.TIF. **2020**,
- 62 Image_2.TIF. **2020**,

61 Image_3.TIF. **2020**,

60 Table_1.DOCX. **2020**,

59 Data_Sheet_1.PDF. **2018**,

58 Table_1.DOC. **2018**,

57 Unique Hypoxia-tolerant Subpopulations of Adipose-derived Stem Cells: ITGB3+ Cells. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2022**, 1.7

56 Overview of the RGD-Based PET Agents Use in Patients With Cardiovascular Diseases: A Systematic Review. *Frontiers in Medicine*, **2022**, 9, 4.9 0

55 Pathobiology of Airway Remodeling in Asthma: The Emerging Role of Integrins.. *Journal of Asthma and Allergy*, **2022**, 15, 595-610 3.1 3

54 Integrin- $\alpha 5$ as a Therapeutic Target in Glioblastoma: Back to the Future?. *Pharmaceutics*, **2022**, 14, 1053 6.4 1

53 PLGA-graphene quantum dot nanocomposites targeted against $\alpha 5 \beta 1$ integrin receptor for sorafenib delivery in angiogenesis. **2022**, 212851 1

52 The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.. *Oncogene*, **2022**, 9.2 0

51 Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference.. *Journal of Colloid and Interface Science*, **2022**, 622, 938-949 9.3

50 Enhancement of the Antiangiogenic Activity of Interleukin-12 by Peptide Targeted Delivery of the Cytokine to $\alpha 5 \beta 1$ Integrin. *Molecular Cancer Research*, **2004**, 2, 663-673 6.6 47

49 Pulsed Microwave-Induced Thermoacoustic Shockwave for Precise Glioblastoma Therapy with the Skin and Skull Intact.. *Small*, **2022**, e2201342 11 0

48 Tumor Microenvironment: Coconspirator in Tumorigenesis. **2022**, 21-28

47 Inhibition of angiogenesis and tumor progression of MK-0429, an integrin $\alpha 5 \beta 1$ antagonist, on oral squamous cell carcinoma. *Journal of Cancer Research and Clinical Oncology*, 4.9 0

46 Palmitic Acid-Conjugated Radiopharmaceutical for Integrin $\alpha 5 \beta 1$ -Targeted Radionuclide Therapy. *Pharmaceutics*, **2022**, 14, 1327 6.4

45 Molecular ZIP codes in targeted drug delivery. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, 11.5 0

44 Extracellular Matrix Regulation of Vascular Morphogenesis, Maturation, and Stabilization. *Cold Spring Harbor Perspectives in Medicine*, a041156 5.4 0

- 43 Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulation. *Bioorganic and Medicinal Chemistry*, **2022**, 70, 116919 3-4 1
- 42 Ultrasonic Imaging of Tumor Angiogenesis Using Contrast Microbubbles Targeted via the Tumor-Binding Peptide Arginine-Arginine-Leucine. **2005**, 65, 533-539 51
- 41 Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. *Molecular Cancer Therapeutics*, **2004**, 3, 499-511 6.1 24
- 40 Systemic single administration of anti-inflammatory microRNA 146a-5p loaded in polymeric nanomedicines with active targetability attenuates neointimal hyperplasia by controlling inflammation in injured arteries in a rat model. **2022**, 36, 0
- 39 Mechanical regulation of signal transduction in angiogenesis. 10, 1
- 38 The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma. **2022**, 14, 4072 0
- 37 Molecular basis for pericyte-induced capillary tube network assembly and maturation. 10, 1
- 36 Two-dimensional silicene photodynamic tumor-targeting nanomedicine. **2022**, 16, 100393 0
- 35 Integrins in Ovarian Cancer: Survival Pathways, Malignant Ascites and Targeted Photochemistry. 0
- 34 Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. **2022**, 14, 4209 1
- 33 Integrin-specific hydrogels for growth factor-free vasculogenesis. **2022**, 7, 0
- 32 Current and promising treatment strategies in glioma. **2022**, 0
- 31 High-Resolution Conformational Analysis of RGDechi-Derived Peptides Based on a Combination of NMR Spectroscopy and MD Simulations. **2022**, 23, 11039 0
- 30 Role of Vitronectin and Its Receptors in Neuronal Function and Neurodegenerative Diseases. **2022**, 23, 12387 0
- 29 A Promising Candidate in Tendon Healing EventsPDGF-BB. **2022**, 12, 1518 0
- 28 Integrin binding peptides facilitate growth and interconnected vascular-like network formation of rat primary cortical vascular endothelial cells in vitro. **2023**, 18, 1052 0
- 27 Multifunctional nanoprobe combined with radiotherapy and hypoxia-activated therapy synergistically improve antitumor efficacy. **2022**, 12, 32297-32306 0
- 26 Liposomes as Targeted Drug-Delivery Systems. **2022**, 69-125 0

25	Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. 2022 , 1, 1-11	0
24	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. 13,	1
23	Evaluation and manipulation of tissue and cellular distribution of cardiac progenitor cell-derived extracellular vesicles. 13,	0
22	Pharmacokinetics of fluorobenzyl polyethylene glycol conjugated tetraiodothyroacetic acid (NP751), a novel anticancer thyrointegrin $\alpha\beta$ antagonist. 13,	0
21	Functional Interplay Between Fibronectin and Matricellular Proteins in the Control of Endothelial Tubulogenesis. 2023 , 29-62	0
20	Non-coding RNA regulation of integrins and their potential as therapeutic targets in cancer.	0
19	Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization. 1998 , 161, 6845-6852	55
18	Inflammatory Cytokines Synergize with the HIV-1 Tat Protein to Promote Angiogenesis and Kaposi's Sarcoma Via Induction of Basic Fibroblast Growth Factor and the $\alpha\beta$ Integrin. 1999 , 163, 1929-1935	8
17	PVA-Microbubbles as a Radioembolization Platform: Formulation and the In Vitro Proof of Concept. 2023 , 15, 217	1
16	Improving Crossing of Multiple Bio-delivery Barriers By a Novel Bio-interface Design Based On Hydrophobic Nanoparticle Surface.	0
15	PET Imaging in Clinical Oncology. 2023 , 1-26	0
14	Synthesis, Radiolabeling, and In Vitro and In Vivo Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin $\alpha\beta$ Targeting. 2023 , 8, 2793-2807	1
13	Targeting the secreted RGDKGE collagen fragment reduces PD-L1 by a proteasome-dependent mechanism and inhibits tumor growth. 2023 , 49,	0
12	RGD Forever! Past, Present, and Future of a 3-Letter-Code in Radiopharmacy and Life Sciences. 2023 , 16, 56	0
11	Tumour Associated Vasculature-on-a-chip for the Evaluation of Microbubble-Mediated Delivery of Targeted Liposomes.	0
10	Mechanisms of Platelet Adhesion. 1999 , 21-34	1
9	miR-92a and integrin expression in fibrovascular membranes in proliferative diabetic retinopathy. 3,	0
8	Design and synthesis of novel N-terminal peptides of integrin and aminopeptidase are new finding for anticancer activity. 2023 , 134, 106434	0

- 7 Anti-angiogenic collagen IV-derived peptide target engagement with $\alpha 5 \beta 1$ and $\alpha 1 \beta 1$ in ocular neovascularization models. **2023**, 26, 106078 ○
- 6 A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis. **2023**, 635, 122698 ○
- 5 The challenges and opportunities of $\alpha 5 \beta 1$ -based therapeutics in cancer: From bench to clinical trials. **2023**, 189, 106694 ○
- 4 Potential of uPAR, $\alpha 5 \beta 1$ Integrin, and Tissue Factor as Targets for Molecular Imaging of Oral Squamous Cell Carcinoma: Evaluation of Nine Targets in Primary Tumors and Metastases by Immunohistochemistry. **2023**, 24, 3853 ○
- 3 Microfibril-Associated Glycoprotein-2 Promoted Fracture Healing via Integrin $\alpha 5 \beta 1$ /PTK2/AKT Signaling. **2023**, 103, 100121 ○
- 2 cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. **2023**, 356, 691-701 ○
- 1 Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis. 11, ○